filename	netmhciipan_version	peptide_length	brackets	score_total	hotspot_max	sequence	prediction_type
chembl_phase_34_biotherapeutics_ABAGOVOMAB_20876.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	32	DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	ba
chembl_phase_34_biotherapeutics_ABAGOVOMAB_20877.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	565	41	QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK	ba
chembl_phase_34_biotherapeutics_ABATACEPT_21574.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	48	MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ABATACEPT_22140.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	48	MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ABCIXIMAB_20830.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	291	43	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ABCIXIMAB_20831.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	181	32	DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	ba
chembl_phase_34_biotherapeutics_ADUCANUMAB_21028.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	144	42	QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ADUCANUMAB_21029.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	84	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_AFLIBERCEPT_21576-22141.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	5	2	SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_AGALSIDASE_ALFA_20704-21614.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL	ba
chembl_phase_34_biotherapeutics_AGALSIDASE_BETA_20704-21614.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL	ba
chembl_phase_34_biotherapeutics_ALBUMIN,_CHROMATED_CR_51_SERUM_21510.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL	ba
chembl_phase_34_biotherapeutics_ALBUMIN,_IODINATED_I_125_SERUM_21510.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL	ba
chembl_phase_34_biotherapeutics_ALBUMIN,_IODINATED_I_131_SERUM_21510.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL	ba
chembl_phase_34_biotherapeutics_ALDESLEUKIN_21485.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	49	32	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT	ba
chembl_phase_34_biotherapeutics_ALEFACEPT_20738.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	14	CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ALEMTUZUMAB_20904-21616.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	215	57	QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ALEMTUZUMAB_20905-21615.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	214	84	DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR	ba
chembl_phase_34_biotherapeutics_ALFIMEPRASE_20705.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	323	24	SFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEIWSNQDLITVTSVSHDTLASFGNWRETDLLRRQRHDNAQLLTAIDFDGDTVGLAYVGGMCQLKHSTGVIQDHSAINLLVALTMAHELGHNLGMNHDGNQCHCGANSCVMAAMLSDQPSKLFSDCSKKDYQTFLTVNNPQCILNKP	ba
chembl_phase_34_biotherapeutics_ALGLUCERASE_21516.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ	ba
chembl_phase_34_biotherapeutics_ALGLUCOSIDASE_ALFA_20744.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	17	QQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	ba
chembl_phase_34_biotherapeutics_ALGLUCOSIDASE_ALFA_21617.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	17	QQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	ba
chembl_phase_34_biotherapeutics_ALIROCUMAB_21618.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	15	EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ALIROCUMAB_21619.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	86	DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ALIROCUMAB_22142.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	15	EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ALIROCUMAB_22143.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	86	DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_AMIVANTAMAB_21577.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	133	41	QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_AMIVANTAMAB_21578.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	24	6	QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_AMIVANTAMAB_21620.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	86	DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_AMIVANTAMAB_21621.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	84	AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_AMUBARVIMAB_21461.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	91	21	EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_AMUBARVIMAB_21462.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	86	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ANAKINRA_21517-21622.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE	ba
chembl_phase_34_biotherapeutics_ANDECALIXIMAB_21273.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	84	DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ANDEXANET_ALFA_21127-21623.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ANSFLFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDAGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK	ba
chembl_phase_34_biotherapeutics_ANIFROLUMAB_21012-21626.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	108	18	EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ANIFROLUMAB_21013-21625.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	175	86	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ANSUVIMAB_21591.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	352	95	DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ANSUVIMAB_21592.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	146	25	EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ANTITHROMBIN_ALFA_21482-21627.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HGSPVDICTAKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRVWELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFAMTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNCRLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYGAKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAINELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCSASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKPEKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIEDGFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAFHKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPFLVFIREVPLNTIIFMGRVANPCVK	ba
chembl_phase_34_biotherapeutics_APADAMTASE_ALFA_21732.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	AAGGILHLELLVAVGPDVFQAHREDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTIAHEIGHSFGLEHDGAPGSGCGPSGHVMASDGAAPRAGLAWSPCSRRQLLSLLSAGRARCVWDPPRPQPGSAGHPPDAQPGLYYSANEQCRVAFGPKAVACTFAREHLDMCQALSCHTDPLDQSSCSRLLVPLLDGTECGVEKWCSKGRCRSLVELTPIAAVHGRWSSWGPRSPCSRSCGGGVVTRRRQCNNPRPAFGGRACVGADLQAEMCNTQACEKTQLEFMSQQCARTDGQPLRSSPGGASFYHWGAAVPHSQGDALCRHMCRAIGESFIMKRGDSFLDGTRCMPSGPREDGTLSLCVSGSCRTFGCDGRMDSQQVWDRCQVCGGDNSTCSPRKGSFTAGRAREYVTFLTVTPNLTSVYIANHRPLFTHLAVRIGGRYVVAGKMSISPNTTYPSLLEDGRVEYRVALTEDRLPRLEEIRIWGPLQEDADIQVYRRYGEEYGNLTRPDITFTYFQPKPRQAWVWAAVRGPCSVSCGAGLRWVNYSCLDQARKELVETVQCQGSQQPPAWPEACVLEPCPPYWAVGDFGPCSASCGGGLRERPVRCVEAQGSLLKTLPPARCRAGAQQPAVALETCNPQPCPARWEVSEPSSCTSAGGAGLALENETCVPGADGLEAPVTEGPGSVDEKLPAPEPCVGMSCPPGWGHLDATSAGEKAPSPWGSIRTGAQAAHVWTPAAGSCSVSCGRGLMELRFLCMDSALRVPVQEELCGLASKPGSRREVCQAVPCPARWQYKLAACSVSCGRGVVRRILYCARAHGEDDGEEILLDTQCQGLPRPEPQEACSLEPCPPRWKVMSLGPCSASCGLGTARRSVACVQLDQGQDVEVDEAACAALVRPEASVPCLIADCTYRWHVGTWMECSVSCGDGIQRRRDTCLGPQAQAPVPADFCQHLPKPVTVRGCWAGPCVGQGTPSLVPHEEAAAPGRTTATPAGASLEWSQARGLLFSPAPQPRRLLPGPQENSVQSSACGRQHLEPTGTIDMRGPGQADCAVAIGRPLGEVVTLRVLESSLNCSAGDMLLLWGRLTWRKMCRKLLDMTFSSKTNTLVVRQRCGRPGGGVLLRYGSQLAPETFYRECDMQLFGPWGEIVSPSLSPATSNAGGCRLFINVAPHARIAIHALATNMGAGTEGANASYILIRDTHSLRTTAFHGQQVLYWESESSQAEMEFSEGFLKAQASLRGQYWTLQSWVPEMQDPQSWKGKGET	ba
chembl_phase_34_biotherapeutics_APITEGROMAB_21436.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	60	24	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_APITEGROMAB_21491.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	22	6	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_APROTININ_21518.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	73	RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA	ba
chembl_phase_34_biotherapeutics_ASFOTASE_ALFA_20837-21628.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD	ba
chembl_phase_34_biotherapeutics_ASPARAGINASE_ERWINIA_CHRYSANTHEMI_21579.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1043	57	ADKLPNIVILATGGTIAGSKAGALGVDTLINAVPEVKKLANVKGEQFSNMASENMTGDVAATGTQTTGYLLARDDVDGVVITHGTDTVEESAYFLHLTVKSDKPVVFVAVLKLSQRVNEDGPMNLLEAVRVAGDKQSRGRGVMVVLNDRIGSARYITKTAMRPATAISANEEGYLGVIIGNRIYYQNRIDKLHTTRSVFDVRGLTSLPKNASTLDTFKAPEYLYDAAIQHGVKGIVYAGMGAGSVSVRGIAGMRKAMEKVDILYGYQDDGNGIVPPDEELPGLVSDSLNPAHARILLMLALTRTSDPKVGVVVIRSTRTIQEYFHTY	ba
chembl_phase_34_biotherapeutics_ASTEGOLIMAB_21593.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	84	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ASTEGOLIMAB_21594.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	11	EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ATACICEPT_21483.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2	2	AMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASICGQHPKQCAYFCENKLRSEPKSSDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ATEZOLIZUMAB_21137-21630.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	76	16	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ATEZOLIZUMAB_21138-21629.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	231	84	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ATOLTIVIMAB_21325.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	43	20	QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ATOLTIVIMAB_21326.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	136	86	DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_AVALGLUCOSIDASE_ALFA_21617.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	17	QQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	ba
chembl_phase_34_biotherapeutics_AVELUMAB_21278-21658.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	52	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_AVELUMAB_21279-21827.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	16	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_AVIPTADIL_21830.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HSDAVFTDNYTRLRKQMAVKKYLNSILN	ba
chembl_phase_34_biotherapeutics_AVOTERMIN_20702.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKDYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS	ba
chembl_phase_34_biotherapeutics_BALSTILIMAB_21437.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	15	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_BALSTILIMAB_21493.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BAMLANIVIMAB_21583.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	208	35	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BAMLANIVIMAB_21584.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	144	84	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BASILIXIMAB_20785-21660.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	173	43	QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BASILIXIMAB_20786-21659.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	261	86	QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE	ba
chembl_phase_34_biotherapeutics_BATIRAXCEPT_21522.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	74	21	EESPFVSNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRDGQILELVDSTQTQVPLGEDEQGDWIVASQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVRLEGLPYFLEEPEDRTVAANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_BATOCLIMAB_21585.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	146	26	QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_BATOCLIMAB_21586.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	46	31	SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BAVITUXIMAB_20750.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	42	DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELKRADAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BAVITUXIMAB_20751.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	134	24	EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BECAPLERMIN_20892-21661.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT	ba
chembl_phase_34_biotherapeutics_BELANTAMAB_MAFODOTIN_21327.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	25	8	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BELANTAMAB_MAFODOTIN_21328.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	231	86	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BELATACEPT_20752-21662.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	6	MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BEMPEGALDESLEUKIN_21601.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	49	32	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT	ba
chembl_phase_34_biotherapeutics_BENMELSTOBART_22478.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	144	21	QITLKESGPTLVKPTQTLTLTCTVSGFSLSTYGVHWIRQPPGKALEWLGVIWRGVTTDYNAAFMSRLTITKDNSKNQVVLTMNNMDPVDTATYYCARLGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BENMELSTOBART_22479.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	303	86	DIQMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKAPKLLIYYAANRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYFCQQDYTSPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BENRALIZUMAB_20753.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	204	84	DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BENRALIZUMAB_20754.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	33	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BENRALIZUMAB_21663.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	33	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BENRALIZUMAB_21664.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	204	84	DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BENTRACIMAB_21438.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	187	23	QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK	ba
chembl_phase_34_biotherapeutics_BENTRACIMAB_21527.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	40	13	QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BERMEKIMAB_21329.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	59	QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BERMEKIMAB_21330.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	81	11	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BEVACIZUMAB_20910-21665.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	18	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT	ba
chembl_phase_34_biotherapeutics_BEVACIZUMAB_21041-22508.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	84	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BEZLOTOXUMAB_21666.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BEZLOTOXUMAB_21667.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	62	12	EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BEZLOTOXUMAB_22145.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	62	12	EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BEZLOTOXUMAB_22146.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BIMAGRUMAB_20987.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	116	43	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_BIMAGRUMAB_20988.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	22	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BIMEKIZUMAB_21439.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	33	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BIMEKIZUMAB_21440.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	237	84	AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BINTRAFUSP_ALFA_21826.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	52	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSGGGGSGIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD	ba
chembl_phase_34_biotherapeutics_BINTRAFUSP_ALFA_21827.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	16	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BIRTAMIMAB_21282.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	176	26	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BIRTAMIMAB_21283.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	148	84	DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BIVALIRUDIN_20525-21668.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	6	FPRPGGGGNGDFEEIPEEYL	ba
chembl_phase_34_biotherapeutics_BLINATUMOMAB_20924-21669.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	518	33	DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH	ba
chembl_phase_34_biotherapeutics_BLISIBIMOD_20970.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	22	5	GCKWDLLIKQWVCDPLGSGSATGGSGSTASSGSGSATHMLPGCKWDLLIKQWVCDPLGGGGGVDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BOCOCIZUMAB_20976.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	33	11	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BOCOCIZUMAB_20977.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	86	DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BRAZIKUMAB_21171.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	41	11	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BRAZIKUMAB_21172.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	12	QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BRENTUXIMAB_VEDOTIN_20647-21670.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	86	DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BRENTUXIMAB_VEDOTIN_20648-21671.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	104	21	QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_BRIAKINUMAB_20642.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	50	12	QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_BRIAKINUMAB_20643.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	70	35	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BRODALUMAB_20685.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	84	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BRODALUMAB_20686.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	17	QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BRODALUMAB_21672.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	84	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_BRODALUMAB_21673.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	17	QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BROLUCIZUMAB_21286-21704.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	355	46	MEIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVLGGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS	ba
chembl_phase_34_biotherapeutics_BUROSUMAB_21135-21706.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	80	9	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_BUROSUMAB_21136-21705.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	114	75	AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CADONILIMAB_21832.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	285	68	DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CADONILIMAB_22125.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	250	26	EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSQVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSAGGGGSGGGGSGGGGSGGGGSQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVLR	ba
chembl_phase_34_biotherapeutics_CALCITONIN_SALMON_21565.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4	4	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP	ba
chembl_phase_34_biotherapeutics_CANAKINUMAB_20552.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	40	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CANAKINUMAB_20553-21708.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	246	75	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CANAKINUMAB_21707.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	40	QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CAPLACIZUMAB_20972-21709.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	324	41	EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSSAAAEVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS	ba
chembl_phase_34_biotherapeutics_CAROTUXIMAB_21258.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	89	24	EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CAROTUXIMAB_21259.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	349	68	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CARPERITIDE_20612.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SLRRSSCFGGRMDDIGAQSGLGCNSFRY	ba
chembl_phase_34_biotherapeutics_CASIRIVIMAB_21828.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	30	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CASIRIVIMAB_21864.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	221	84	DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CATRIDECACOG_20793-21710.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPRGVNLQEFLNVTSVHLFKERWDTNKVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVPIVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDTYILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFRNNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLEQASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVEFTNPLKETLRNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGELDVQIQRRPSM	ba
chembl_phase_34_biotherapeutics_CEMIPLIMAB_21313-21712.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	99	26	EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_CEMIPLIMAB_21314-21711.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	78	DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CENDAKIMAB_21595.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	219	84	DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CENDAKIMAB_21596.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	170	29	EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CEPEGINTERFERON_ALFA-2B_21549.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	ba
chembl_phase_34_biotherapeutics_CERLIPONASE_ALFA_21097-21713.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP	ba
chembl_phase_34_biotherapeutics_CETRELIMAB_21331.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	76	39	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_CETRELIMAB_21332.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	136	84	EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CETUXIMAB_20869-21715.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	256	45	QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CETUXIMAB_20870-21714.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	242	68	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA	ba
chembl_phase_34_biotherapeutics_CHORIOGONADOTROPIN_ALFA_21716-22193.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ	ba
chembl_phase_34_biotherapeutics_CHORIOGONADOTROPIN_ALFA_22162-22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_CILGAVIMAB_21869.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	65	27	EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CILGAVIMAB_21870.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	168	84	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CINTREDEKIN_BESUDOTOX_20939.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	931	65	MHSPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFNKASGGPEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAANGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDQEQAISALPDYASQPGQPPREDLR	ba
chembl_phase_34_biotherapeutics_CIPAGLUCOSIDASE_ALFA_21431.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	QQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	ba
chembl_phase_34_biotherapeutics_CLAZAKIZUMAB_22147.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	117	14	EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CLAZAKIZUMAB_22148.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	310	84	AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CLESROVIMAB_21833.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	23	EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CLESROVIMAB_22126.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	86	DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_COLLAGENASE_CLOSTRIDIUM_HISTOLYTICUM_20950-21717.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1872	63	MKRKCLSKRLMLAITMATIFTVNSTLPIYAAVDKNNATAAVQNESKRYTVSYLKTLNYYDLVDLLVKTEIENLPDLFQYSSDAKEFYGNKTRMSFIMDEIGRRAPQYTEIDHKGIPTLVEVVRAGFYLGFHNKELNEINKRSFKERVIPSILAIQKNPNFKLGTEVQDKIVSATGLLAGNETAPPEVVNNFTPILQDCIKNIDRYALDDLKSKALFNVLAAPTYDITEYLRATKEKPENTPWYGKIDGFINELKKLALYGKINDNNSWIIDNGIYHIAPLGKLHSNNKIGIETLTEVMKVYPYLSMQHLQSADQIKRHYDSKDAEGNKIPLDKFKKEGKEKYCPKTYTFDDGKVIIKAGARVEEEKVKRLYWASKEVNSQFFRVYGIDKPLEEGNPDDILTMVIYNSPEEYKLNSVLYGYDTNNGGMYIEPEGTFFTYEREAQESTYTLEELFRHEYTHYLQGRYAVPGQWGRTKLYDNDRLTWYEEGGAELFAGSTRTSGILPRKSIVSNIHNTTRNNRYKLSDTVHSKYGASFEFYNYACMFMDYMYNKDMGILNKLNDLAKNNDVDGYDNYIRDLSSNYALNDKYQDHMQERIDNYENLTVPFVADDYLVRHAYKNPNEIYSEISEVAKLKDAKSEVKKSQYFSTFTLRGSYTGGASKGKLEDQKAMNKFIDDSLKKLDTYSWSGYKTLTAYFTNYKVDSSNRVTYDVVFHGYLPNEGDSKNSLPYGKINGTYKGTEKEKIKFSSEGSFDPDGKIVSYEWDFGDGNKSNEENPEHSYDKVGTYTVKLKVTDDKGESSVSTTTAEIKDLSENKLPVIYMHVPKSGALNQKVVFYGKGTYDPDGSIAGYQWDFGDGSDFSSEQNPSHVYTKKGEYTVTLRVMDSSGQMSEKTMKIKITDPVYPIGTEKEPNNSKETASGPIVPGIPVSGTIENTSDQDYFYFDVITPGEVKIDINKLGYGGATWVVYDENNNAVSYATDDGQNLSGKFKADKPGRYYIHLYMFNGSYMPYRINIEGSVGR	ba
chembl_phase_34_biotherapeutics_CONBERCEPT_20839.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	2	GRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPGPGDKTHTCPLCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKATPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CONCIZUMAB_21597.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	28	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_CONCIZUMAB_21598.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	145	84	DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CONESTAT_ALFA_20913.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NPNATSSSSQDPESLQDRGEGKVATTVISKMLFVEPILEVSSLPTTNSTTNSATKITANTTDEPTTQPTTEPTTQPTIQPTQPTTQLPTDSPTQPTTGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFVLWDQQHKFPVFMGRVYDPRA	ba
chembl_phase_34_biotherapeutics_CORIFOLLITROPIN_ALFA_20609-21718.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKESSSSKAPPPSLPSPSRLPGPSDTPILPQ	ba
chembl_phase_34_biotherapeutics_CORIFOLLITROPIN_ALFA_22162-22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_CORTICORELIN_20608.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	81	23	AIDLLKRNSHAQQALQDAKTMELVEALLHFTLDLSIPPEQS	ba
chembl_phase_34_biotherapeutics_CORTICORELIN_OVINE_TRIFLUTATE_21519.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	7	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	ba
chembl_phase_34_biotherapeutics_CORTICOTROPIN_21520.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF	ba
chembl_phase_34_biotherapeutics_CORTICOTROPIN_ZINC_HYDROXIDE_21520.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF	ba
chembl_phase_34_biotherapeutics_COSIBELIMAB_21872.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	27	EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_COSIBELIMAB_21873.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	14	7	NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_CRENEZUMAB_20691.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	121	84	DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CRENEZUMAB_20692.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	52	9	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_CRIZANLIZUMAB_21317-21755.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	12	QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVTSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGMEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCAVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_CRIZANLIZUMAB_21318-21754.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	206	84	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_CROVALIMAB_21631.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	48	QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELRRGPKVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHAHYTRKELSLSP	ba
chembl_phase_34_biotherapeutics_CROVALIMAB_21632.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	114	84	DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DACLIZUMAB_20890-21757.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	36	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DACLIZUMAB_20891-21756.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	52	DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR	ba
chembl_phase_34_biotherapeutics_DALANTERCEPT_22149.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	19	11	DPVKPSRGPLVTCTCESPHCKGPTCRGAWCTVVLVREEGRHPQEHRGCGNLHRELCRGRPTEFVNHYCCDSHLCNHNVSLVLEATQPPSEQPGTDGQLATGGGTHTCPPCPAPEALGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGPFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DARATUMUMAB_20801.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DARATUMUMAB_20802.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	78	EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DARATUMUMAB_21758.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	78	EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DARATUMUMAB_21759.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DARBEPOETIN_ALFA_20878-21760.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	16	10	APPRLICDSRVLERYLLEAKEAENITTGCNETCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQVNETLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGD	ba
chembl_phase_34_biotherapeutics_DATOPOTAMAB_DERUXTECAN_22524.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	29	QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DATOPOTAMAB_DERUXTECAN_22525.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	284	86	DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DAXIBOTULINUMTOXINA_21132.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1536	58	PFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSK	ba
chembl_phase_34_biotherapeutics_DAXIBOTULINUMTOXINA_21208.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2794	78	ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL	ba
chembl_phase_34_biotherapeutics_DAZUKIBART_22528.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	10	QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWMHWVRQAPGQGLEWMGHIDPSDSYTYYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWDYGNLLFEYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_DAZUKIBART_22555.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	84	DIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DENILEUKIN_DIFTITOX_20805-21337.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	878	56	MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT	ba
chembl_phase_34_biotherapeutics_DEPATUXIZUMAB_MAFODOTIN_21130.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	225	51	QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DEPATUXIZUMAB_MAFODOTIN_21131.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	153	86	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DEPEMOKIMAB_22167.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	28	QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DEPEMOKIMAB_22168.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	182	86	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DIBOTERMIN_ALFA_20721-21761.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR	ba
chembl_phase_34_biotherapeutics_DINUTUXIMAB_20980-21763.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	126	39	EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DINUTUXIMAB_20981-21762.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	68	EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DOMVANALIMAB_21784.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	255	48	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAFISSGSSSIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMRLDYYAMDYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_DOMVANALIMAB_22556.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	199	84	DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DONANEMAB_21290-22557.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	101	29	QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_DONANEMAB_21291-22558.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	227	86	DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DORNASE_ALFA_21509.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK	ba
chembl_phase_34_biotherapeutics_DOSTARLIMAB_21292-21765.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	55	23	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_DOSTARLIMAB_21293-21764.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	86	DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DROTRECOGIN_ALFA_(ACTIVATED)_20906-21766.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP	ba
chembl_phase_34_biotherapeutics_DULAGLUTIDE_20729-21768.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	32	9	HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_DURVALUMAB_21116.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	26	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DURVALUMAB_21117.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	116	84	EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_DURVALUMAB_21769.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	26	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_DURVALUMAB_21770.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	116	84	EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ECALLANTIDE_20748.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	14	7	EAMHSFCAFKADDGPCRAAHPRWFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRD	ba
chembl_phase_34_biotherapeutics_EFGARTIGIMOD_ALFA_21771.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	36	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_EFPEGLENATIDE_21919.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	6	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	ba
chembl_phase_34_biotherapeutics_EFPEGLENATIDE_22662.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	PSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_EFUNGUMAB_20644.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	269	54	MAEVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIKRAAALEHHHHHH	ba
chembl_phase_34_biotherapeutics_ELOTUZUMAB_20934-21801.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	214	84	DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ELOTUZUMAB_20935-21800.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	71	15	EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ELRANATAMAB_21920.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	198	44	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCRVRCPRCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ELRANATAMAB_21921.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	18	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGSGGSLPYADIVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCEVECPECPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ELRANATAMAB_22589.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ELRANATAMAB_22590.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	246	86	DIVMTQSPDSLAVSLGERATINCKSSQSLFNVRSRKNYLAWYQQKPGQPPKLLISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYDLFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EMACTUZUMAB_21047.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	44	9	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_EMACTUZUMAB_21048.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	296	86	DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EMAPALUMAB_21161.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_EMAPALUMAB_21162.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	4	NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_EMICIZUMAB_21163-21804.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	18	QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNRYTQKSLSLSP	ba
chembl_phase_34_biotherapeutics_EMICIZUMAB_21164-21803.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	5	QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQESLSLSP	ba
chembl_phase_34_biotherapeutics_EMICIZUMAB_21165-21802.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	143	84	DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ENFORTUMAB_VEDOTIN_21123.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	46	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ENFORTUMAB_VEDOTIN_21124.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	84	DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ENFORTUMAB_VEDOTIN_21805.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	46	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ENFORTUMAB_VEDOTIN_21806.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	84	DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ENFUVIRTIDE_20640-21807.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	15	FWNWLSAWKDLELLEQENKEQQNQSEEILSHILSTY	ba
chembl_phase_34_biotherapeutics_EPAFIPASE_20619.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	AAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHIMLQNSSGIEKYN	ba
chembl_phase_34_biotherapeutics_EPCORITAMAB_21992.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	195	27	EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_EPCORITAMAB_21993.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	75	14	EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_EPCORITAMAB_22597.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	124	86	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EPCORITAMAB_22598.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	80	17	QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_EPOETIN_DELTA_20716-21808.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGD	ba
chembl_phase_34_biotherapeutics_EPTINEZUMAB_21166-21811.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	21	EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDARVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_EPTINEZUMAB_21167-21810.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	188	84	QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EPTOTERMIN_ALFA_20940-21812.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	STGSKQRSQNRSKTPKNQEALRMANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH	ba
chembl_phase_34_biotherapeutics_ERENUMAB_21173-21814.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	187	64	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ERENUMAB_21174-21813.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	6	QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_ETANERCEPT_20782-21815.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	14	LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ETESEVIMAB_21922.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	229	65	EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ETESEVIMAB_21923.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	134	86	DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ETROLIZUMAB_20667.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	116	24	EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ETROLIZUMAB_20668.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	108	84	DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EVINACUMAB_21085-21816.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	129	30	EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_EVINACUMAB_21086-21817.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	170	86	DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_EVOLOCUMAB_21016-21818.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	48	12	EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_EVOLOCUMAB_21017-21850.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	14	5	ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_EXEBACASE_21296-22630.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	301	43	TTVNEALNNVRAQVGSGVSVGNGECYALASWYERMISPDATVGLGAGVGWVSGAIGDTISAKNIGSSYNWQANGWTVSTSGPFKAGQIVTLGATPGNPYGHVVIVEAVDGDRLTILEQNYGGKRYPVRNYYSAASYRQQVVHYITPPGTVAQSAPNLAGSRSYRETGTMTVTVDALNVRRAPNTSGEIVAVYKRGESFDYDTVIIDVNGYVWVSYIGGSGKRNYVATGATKDGKRFGNAWGTFK	ba
chembl_phase_34_biotherapeutics_EXENATIDE_20531-21851.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	15	SPPPAGSSPGGNKLWEIFLRVAEEEMQKSLDSTFTGEGH	ba
chembl_phase_34_biotherapeutics_FARICIMAB_21365.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	18	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_FARICIMAB_21366.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	215	27	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_FARICIMAB_21852.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	36	19	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC	ba
chembl_phase_34_biotherapeutics_FARICIMAB_22368.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	84	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FARLETUZUMAB_20556.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	84	DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FARLETUZUMAB_20557.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	18	EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_FASINUMAB_22189.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	88	20	QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_FASINUMAB_22190.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	84	DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FAVEZELIMAB_22631.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	74	15	QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_FAVEZELIMAB_22632.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	143	84	DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FELADILIMAB_21924.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	66	14	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_FELADILIMAB_21925.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	224	86	EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FIANLIMAB_21367.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	77	25	QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_FIANLIMAB_21368.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	175	84	EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FIBRINOGEN_I_125_21511.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	YVATRDNCCILDERFGSYCPTTCGIADFLSTYQTKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIMKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEGFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKYRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTIGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL	ba
chembl_phase_34_biotherapeutics_FIBRINOGEN_I_125_21512.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GHRPLDKKREEAPSLRPAPPPISGGGYRARPAKAAATQKKVERKAPDAGGCLHADPDLGVLCPTGCQLQEALLQQERPIRNSVDELNNNVEAVSQTSSSSFQYMYLLKDLWQKRQKQVKDNENVVNEYSSELEKHQLYIDETVNSNIPTNLRVLRSILENLRSKIQKLESDVSAQMEYCRTPCTVSCNIPVVSGKECEEIIRKGGETSEMYLIQPDSSVKPYRVYCDMNTENGGWTVIQNRQDGSVDFGRKWDPYKQGFGNVATNTDGKNYCGLPGEYWLGNDKISQLTRMGPTELLIEMEDWKGDKVKAHYGGFTVQNEANKYQISVNKYRGTAGNALMDGASQLMGENRTMTIHNGMFFSTYDRDNDGWLTSDPRKQCSKEDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKHGTDDGVVWMNWKGSWYSMRKMSMKIRPFFPQQ	ba
chembl_phase_34_biotherapeutics_FIBRINOGEN_I_125_21513.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GPRVVERHQSACKDSDWPFCSDEDWNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSANNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSCRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTKEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFSVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQRGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSHNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENGVVWVSFRGADYSLRAVRMKIRPLVTQ	ba
chembl_phase_34_biotherapeutics_FIGITUMUMAB_20558.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	187	86	DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FIGITUMUMAB_20559.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	147	24	EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDGWSDSYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTIQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY	ba
chembl_phase_34_biotherapeutics_FILGRASTIM_21521-22028.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_21566.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_ALFA_21566-21853.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_ALFA_22162-22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_BETA_21566-21853.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_BETA_22162-22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_DELTA_21853.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE	ba
chembl_phase_34_biotherapeutics_FOLLITROPIN_DELTA_22162.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_FORIGERIMOD_ACETATE_20954.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	RIHMVYSKRSGKPRGYAFIEY	ba
chembl_phase_34_biotherapeutics_FREMANEZUMAB_21297-21855.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	102	18	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_FREMANEZUMAB_21298-21854.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	315	86	EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FULRANUMAB_20584.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	34	EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_FULRANUMAB_21126.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	112	84	AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_FUTUXIMAB_21026.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	131	18	EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_FUTUXIMAB_21027.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	262	86	DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GALCANEZUMAB_21150-21858.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	9	QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_GALCANEZUMAB_21151-21859.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	84	DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GALINPEPIMUT-S_21176.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SGQAYMFPNAPYLPSCLES	ba
chembl_phase_34_biotherapeutics_GALINPEPIMUT-S_21177.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	RSDELVRHHNMHQRNMTKL	ba
chembl_phase_34_biotherapeutics_GALINPEPIMUT-S_21178.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	PGCNKRYFKLSHLQMHSRKHTG	ba
chembl_phase_34_biotherapeutics_GALSULFASE_20743.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	AGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM	ba
chembl_phase_34_biotherapeutics_GALSULFASE_21860.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	AGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM	ba
chembl_phase_34_biotherapeutics_GANITUMAB_20826.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GANITUMAB_20827.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	50	11	QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_GANTENERUMAB_20657.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	172	84	DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GANTENERUMAB_20658.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	31	QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_GARETOSMAB_21371.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	174	32	QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_GARETOSMAB_22765.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GEFURULIMAB_22664.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	301	35	EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSSGGGGAGGGGAGGGGSEVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS	ba
chembl_phase_34_biotherapeutics_GEVOKIZUMAB_20669.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	86	DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GEVOKIZUMAB_20670.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	128	29	QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVTSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGMEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_GIRENTUXIMAB_20847.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	41	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_GIRENTUXIMAB_20848.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	351	86	DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GLOFITAMAB_21599.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	262	52	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKSCDGGGGSGGGGSQAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVLSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_GLOFITAMAB_21600.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	243	52	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_GLOFITAMAB_22666.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	201	34	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GLOFITAMAB_22667.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	84	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIKRTVAAPSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GLUCAGON_HYDROCHLORIDE_21567.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	ba
chembl_phase_34_biotherapeutics_GLUCARPIDASE_20779-21862.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1283	51	MRPSIHRTAIAAVLATAFVAGTALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMARRLIMDLGAGK	ba
chembl_phase_34_biotherapeutics_GONADOTROPIN,_CHORIONIC_22193.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ	ba
chembl_phase_34_biotherapeutics_GONADOTROPIN,_CHORIONIC_22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_GOTISTOBART_22214.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	16	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGLSWIRQPPGKGLEWIGYIWYDGNTNFHSPLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKTEGHYYGSNYGYYALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIAATISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_GOTISTOBART_22215.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	191	86	DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKQGKAPKLLLYAATNLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQHLWGTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_GUSELKUMAB_21001-21894.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	29	6	EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_GUSELKUMAB_21002-21863.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	32	10	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_IANALUMAB_21836.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	43	QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_IANALUMAB_21837.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	254	84	DIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_IBALIZUMAB_20540-21896.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	244	86	DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_IBALIZUMAB_20541-21895.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	29	QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_IBRITUMOMAB_TIUXETAN_20873.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	52	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN	ba
chembl_phase_34_biotherapeutics_IBRITUMOMAB_TIUXETAN_20874.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	813	85	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR	ba
chembl_phase_34_biotherapeutics_IBRITUMOMAB_TIUXETAN_21897.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	52	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN	ba
chembl_phase_34_biotherapeutics_IBRITUMOMAB_TIUXETAN_21898.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	813	85	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR	ba
chembl_phase_34_biotherapeutics_IDARUCIZUMAB_21089-21899.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	201	53	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC	ba
chembl_phase_34_biotherapeutics_IDARUCIZUMAB_21090-21900.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	84	DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_IMDEVIMAB_21929.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	23	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_IMDEVIMAB_21930.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	6	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_IMIGLUCERASE_21548-21901.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWHRQ	ba
chembl_phase_34_biotherapeutics_IMLIFIDASE_21902.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	497	34	MDSFSANQEIRYSEVTPYHVTSVWTKGVTPPANFTQGEDVFHAPYVANQGWYDITKTFNGKDDLLCGAATAGNMLHWWFDQNKDQIKRYLEEHPEKQKINFNGEQMFDVKEAIDTKNHQLDSKLFEYFKEKAFPYLSTKHLGVFPDHVIDMFINGYRLSLTNHGPTPVKEGSKDPRGGIFDAVFTRGDQSKLLTSRHDFKEKNLKEISDLIKKELTEGKALGLSHTYANVRINHVINLWGADFDSNGNLKAIYVTDSDSNASIGMKKYFVGVNSAGKVAISAKEIKEDNIGAQVLGLFTLSTGQDSWNQTN	ba
chembl_phase_34_biotherapeutics_IMSIDOLIMAB_21931.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	28	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWVRQAPRQGLEWMGMFHPTGDVTRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARTTSMIIGGFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_IMSIDOLIMAB_21972.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	84	DIVMTQTPLSLSVTPGQPASISCRSSKSLLHRNAITYFYWYLHKPGQPPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_INCLACUMAB_22195.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	94	38	EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_INCLACUMAB_22196.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_INDIUM_IN_111_SATUMOMAB_PENDETIDE_20918.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	542	85	QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR	ba
chembl_phase_34_biotherapeutics_INDIUM_IN_111_SATUMOMAB_PENDETIDE_20919.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	165	49	DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN	ba
chembl_phase_34_biotherapeutics_INSULIN_ASPART_20895-21904.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTDKT	ba
chembl_phase_34_biotherapeutics_INSULIN_ASPART_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_DEGLUDEC_20585-21905.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPL	ba
chembl_phase_34_biotherapeutics_INSULIN_DEGLUDEC_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_DETEMIR_20615-21906.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPK	ba
chembl_phase_34_biotherapeutics_INSULIN_DETEMIR_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_GLARGINE_20706-21908.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCG	ba
chembl_phase_34_biotherapeutics_INSULIN_GLARGINE_20707-21907.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR	ba
chembl_phase_34_biotherapeutics_INSULIN_GLULISINE_20712-21909.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVKQHLCGSHLVEALYLVCGERGFFYTPET	ba
chembl_phase_34_biotherapeutics_INSULIN_GLULISINE_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_HUMAN_21515-21910.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPKT	ba
chembl_phase_34_biotherapeutics_INSULIN_HUMAN_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_LISPRO_21568-21911.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTKPT	ba
chembl_phase_34_biotherapeutics_INSULIN_LISPRO_21570-21912.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_LISPRO_PROTAMINE_RECOMBINANT_21568.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTKPT	ba
chembl_phase_34_biotherapeutics_INSULIN_LISPRO_PROTAMINE_RECOMBINANT_21570.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_PORK_21570.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_PORK_21571.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPKA	ba
chembl_phase_34_biotherapeutics_INSULIN_PURIFIED_BEEF_21569.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCASVCSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_PURIFIED_BEEF_21571.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPKA	ba
chembl_phase_34_biotherapeutics_INSULIN_PURIFIED_PORK_21570.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GIVEQCCTSICSLYQLENYCN	ba
chembl_phase_34_biotherapeutics_INSULIN_PURIFIED_PORK_21571.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FVNQHLCGSHLVEALYLVCGERGFFYTPKA	ba
chembl_phase_34_biotherapeutics_INTERFERON_ALFA-2B_21549-22031.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	ba
chembl_phase_34_biotherapeutics_INTERFERON_ALFACON-1_20902-21913.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	10	3	MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE	ba
chembl_phase_34_biotherapeutics_INTERFERON_BETA-1A_21550-21914.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN	ba
chembl_phase_34_biotherapeutics_INTERFERON_BETA-1B_21551-21915.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	16	14	SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN	ba
chembl_phase_34_biotherapeutics_INTERFERON_GAMMA-1B_21514.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGR	ba
chembl_phase_34_biotherapeutics_IODINE_I_124_GIRENTUXIMAB_20847.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	41	DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_IODINE_I_124_GIRENTUXIMAB_20848.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	351	86	DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ISATUXIMAB_21065-21917.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	54	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ISATUXIMAB_21066-21916.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	368	86	DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ISUNAKINRA_21099.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	7	APVRSLNCRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWFLCTAMEADQPVSLTNMPDEGVMVTKFYMQFVSS	ba
chembl_phase_34_biotherapeutics_ITEPEKIMAB_21973.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	70	EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_ITEPEKIMAB_21974.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	86	DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ITOLIZUMAB_20828-22089.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	249	86	DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ITOLIZUMAB_20829-22088.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	224	54	EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_IXEKIZUMAB_20936-21952.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	246	86	DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_IXEKIZUMAB_20937-21918.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	41	11	QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_IZOKIBEP_22091.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	11	AEAKYAKEADDAAVEIASLPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPKASGSLAEAKEAANAELDSYGVSDFYKRLIDKAKTVEGVEALKDAILAALPGTGGGGSAEAKYAKEADDAAVEIASLPNLTWDQWYAFIQKLRDDPSQSSELLSEAKKLNDSQAPK	ba
chembl_phase_34_biotherapeutics_LAMPALIZUMAB_20995.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	55	27	EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT	ba
chembl_phase_34_biotherapeutics_LAMPALIZUMAB_20996.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	165	84	DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LANADELUMAB_21043-21954.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	242	58	EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_LANADELUMAB_21044-21953.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	84	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LARONIDASE_20866-21955.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	AEAPHLVHVDAARALWPLRRFWRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTHWLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSASGHFTDFEDKQQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNEPDHHDFDNVSMTMQGFLNYYDACSEGLRAASPALRLGGPGDSFHTPPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGARSSISILEQEKVVAQQIRQLFPKFADTPIYNDEADPLVGWSLPQPWRADVTYAAMVVKVIAQHQNLLLANTTSAFPYALLSNDNAFLSYHPHPFAQRTLTARFQVNNTRPPHVQLLRKPVLTAMGLLALLDEEQLWAEVSQAGTVLDSNHTVGVLASAHRPQGPADAWRAAVLIYASDDTRAHPNRSVAVTLRLRGVPPGPGLVYVTRYLDNGLCSPDGEWRRLGRPVFPTAEQFRRMRAAEDPVAAAPRPLPAGGRLTLRPALRLPSLLLVHVCARPEKPPGQVTRLRALPLTQGQLVLVWSDEHVGSKCLWTYEIQFSQDGKAYTPVSRKPSTFNLFVFSPDTGAVSGSYRVRALDYWARPGPFSDPVPYLEVPVPRGPPSPGNP	ba
chembl_phase_34_biotherapeutics_LATOZINEMAB_22128.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	32	9	QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGTIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQGSIKQGYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LATOZINEMAB_22129.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	170	84	DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSTGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRAEAEDVGVYYCMQQQEAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LEBRIKIZUMAB_20570.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	206	84	DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LEBRIKIZUMAB_20571.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	198	74	QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_LECANEMAB_21680.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	68	EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LECANEMAB_21681.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	86	DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LEMZOPARLIMAB_22130.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	98	23	EVQLVESGGGLVKPGGSLRLSCAASGLTFERAWMNWVRQAPGKGLEWVGRIKRKTDGETTDYAAPVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCAGSNRAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_LEMZOPARLIMAB_22131.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	86	DIVMTQSPDSLAVSLGERATINCKSSQSVLYAGNNRNYLAWYQQKPGQPPKLLINQASTRASGVPDRFSGSGSGTEFTLIISSLQAEDVAIYYCQQYYTPPLAFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LENZILUMAB_21104.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	89	22	QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LENZILUMAB_21105.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	277	84	EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LEPIRUDIN_20849-21956.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	7	7	LTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ	ba
chembl_phase_34_biotherapeutics_LERONLIMAB_21377.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	24	7	EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_LERONLIMAB_21378.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	84	DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LIGELIZUMAB_21061.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	16	QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LIGELIZUMAB_21062.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	211	84	EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LINVOSELTAMAB_22414.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	99	43	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_LINVOSELTAMAB_22734.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	86	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LINVOSELTAMAB_22735.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	29	9	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNRFTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LIRENTELIMAB_21977.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	253	76	EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LIRENTELIMAB_21978.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	95	19	EVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LITIFILIMAB_22133.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	37	DVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGKGLEWVATISPGDSFGYYYPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRDIYYNYGAWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_LITIFILIMAB_22134.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	84	DIQLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANEDPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_LIXISENATIDE_20879-21958.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	23	6	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK	ba
chembl_phase_34_biotherapeutics_LONCASTUXIMAB_TESIRINE_21309.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	19	QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_LUSPATERCEPT_20974.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWDDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTGGGTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_LUSPATERCEPT_21960.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWDDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTGGGTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MAFTIVIMAB_21382.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	133	86	DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MAFTIVIMAB_21383.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	67	20	EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MAGROLIMAB_21643.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	187	86	DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MAGROLIMAB_21644.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	25	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_MARGETUXIMAB_21003.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	14	QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELVGGPSVFLLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPPEEQYNSTLRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPLVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MARGETUXIMAB_21004.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	349	84	DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MARSTACIMAB_21198.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	140	41	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_MARSTACIMAB_21199.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	6	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_MECASERMIN_21961-22197.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	ba
chembl_phase_34_biotherapeutics_MECASERMIN_RINFABATE_20943.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	22	12	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAGASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK	ba
chembl_phase_34_biotherapeutics_MIRIKIZUMAB_21200.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	43	QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_MIRIKIZUMAB_21201.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	84	DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MIRVETUXIMAB_SORAVTANSINE_21091.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	17	QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_MIRVETUXIMAB_SORAVTANSINE_21092.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	413	86	DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MODOTUXIMAB_21202.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	146	27	QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_MODOTUXIMAB_21203.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	358	86	DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOGAMULIZUMAB_20673.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	25	QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MOGAMULIZUMAB_20674.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOGAMULIZUMAB_21962.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	25	QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MOGAMULIZUMAB_21963.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOSUNETUZUMAB_21964.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	27	EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MOSUNETUZUMAB_21965.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	84	DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOSUNETUZUMAB_21966.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	134	17	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MOSUNETUZUMAB_22330.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	144	84	DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOTAVIZUMAB_20765.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	135	54	QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MOTAVIZUMAB_20766.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	84	DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MOXETUMOMAB_PASUDOTOX_20677.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1040	65	MEVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSAKASGGPEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAANGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPREDLK	ba
chembl_phase_34_biotherapeutics_MOXETUMOMAB_PASUDOTOX_20678.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	38	MDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEIK	ba
chembl_phase_34_biotherapeutics_MOXETUMOMAB_PASUDOTOX_21967.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	38	MDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEIK	ba
chembl_phase_34_biotherapeutics_MOXETUMOMAB_PASUDOTOX_21968.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1040	65	MEVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSAKASGGPEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAANGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPREDLK	ba
chembl_phase_34_biotherapeutics_MUPADOLIMAB_21878.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	60	13	QVQLVQSGAEVEKPGASVKVSCKASGYTFTSYWITWVRQAPGQGLEWMGDIYPGSGNTNYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCAKEGGLTTEDYALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MUPADOLIMAB_21879.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	222	84	EIVLTQSPATLSLSPGERATLSCRASKNVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQHSRELPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_MUROMONAB-CD3_20859.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	268	43	QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSAKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_MUROMONAB-CD3_20860.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	256	42	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	ba
chembl_phase_34_biotherapeutics_NARLUMOSBART_22387.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	7	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_NARLUMOSBART_22388.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	84	EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NARSOPLIMAB_21384.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	30	QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_NARSOPLIMAB_21385.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	7	5	QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_NAVICIXIZUMAB_21204.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	187	27	QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVEGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSELTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NAVICIXIZUMAB_21205.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	196	84	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NAVICIXIZUMAB_21206.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	66	12	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREKMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLKSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NAVICIXIZUMAB_21207.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	204	84	DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVVYYCQQSKEVPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NAXITAMAB_21386.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	156	25	QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NAXITAMAB_21387.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	408	86	EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NECITUMUMAB_20572.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	77	EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NECITUMUMAB_20573.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	68	15	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NECITUMUMAB_21969.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	77	EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NECITUMUMAB_21970.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	68	15	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NEPIDERMIN_20840.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR	ba
chembl_phase_34_biotherapeutics_NESIRITIDE_20915.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	ba
chembl_phase_34_biotherapeutics_NIPOCALIMAB_21719.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	151	21	EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_NIPOCALIMAB_21720.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	6	QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_NIRSEVIMAB_21341-22012.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	128	17	QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NIRSEVIMAB_21342-21971.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	84	DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NISEVOKITUG_22433.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	128	44	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLWEVRALPSVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVTSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGMEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_NISEVOKITUG_22434.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	3	SYELTQPPSVSVAPGQTARITCGANDIGSKSVHWYQQKAGQAPVLVVSEDIIRPSGIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDRDSDQYVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_NIVOLUMAB_22013.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	132	64	QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_NIVOLUMAB_22014.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	107	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NIVOLUMAB_22198.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	132	64	QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_NIVOLUMAB_22199.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	107	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_NOGAPENDEKIN_ALFA_21721.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	64	25	NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANDSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS	ba
chembl_phase_34_biotherapeutics_NOMACOPAN_21343.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	103	27	DSESDCTGSEPVDAFQAFSEGKEAYVLVRSTDPKARDCLKGEPAGEKQDNTLPVMMTFKNGTDWASTDWTFTLDGAKVTATLGNLTQNREVVYDSQSHHCHVDKVEKEVPDYEMWMLDAGGLEVEVECCRQKLEELASGRNQMYPHLKDC	ba
chembl_phase_34_biotherapeutics_NONACOG_BETA_PEGOL_20908-22015.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	18	9	YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT	ba
chembl_phase_34_biotherapeutics_OBILTOXAXIMAB_21080.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	51	QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OBILTOXAXIMAB_21081.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	253	91	DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OBINUTUZUMAB_20930-22017.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	251	84	DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OBINUTUZUMAB_20931-22016.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	128	52	QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OCIPERLIMAB_21467.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	11	EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OCIPERLIMAB_21468.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	84	EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OCRIPLASMIN_20663-22018.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN	ba
chembl_phase_34_biotherapeutics_OCRIPLASMIN_20664-22019.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APSFDCGKPQVEPKKCPGR	ba
chembl_phase_34_biotherapeutics_ODESIVIMAB_21390.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	43	12	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ODESIVIMAB_21391.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	84	DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OLARATUMAB_20767.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OLARATUMAB_20768.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	215	63	QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OLARATUMAB_22020.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OLARATUMAB_22021.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	215	63	QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OLECLUMAB_21214.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	107	32	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OLECLUMAB_21215.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	139	63	QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_OLIPUDASE_ALFA_21157-22022.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC	ba
chembl_phase_34_biotherapeutics_OLOKIZUMAB_20797.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	240	86	DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OLOKIZUMAB_20798.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	90	23	EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_OMALIZUMAB_20739-22024.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	23	EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OMALIZUMAB_20740-22023.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	158	84	DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR	ba
chembl_phase_34_biotherapeutics_ONARTUZUMAB_20679.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	196	27	EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ONARTUZUMAB_20680.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	3	3	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ONARTUZUMAB_20681.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	84	DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_OPORTUZUMAB_MONATOX_20811-22230.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1394	53	HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRATPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL	ba
chembl_phase_34_biotherapeutics_OPRELVEKIN_20875.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL	ba
chembl_phase_34_biotherapeutics_OTELIXIZUMAB_20545.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	192	48	DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_OTELIXIZUMAB_20546.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	165	42	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OTILIMAB_21347.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	24	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_OTILIMAB_21348.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	55	14	DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_PALIFERMIN_20742.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT	ba
chembl_phase_34_biotherapeutics_PALIFERMIN_22026.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT	ba
chembl_phase_34_biotherapeutics_PAMREVLUMAB_21218.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	51	37	EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_PAMREVLUMAB_21219.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	86	DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PARATHYROID_HORMONE_20591-22027.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTKAKSQ	ba
chembl_phase_34_biotherapeutics_PATRITUMAB_22202.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	6	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_PATRITUMAB_22203.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	174	84	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PATRITUMAB_DERUXTECAN_22259.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	174	84	DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PATRITUMAB_DERUXTECAN_22260.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	6	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_PEGADEMASE_BOVINE_21552.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	209	19	AQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDTTLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPA	ba
chembl_phase_34_biotherapeutics_PEGARGIMINASE_21073.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1398	62	SVFDSKFNGIHVYSEIGELETVLVHEPGREIDYITPARLDELLFSAILESHDARKEHQSFVKIMKDRGINVVELTDLVAETYDLASKAAKEEFIETFLEETVPVLTEANKEAVRAFLLSKPTHEMVEFMMSGITKYELGVESENELIVDPMPNLYFTRDPFASVGNGVTIHFMRYIVRRRETLFARFVFRNHPKLVKTPWYYDPAMKMSIEGGDVFIYNNETLVVGVSERTDLDTITLLAKNIKANKEVEFKRIVAINVPKWTNLMHLDTWLTMLDKNKFLYSPIANDVFKFWDYDLVNGGAEPQPQLNGLPLDKLLASIINKEPVLIPIGGAGATEMEIARETNFDGTNYLAIKPGLVIGYDRNEKTNAALKAAGITVLPFHGNQLSLGMGNARCMSMPLSRKDVKW	ba
chembl_phase_34_biotherapeutics_PEGFILGRASTIM_21521-22028.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP	ba
chembl_phase_34_biotherapeutics_PEGINTERFERON_ALFA-2A_20741-22029.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	140	34	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	ba
chembl_phase_34_biotherapeutics_PEGINTERFERON_ALFA-2B_21549-22031.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	ba
chembl_phase_34_biotherapeutics_PEGLOTICASE_20965-22030.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	674	67	TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL	ba
chembl_phase_34_biotherapeutics_PEGOZAFERMIN_21506.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	8	8	MHPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPTQGASPSYAS	ba
chembl_phase_34_biotherapeutics_PEGUNIGALSIDASE_ALFA_21724.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	GLDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLLSEKDEL	ba
chembl_phase_34_biotherapeutics_PEGVISOMANT_21549-22031.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	ba
chembl_phase_34_biotherapeutics_PEGZILARGINASE_22262.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK	ba
chembl_phase_34_biotherapeutics_PEMBROLIZUMAB_21014-22063.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	103	18	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_PEMBROLIZUMAB_21015-22064.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	172	84	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PENPULIMAB_21832.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	285	68	DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PENPULIMAB_22177.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	90	20	EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_PEXIGANAN_20700.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	32	KKLIKVFAKGFKKAKKLFKGIG	ba
chembl_phase_34_biotherapeutics_POLATUZUMAB_VEDOTIN_21112-22066.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	27	EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_POLATUZUMAB_VEDOTIN_21113-22065.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	206	84	DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_POZELIMAB_21401.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	10	QVQLQESGPGLVKPSETLSLTCTVSGDSVSSSYWTWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCAREGNVDTTMIFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_POZELIMAB_21402.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	116	84	AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFAGRGSGTDFTLTISSLQPEDFATYYCLQDFNYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_PRABOTULINUMTOXIN_A_21349.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	3804	75	MNINDNLSINSPVDNKNVVVVRARKTDTVFKAFKVAPNIWVAPERYYGESLSIDEEYKVDGGIYDSNFLSQDSEKDKFLQAIITLLKRINSTNAGEKLLSLISTAIPFPYGYIGGGYYAPNLVITFGSAPKSNKKLNSLISSTIPFPYAGYRETNYLSSEDNKSFYASNIVIFGPGANIVENNTVFYKKEDAENGMGTMTEIWFQPFLTYKYDEFYIDPAIELIKCLIKSLYFLYGIKPSDDLVIPYRLRSELENIEYSQLNIVDLLVSGGIDPKFINTDPYWFTDNYFSNAKKVFEDHRNIYETEIEGNNAIGNDIKLRLKQKFRININDIWELNLNYFSKEFSIMMPDRFNNALKHFYRKQYYKIDYPENYSINGFVNGQINAQLSLSDRNQDIINKPEEIINILLNGNNVSLMRSNIYGDGLKSTVDDFYSNYKIPYNRAYEYHFNNSNDSSLDNVNIGVIDNIPEIIDVNPYKENCDKFSPVQKITSTREINTNIPWPINYLQAQNTNNEKFSLSSDFVEVVSSKDKSLVYSFLSNVMFYLDSIKDNSPIDTDKKYYLWLREIFRNYSFDITATQEINTNCGINKVVTWFGKALNILNTSDSFVEEFQNLGAISLINKKENLSMPIIESYEIPNDMLGLPLNDLNEKLFNIYSKNTAYFKKIYYNFLDQWWTQYYSQYFDLICMAKRSVLAQETLIKRIIQKKLSYLIGNSNISSDNLALMNLTTTNTLRDISNESQIAMNNVDSFLNNAAICVFESNIYPKFISFMEQCINNINIKTKEFIQKCTNINEDEKLQLINQNVFNSLDFEFLNIQNMKSLFSSETALLIKEETWPYELVLYAFKEPGNNVIGDASGKNTSIEYSKDIGLVYGINSDALYLNGSNQSISFSNDFFENGLTNSFSIYFWLRNLGKDTIKSKLIGSKEDNCGWEIYFQDTGLVFNMIDSNGNEKNIYLSDVSNNSWHYITISVDRLKEQLLIFIDDNLVANESIKEILNIYSSNIISLLSENNPSYIEGLTILNKPTTSQEVLSNYFEVLNNSYIRDSNEERLEYNKTYQLYNYVFSDKPICEVKQNNNIYLTINNTNNLNLQASKFKLLSINPNKQYVQKLDEVIISVLDNMEKYIDISEDNRLQLIDNKNNAKKMIISNDIFISNCLTLSYNGKYICLSMKDENHNWMICNNDMSKYLYLWSFK	ba
chembl_phase_34_biotherapeutics_PRABOTULINUMTOXIN_A_21350.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2796	78	ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIPDITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL	ba
chembl_phase_34_biotherapeutics_PRABOTULINUMTOXIN_A_21351.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1600	58	PFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNK	ba
chembl_phase_34_biotherapeutics_PRAMLINTIDE_20528.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	7	YTNSGVNTPPLIPGFNNSSHVLFNALRQTACTATNCK	ba
chembl_phase_34_biotherapeutics_QUAVONLIMAB_21542.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	89	14	EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_QUAVONLIMAB_21543.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	291	86	DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RACOTUMOMAB_20841.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	255	32	DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	ba
chembl_phase_34_biotherapeutics_RACOTUMOMAB_20842.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	548	41	QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMNTNGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK	ba
chembl_phase_34_biotherapeutics_RAMUCIRUMAB_20562.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	61	DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RAMUCIRUMAB_20563.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	8	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_RAMUCIRUMAB_22067.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	142	61	DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RAMUCIRUMAB_22068.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	8	EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_RANIBIZUMAB_20745-22069.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	100	18	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK	ba
chembl_phase_34_biotherapeutics_RANIBIZUMAB_20746-22070.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	84	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE	ba
chembl_phase_34_biotherapeutics_RANPIRNASE_20629.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	192	91	EDWLTFQKKHITNTRDVDCDNIMSTNLFHCKDKNTFIYSRPEPVKAICKGIIASKNVLTTSEFYLSDCNVTSRPCKYKLKKSTNKFCVTCENQAPVHFVGVGSC	ba
chembl_phase_34_biotherapeutics_RASBURICASE_20903-22071.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	507	58	SAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKADNSVIVATDSIKNTIYITAKQNPVTPPELFGSILGTHFIEKYNHIHAAHVNIVCHRWTRMDIDGKPHPHSFIRDSEEKRNVQVDVVEGKGIDIKSSLSGLTVLKSTNSQFWGFLRDEYTTLKETWDRILSTDVDATWQWKNFSGLQEVRSHVPKFDATWATAREVTLKTFAEDNSASVQATMYKMAEQILARQQLIETVEYSLPNKHYFEIDLSWHKGLQNTGKNAEVFAPQSDPNGLIKCTVGRSSLKSKL	ba
chembl_phase_34_biotherapeutics_RAVULIZUMAB_21228-22073.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	183	84	DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RELABOTULINUMTOXINA_21727.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4395	78	PFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL	ba
chembl_phase_34_biotherapeutics_RELATLIMAB_21230.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	71	EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_REMTERNETUG_21545.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	44	18	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGGSGSYYNGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_REMTERNETUG_21546.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	84	DIQMTQSPSTLSASVGDRVTITCRASQSLGNWLAWYQQKPGKAPKLLIYQASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYKGSFWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RETIFANLIMAB_21728.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	81	21	QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_RETIFANLIMAB_21729.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	168	84	EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_REVEGLUCOSIDASE_ALFA_21139.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	61	17	ALCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLETYCATPAKSEGAPAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC	ba
chembl_phase_34_biotherapeutics_RILONACEPT_20747-22074.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	3	3	SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_RILOTUMUMAB_20564.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	125	86	EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RILOTUMUMAB_20565.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	97	22	QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_RIMABOTULINUMTOXINB_21563-22076.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1041	52	MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVK	ba
chembl_phase_34_biotherapeutics_RIMABOTULINUMTOXINB_21564-22075.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2749	74	APGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE	ba
chembl_phase_34_biotherapeutics_RISANKIZUMAB_21232-22104.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	33	9	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_RISANKIZUMAB_21233-22077.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	238	86	DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_RITUXIMAB_20834-22106.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	145	20	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_RITUXIMAB_20835-22105.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	364	86	QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ROCATINLIMAB_22301.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	62	24	QITLKESGPTLVKPKQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAVIYWDDHQLYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRGAFQHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ROCATINLIMAB_22302.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	108	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ROMIPLOSTIM_20547.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	22	MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA	ba
chembl_phase_34_biotherapeutics_ROMIPLOSTIM_22107.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	22	MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA	ba
chembl_phase_34_biotherapeutics_ROMLUSEVIMAB_21602.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	40	QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSSEITTLGGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ROMLUSEVIMAB_21603.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	8	SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_ROMOSOZUMAB_22108-22206.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	251	84	DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ROMOSOZUMAB_22109-22205.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	46	9	EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ROSMANTUZUMAB_21234.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	78	15	QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_ROSMANTUZUMAB_21235.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	68	DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ROVALPITUZUMAB_TESIRINE_21238.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	291	86	EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ROZANOLIXIZUMAB_22326.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	19	EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_ROZANOLIXIZUMAB_22327.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	260	86	DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SABATOLIMAB_21932.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	75	18	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_SABATOLIMAB_21933.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	210	84	AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SACITUZUMAB_GOVITECAN_21140-22746.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	104	27	QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SACITUZUMAB_GOVITECAN_21141-22747.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	234	84	DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SARGRAMOSTIM_22207.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	17	APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE	ba
chembl_phase_34_biotherapeutics_SARILUMAB_21473.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	51	EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SARILUMAB_21474.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	86	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SARILUMAB_22110.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	51	EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SARILUMAB_22111.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	86	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SASANLIMAB_21408.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	75	19	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_SASANLIMAB_22331.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	151	84	DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SATRALIZUMAB_21239-22113.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	40	QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKSCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHAHYTQKSLSLSP	ba
chembl_phase_34_biotherapeutics_SATRALIZUMAB_21240-22112.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	43	DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIERTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SEBELIPASE_ALFA_21025.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ	ba
chembl_phase_34_biotherapeutics_SEBELIPASE_ALFA_22114.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ	ba
chembl_phase_34_biotherapeutics_SECRETIN_SYNTHETIC_HUMAN_21572.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HSDGTFTSELSRLREGARLQRLLQGLV	ba
chembl_phase_34_biotherapeutics_SECRETIN_SYNTHETIC_PORCINE_21573.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	12	HSDGTFTSELSRLRDSARLQRLLQGLV	ba
chembl_phase_34_biotherapeutics_SECUKINUMAB_20926.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	86	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SECUKINUMAB_20927.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	238	65	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SECUKINUMAB_22115.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	86	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SECUKINUMAB_22116.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	238	65	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SEMAGLUTIDE_20690-22117.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	48	23	HEGTFTSDVSESYLEGQAAKEFIAWLVRGRG	ba
chembl_phase_34_biotherapeutics_SEMZUVOLIMAB_22059.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	86	DIVLTQSPASLAVSLGQRATITCKAGQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEENDAATYYCQQSYKDPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SEMZUVOLIMAB_22060.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	94	13	QVQLVQSGPELKKPGASVKVSCKASGYTFTDYVIHWVKQATGQGLEWIGEIYPGSGSAYSNAKFKDRVTMTADKSSNTAYMELSSLTSDDTAVYFCARRGNGTGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYHSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SERACTIDE_ACETATE_21553.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	9	9	SYSMEHFRWGKPVGKKRRPVKVYPDAGEDQSAEAFPLEF	ba
chembl_phase_34_biotherapeutics_SERELAXIN_20922.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	QLYSALANKCCHVGCTKRSLARFC	ba
chembl_phase_34_biotherapeutics_SERELAXIN_20923.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DSWMEEVIKLCGRELVRAQIAICGMSTWS	ba
chembl_phase_34_biotherapeutics_SERMORELIN_ACETATE_21554.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	YADAIFTNSYRKVLGQLSARKLLQDIMSR	ba
chembl_phase_34_biotherapeutics_SILTUXIMAB_20661-22119.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	342	86	QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SILTUXIMAB_20662-22118.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	214	31	EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SIMOCTOCOG_ALFA_20844-22152.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	8	4	ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHQAYRYRRGEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY	ba
chembl_phase_34_biotherapeutics_SINTILIMAB_21934.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	78	16	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_SINTILIMAB_21935.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	256	84	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SIRUKUMAB_20928.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	229	84	EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SIRUKUMAB_20929.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	173	67	EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SOCAZOLIMAB_21612.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	67	32	EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPYYYYYMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SOCAZOLIMAB_21613.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	36	9	QSALTQPASVSGSLGQSVTISCTGSSSDVGSYNLVSWYQQHPGKAPNLMIYDVSKRSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGISTVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_SOLANEZUMAB_20651.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	84	DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SOLANEZUMAB_20652.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	102	43	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_SOMATREM_21555.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	ba
chembl_phase_34_biotherapeutics_SOMATROPIN_21556-22153.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	ba
chembl_phase_34_biotherapeutics_SOMAVARATAN_21155.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	21	8	AEPAGSPTSTEEGTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAPGFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGFGGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPG	ba
chembl_phase_34_biotherapeutics_SOTATERCEPT_21476.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	11	ILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPTGGGTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SPARTALIZUMAB_21409.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	13	EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG	ba
chembl_phase_34_biotherapeutics_SPARTALIZUMAB_21410.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	118	84	EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SPESOLIMAB_21937.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	127	37	QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SPESOLIMAB_21938.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	274	86	QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_STAPOKIBART_22238.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	44	EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVSTISSGGSYTNYADSVKGRFTISRDNVKNTLYLQMNSLRAEDTAVYYCARATARATEFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_STAPOKIBART_22239.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	219	84	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SUPTAVUMAB_21144.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	25	EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SUPTAVUMAB_21145.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	84	EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SUTIMLIMAB_21776.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	80	22	EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_SUTIMLIMAB_21777.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	86	QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_SUVRATOXUMAB_21241.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	24	9	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_SUVRATOXUMAB_21242.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	105	84	DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TABALUMAB_20689.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	28	6	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TABALUMAB_21250.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	152	84	EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSNTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TADEKINIG_ALFA_20734.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	TPVSQTTTAATASVRSTKDPHCPSQPPVFPAAKQCPALEVTWPEVEVPLNGTLSLSCVACSRFPNFSILYWLGNGSFIEHLPGRLWEGSTSRERGSTGTQLCKALVLEQLTPALHSTNFSCVLVDPEQVVQRHVVLAQLWAGLRATLPPTQEALPSSHSSPQQQG	ba
chembl_phase_34_biotherapeutics_TAFASITAMAB_21411.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	125	37	EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TAFASITAMAB_21412.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	206	86	DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TAGRAXOFUSP_22154.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	880	56	MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTRPHMAPMTQTTSLKTSWVNCSNMIDEIITHLKQPPLPLLDFNNLNGEDQDILMENNLRRPNLEAFNRAVKSLQNASAIESILKNLLPCLPLATAAPTRHPIHIKDGDWNEFRRKLTFYLKTLENAQAQQTTLSLAIF	ba
chembl_phase_34_biotherapeutics_TALACTOFERRIN_ALFA_20945.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	22	GRRRRSVQWCTVSQPEATKCFQWQRNMRRVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK	ba
chembl_phase_34_biotherapeutics_TALDEFGROBEP_ALFA_21358-22364.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	193	48	DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESAAEAQEGELEGVSDVPRDLEVVAATPTSLLISWSLPHQGKANYYRITYGETGGNSPVQEFTVPGRGVTATISGLKPGVDYTITVYAVTVTDTGYLKYKPISINYRTEI	ba
chembl_phase_34_biotherapeutics_TALQUETAMAB_21939.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	50	QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TALQUETAMAB_21940.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	212	29	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TALQUETAMAB_22365.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	6	QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TALQUETAMAB_22366.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	290	86	DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TARCOCIMAB_TEDROMER_22367.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	18	EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSCSPGK	ba
chembl_phase_34_biotherapeutics_TARCOCIMAB_TEDROMER_22368.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	84	DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TARLATAMAB_21652.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	277	22	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS	ba
chembl_phase_34_biotherapeutics_TASONERMIN_20588-22155.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL	ba
chembl_phase_34_biotherapeutics_TEBENTAFUSP_22156.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	298	45	AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSGGGGSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLIYYSWAQGDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWGAPYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD	ba
chembl_phase_34_biotherapeutics_TEBENTAFUSP_22157.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	9	AQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREKHSGRLRVTLDTSKKSSSLLITASRAADTASYFCATDGSTPMQFGKGTRLSVIANIQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDT	ba
chembl_phase_34_biotherapeutics_TECEMOTIDE_21034.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	STAPPAHGVTSAPDTRPAPGSTAPPKG	ba
chembl_phase_34_biotherapeutics_TECHNETIUM_TC_99M_ALBUMIN_21510.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL	ba
chembl_phase_34_biotherapeutics_TECHNETIUM_TC_99M_ALBUMIN_AGGREGATED_21510.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL	ba
chembl_phase_34_biotherapeutics_TECHNETIUM_TC_99M_ARCITUMOMAB_20795.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	66	QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC	ba
chembl_phase_34_biotherapeutics_TECHNETIUM_TC_99M_ARCITUMOMAB_20796.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	911	85	EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIVPRDCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR	ba
chembl_phase_34_biotherapeutics_TECLISTAMAB_21457.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	40	14	QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TECLISTAMAB_21940.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	212	29	EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TECLISTAMAB_22158.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	7	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKGDSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TECLISTAMAB_22365.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	37	6	QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TEDUGLUTIDE_20633-22159.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	ba
chembl_phase_34_biotherapeutics_TEPLIZUMAB_20774.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	240	84	DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQITRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TEPLIZUMAB_20775.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	19	QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TEPROTUMUMAB_20574.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	66	23	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TEPROTUMUMAB_20575.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	26	QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TERIPARATIDE_ACETATE_21557.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF	ba
chembl_phase_34_biotherapeutics_TERTOMOTIDE_20833.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	EARPALLTSRLRFIPK	ba
chembl_phase_34_biotherapeutics_TESAMORELIN_20749.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	18	LRARAGREQNSEGQQRSMIDQLLKRASLQGLVKRYSNTFIADAY	ba
chembl_phase_34_biotherapeutics_TESAMORELIN_ACETATE_20968.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL	ba
chembl_phase_34_biotherapeutics_TEZEPELUMAB_21152-22161.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	97	17	QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TEZEPELUMAB_21153-22160.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	10	7	SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_THROMBOMODULIN_ALFA_20946.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLMTVRSSVAADVISLLLNGDGGVGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYSRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEVKADGFLCEFHFPATCRPLAVEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAPGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNPDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALVRHIGTDCDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSG	ba
chembl_phase_34_biotherapeutics_THYMALFASIN_20601.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SDAAVDTSSEITTKDLKEKKEVVEEAEN	ba
chembl_phase_34_biotherapeutics_THYROTROPIN_21558.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	64	40	FPDGEFTMQGCPECKLKENKYFSKPDAPIYQCMGCCFSRAYPTPARSKKTMLVPKNITSEATCCVAKAFTKATVMGNVRVENHTECHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_THYROTROPIN_21559.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	17	FCIPTEYMMHVERKECAYCLTINTTVCAGYCMTRDVNGKLFLPKYALSQDVCTYRDFMYKTAEIPGCPRHVTPYFSYPVAISCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY	ba
chembl_phase_34_biotherapeutics_THYROTROPIN_ALFA_20861-22163.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSYLVGFSV	ba
chembl_phase_34_biotherapeutics_THYROTROPIN_ALFA_22162-22194.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS	ba
chembl_phase_34_biotherapeutics_TIFACOGIN_20698.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ADSEEDEEHTIITDTELPPLKLMHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQEKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPNGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIFVKNM	ba
chembl_phase_34_biotherapeutics_TIGATUZUMAB_20818.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	216	84	DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TIGATUZUMAB_20819.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	58	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TIMBETASIN_ACETATE_21778.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES	ba
chembl_phase_34_biotherapeutics_TIRAGOLUMAB_21415.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	127	53	EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TIRAGOLUMAB_21416.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	140	84	DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TISLELIZUMAB_21417.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	90	17	QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TISLELIZUMAB_21418.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	210	86	DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TISOTUMAB_VEDOTIN_21779.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	49	22	EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TISOTUMAB_VEDOTIN_21780.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	136	86	DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TIXAGEVIMAB_22079.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	175	66	QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TIXAGEVIMAB_22080.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	107	84	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TOMINERSEN_21688.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	361	86	DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TOMINERSEN_21689.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	102	17	QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TOPSALYSIN_20971.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	543	39	AEPVYPDQLRLFSLGQGVCGDKYRPVNREEAQSVKSNIVGMMGQWQISGLANGWVIMGPGYNGEIKPGTASNTWCYPTNPVTGEIPTLSALDIPDGDEVDVQWRLVHDSANFIKPTSYLAHYLGYAWVGGNHSQYVGEDMDVTRDGDGWVIRGNNDGGCDGYRCGDKTAIKVSNFAYNLDPDSFKHGDVTQSDRQLVKTVVGWAVNDSDTPQSGYDVTLRYDTATNWSKTNTYGLSEKVTTKNKFKWPLVGETELSIEIAANQSWASQNGGSTTTSLSQSVRPTVPARSKIPVKIELYKADISYPYEFKADVSYDLTLSGFLRWGGNAWYTHPDNRPNWNHTFVIGPYKDKASSIRYQWDKRYIPGEVKWWDWNWTIQQNGLSTMQNNLARVLRPVRAGITGDFSAESQFAGNIEIGAPVPLAADSHSSKLQSVDGAGQGLRLEIPLDAQELSGLGFNNVSLSVTPAANQHHHHHH	ba
chembl_phase_34_biotherapeutics_TORIPALIMAB_21987.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	71	9	QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TORIPALIMAB_21988.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	176	86	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TOSITUMOMAB_20886.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	296	68	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR	ba
chembl_phase_34_biotherapeutics_TOSITUMOMAB_20887.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	18	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TOZORAKIMAB_21655.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	103	21	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISAIDQSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQKFMQLWGGGLRYPFGYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TOZORAKIMAB_22404.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	9	SYVLTQPPSVSVSPGQTASITCSGEGMGDKYAAWYQQKPGQSPVLVIYRDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCGVIQDNTGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TRALOKINUMAB_20776.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	6	SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TRALOKINUMAB_20777.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	41	6	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TRALOKINUMAB_22165.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	41	6	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_TRALOKINUMAB_22166.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	6	SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_20867-21443.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	5	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_20868-22335.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	84	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_DERUXTECAN_22309.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	5	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_DERUXTECAN_22335.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	84	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_DUOCARMAZINE_22306.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	5	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_DUOCARMAZINE_22335.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	84	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_EMTANSINE_20778-22306.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	5	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_EMTANSINE_20868-22335.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	84	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_VEDOTIN_22309.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	27	5	EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_TRASTUZUMAB_VEDOTIN_22335.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	84	DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_TREBANANIB_20956.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	13	4	MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGAQQEECEWDPWTCEHMGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE	ba
chembl_phase_34_biotherapeutics_TRENONACOG_ALFA_21024.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT	ba
chembl_phase_34_biotherapeutics_TUROCTOCOG_ALFA_20799-21444.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY	ba
chembl_phase_34_biotherapeutics_TUSAMITAMAB_RAVTANSINE_21657.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	167	27	EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_TUSAMITAMAB_RAVTANSINE_21692.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	86	DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_UBLITUXIMAB_21100.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	110	17	QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_UBLITUXIMAB_21101.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	387	86	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ULARITIDE_20596.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	TAPRSLRRSSCFGGRMDRIGAQSGLGCNSFRY	ba
chembl_phase_34_biotherapeutics_UMESOLERBART_22344.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	64	EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSFISDSSSNIYYADSVKGRFTISRDNAKKSLYLQMTSLRAEDTAVYYCAREAIGSTSFDNWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_UMESOLERBART_22345.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	288	84	EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRRLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCHQYNNWPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_UROKINASE_21560.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	KPSSPPEELKFQCGQKTLRPRF	ba
chembl_phase_34_biotherapeutics_UROKINASE_21561.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	IIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL	ba
chembl_phase_34_biotherapeutics_UTOMILUMAB_21102.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	46	20	EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_UTOMILUMAB_21103.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	50	16	SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_VATREPTACOG_ALFA_(ACTIVATED)_20851.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	37	IVGGKDCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALVLQVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP	ba
chembl_phase_34_biotherapeutics_VATREPTACOG_ALFA_(ACTIVATED)_20852.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR	ba
chembl_phase_34_biotherapeutics_VEDOLIZUMAB_20566-21447.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	219	84	DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_VEDOLIZUMAB_20567-21446.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	110	24	QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_VELAGLUCERASE_ALFA_21448-21516.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ	ba
chembl_phase_34_biotherapeutics_VELMANASE_ALFA_21697.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	GGYETCPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTRRFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTLGLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLEMEQVWRASTSLKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELVDYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQAKGSSVHVLYSTPACYLWELNKANLTWSVKHDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFLQVCNQLEALVGLAANVGPYGSGDSAPLNEAMAVLQHHDAVSGTSRQHVANDYARQLAAGWGPCEVLLSNALARLRGFKDHFTFCQQLNISICPLSQTAARFQVIVYNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPSDVVIFPSSDSQAHPPELLFSASLPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPDTGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNESDQASGAYIFRPNQQKPLPVSRWAQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFDTPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGNMQLTVLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMENGSGAWVRGRHLVLLDTAQAAAAGHRLLAEQEVLAPQVVLAPGGGAAYNLGAPPRTQFSGLRRDLPPSVHLLTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQLREAASRLKWTTNTGPTPHQTPYQLDPANITLEPMEIRTFLASVQWKEVDG	ba
chembl_phase_34_biotherapeutics_VIBOSTOLIMAB_21819.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	91	30	EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_VIBOSTOLIMAB_21820.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	182	86	DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_VONAPANITASE_21098.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	115	50	VVGGTEAGRNSWPSQISLQYRSGGSWYHTCGGTLIRQNWVMTAAHCVDYQKTFRVVAGDHNLSQNDGTEQYVSVQKIVVHPYWNSDNVAAGYDIALLRLAQSVTLNSYVQLGVLPQEGAILANNSPCYITGWGKTKTNGQLAQTLQQAYLPSVDYAICSSSSYWGSTVKNTMVCAGGDGVRSGCQGDSGGPLHCLVNGKYSLHGVTSFVSSRGCNVSRKPTVFTRVSAYISWINNVIASN	ba
chembl_phase_34_biotherapeutics_VOSORITIDE_21156-21449.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	ba
chembl_phase_34_biotherapeutics_YTTRIUM_Y_90_CLIVATUZUMAB_TETRAXETAN_21114.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	51	12	QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
chembl_phase_34_biotherapeutics_YTTRIUM_Y_90_CLIVATUZUMAB_TETRAXETAN_21115.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	86	DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ZANIDATAMAB_22083.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	139	19	GEVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ZANIDATAMAB_22084.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	185	35	GDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG	ba
chembl_phase_34_biotherapeutics_ZANIDATAMAB_22529.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	271	84	GDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ZICONOTIDE_20527-21450.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1	1	CKGSRCSGTCCDYMLRSCKAGKGKC	ba
chembl_phase_34_biotherapeutics_ZICONOTIDE_ACETATE_21481.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	CKGKGAKCSRLMYDCCTGSCRSGKC	ba
chembl_phase_34_biotherapeutics_ZIGAKIBART_22467.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	155	32	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDAPKYNEKFKGKATMTSDTSASTAYMELSSLRSDDTAVYYCARGLGYALYYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_ZIGAKIBART_22502.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	181	86	DIVMTQSPSTLSASVGDRVTITCKASQNVGNNVAWYQQKPGKAPKLLISSASNRDSGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNIYPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ZIMBERELIMAB_21990.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	155	33	QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK	ba
chembl_phase_34_biotherapeutics_ZIMBERELIMAB_21991.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	12	QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS	ba
chembl_phase_34_biotherapeutics_ZINPENTRAXIN_ALFA_21742.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	HTDLSGKVFVFPRESVTDHVNLITPLEKPLQNFTLCFRAYSDLSRAYSLFSYNTQGRDNELLVYKERVGEYSLYIGRHKVTSKVIEKFPAPVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPKIVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIRGYVIIKPLVWV	ba
chembl_phase_34_biotherapeutics_ZOLBETUXIMAB_21743.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	208	86	DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	ba
chembl_phase_34_biotherapeutics_ZOLBETUXIMAB_21744.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	104	22	QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_AIMP1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	281	33	MATNDAVLKRLEQKGAEADQIIEYLKQQVALLKEKAILQATMREEKKLRVENAKLKKEIEELKQELILAEIHNGVEQVRVRLSTPLQTNCTASESVVQSPSVATTASPATKEQIKAGEEKKVKEKTEKKGEKKEKQQSAAASTDSKPIDASRLDLRIGCIVTAKKHPDADSLYVEEVDVGEAAPRTVVSGLVNHVPLEQMQNRMVVLLCNLKPAKMRGVLSQAMVMCASSPEKVEILAPPNGSVPGDRITFDAFPGEPDKELNPKKKIWEQIQPDLHTNAECVATYKGAPFEVKGKGVCRAQTMANSGIK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_ALKL1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	191	49	MWLTKPSTPVSALLLLALALSPPGTQGRPQRSLAARVAELRPELFLPVTGTRLPPRASRSTEIFPRDLTLKDKFIKHFTGPVTFSAECSKHFHRLYHNTRDCSTPAYYKRCARLLTRLAVSPLCSQT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_ALKL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	159	29	MRVSGRPMLLALLLLLSTVGDRGRAQSRGPADRQTLLRLLVELVQELKKFHIGDSKRLQLLGESDFALGRREATDYGADQEEQRVEIVPRDLRMKDKFLKHLTGPLYFSPKCSKHFHRLYHNTRDCTIPAYYKRCARLLTRLAVSPMCMER	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_AREG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	37	MRTPLLPLARSVLLLLVLGSGHYAAALELNDPSSGKGESLSGDHSAGGLELSVGREVSTISEMPSGSELSTGDYDYSEEYDNEPQISGYIIDDSVRVEQVIKPKKNKTEGEKSTEKPKRKKKGGKNGKGRRNKKKKNPCTAKFQNFCIHGECRYIENLEVVTCNCHQDYFGERCGEKSMKTHSEDDKDLSKIAVVAVTIFVSAIILAAIGIGIVITVHLWKRYFREYEGETEERRRLRQENGTVHAIA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	478	78	MPGVARPPLPLLSLPLLLLLLLLPRAGRPLDLADYTYDLGEEDAPELLNYKDPCKAAAFLGDIALDEEDLRAFQVQQAAVLRQQTARRPSIKAAGNSSALGGQGTSGQPQRESRGRWRGRPRSRRAATSRPERVWPDGVIPFVIGGNFTGSQRAVFRQAMRHWEKHTCVTFLERTDEDSYIVFTYRPCGCCSYVGRRGGGPQAISIGKNCDKFGIVVHELGHVIGFWHEHTRPDRDRHVSIVRENIQPGQEYNFLKMEVQEVESLGETYDFDSIMHYARNTFSRGIFLDTIVPKYEVNGVKPSIGQRTRLSKGDIAQARKLYKCPACGETLQDSTGNFSSPEYPNGYSAHMHCVWRISVTPGEKIILNFTSMDLYRSRLCWYDYVEVRDGFWRKAPLRGRFCGGKLPEPIVSTDSRLWVEFRSSSNWVGKGFFAVYEAICGGDVKKDNGHIQSPNYPDDYRPSKVCIWRIQVSEGFHVGLTFQSFEIERHDSCAYDYLEVRDGHSESSNLIGRYCGYEKPDDIKSTSSRLWLKFVSDGSINKAGFAVNFFKEVDECSRPNRGGCEQRCLNTLGSYKCSCDPGYELAPDKRRCEAACGGFLTKLNGSITSPGWPKEYPPNKNCIWQLVAPTQYRISLQFDFFETEGNDVCKYDFVEVRSGLTADSKLHGKFCGSEKPEVITSQYNNMRVEFKSDNTVSKKGFKAHFFSDKDECSKDNGGCQQDCVNTFGSYECQCRSGFVLHDNKHDCKEAGCEHKVTSTSGTITSPNWPDKYPSKKECTWAISSTPGHRVKLTFVEMDIESQPECAYDHLEVFDGRDAKAPVLGRFCGSKKPEPVLATGNRMFLRFYSDNSVQRKGFQASHSTECGGQVRADVKTKDLYSHAQFGDNNYPGGVDCEWVIVAEEGYGVELVFQTFEVEEETDCGYDYIELFDGYDSTAPRLGRYCGSGPPEEVYSAGDSVLVKFHSDDTISKKGFHLRYTSTKFQDTLHSRK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	MGSLVLPLSAVFCLVAHSASGSPIMGLEQSPLEEDMPFFDDIFTEQDGIDFNTLLQSMKNEFLKTLNLSDIPVQDTGRVDPPEYMLELYNKFATDRTSMPSANIIRSFKNEDLFSQPVTFNGLRKYPLLFNVSIPHHEEVVMAELRLYTLVQRDRMMYDGVDRKITIFEVLESADGSEEERSMLVLVSTEIYGTNSEWETFDVTDATRRWQKSGPSTHQLEIHIESRQNQAEDTGRGQLEIDMSAQNKHDPLLVVFSDDQSNDKEQKEELNELITHEQDLDLDSDAFFSGPDEEALLQMRSNMIDDSSARIRRNAKGNYCKKTPLYIDFKEIGWDSWIIAPPGYEAYECRGVCNYPLAEHLTPTKHAIIQALVHLKNSQKASKACCVPTKLDPISILYLDKGVVTYKFKYEGMAVSECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1047	83	MALLTILRILLWGVVLFMEQRVQMAKPGWPSTALLADDPTLPSILDLAKEAPGKEMKQWPQGYPLRYMLKLYHRSADPHGHPRENRTIGAKMVRLVKPSANTVRPPRGSWHVQTLDFPLASNQVAYELIRATVVYRHQLHLVNYHLSCHVETWVPKCRTKHLPSSKSGSSKPSPMSKAWTEIDITHCIQQKLWNRKGRSVLRLRFMCQQQKGNETREFRWHGMTSLDVAFLLLYFNDTDDRVQGKLLARGQEELTDRESSFLMRSVRQACSIESDASCPSQEHDGSVNNQCSLHPYKVSFHQLGWDHWIIAPRLYTPNYCKGICTRVLPYGLNSPNHAIIQSLVNELVNHSVPQPSCVPYNFLPMSILLIETNGSILYKEYEGMIAQSCTCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	39	MAGARGLLCLWLGYFCLNLAQGQRPNLHLPGLRETEPSDRATGGSPSPDLRPHDKVSEHMLWLYDRYSGSSRVQATRTPGSQLPGPQPLRGGNTVRSFRAAAAGTPQTKGLHTFNLTSLTKSENILSATLYFYVGELVNISLSCPEPQGCSHHTQRQHIQIDLSAWILKSNQSQLLGHLSVDVVRPYRDSVSWLSKDITQLLRKAKQNEEFLIGFNITSRAHELPKRMLFFPEPYILVYANDAAISEPESVVSSLQRHRDFTAGTGPRLDSHVREALSVERRKKRSTGILLPLQNNELPGAEYQYKEEGAWEERKPYKSLQTQPPEKSRNKKKQRKGSHQKGQTLQFDEQTLKKARRKQWVEPRNCARRYLKVDFADIGWSEWIISPKSFDAFYCSGACQFPMPKSLKPSNHATIQSIVRAVGVVSGIPEPCCVPEKMSSLSILFFDENKNVVLKVYPNMTVDSCACR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	5	MIPGNRMLMVVLLCQVLLGGASHASLIPETGKKKVAEIQGHAGGRRSGQSHELLRDFEATLLQMFGLRRRPQPSKSAVIPDYMRDLYRLQSGEEEEEEQSQGTGLEYPERPASRANTVRSFHHEEHLENIPGTSESSAFRFLFNLSSIPENEVISSAELRLFREQVDQGPDWEQGFHRINIYEVMKPPAEMVPGHLITRLLDTRLVHHNVTRWETFDVSPAVLRWTREKQPNYGLAIEVTHLHQTRTHQGQHVRISRSLPQGSGDWAQLRPLLVTFGHDGRGHTLTRRRAKRSPKHHPQRSRKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFPLADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKVVLKNYQEMVVEGCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	40	MHWTVFLLRGIVGFLWSGWVQVGYAKGGLGDNHVHSSFIYRRLRNHERREIQREILSILGLPHRPRPFSPGKQASSAPLFMLDLYNAMASEDNPEEYLVRVSLAGEAKETRKGYPASPNGYAHRLHLPPRTPLTTQSPPLASLHDTNFLNDADMVMSFVNLVERDKDFSHQRRHYKEFRFDLTQIPHGEAVTAAEFRIYKDKGNHRFENETIKISIYQIIKEYTNRDADLFLLDTRKTQALDVGWLVFDITVTSNHWVINPQNNLGLQLCAETGDGRSINVKSAGLVGRHGPQSKQPFMVAFFKASEVLLRSVRAASKRKNQNRNKSNSHQDPSRMPSAGDYNTSEQKQACKKHELYVSFRDLGWQDWIIAPEGYAAFYCDGECSFPLNAHMNATNHAIVQTLVHLMFPDHVPKPCCAPTKLNAISVLYFDDSSNVILKKYRNMVVRSCGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	130	16	MPGLGRRAQWLCWWWGLLCSCGPPPLRPPLPVAAAAAGGQLLGAGGSPVRAEQPPPQSSSSGFLYRRLKTHEKREMQKEILSVLGLPHRPRPLHGLQQPQPPVLPPQQQQQQQQQQTAREEPPPGRLKSAPLFMLDLYNALSNDDEEDGASEGVGQEPGSHGGASSSQLRQPSPGAAHSLNRKSLLAPGPGGGASPLTSAQDSAFLNDADMVMSFVNLVEYDKEFSPHQRHHKEFKFNLSQIPEGEAVTAAEFRVYKDCVVGSFKNQTFLISIYQVLQEHQHRDSDLFLLDTRVVWASEEGWLEFDITATSNLWVVTPQHNMGLQLSVVTRDGLHVNPRAAGLVGRDGPYDKQPFMVAFFKVSEVHVRTTRSASSRRRQQSRNRSTQSQDVSRGSGSSDYNGSELKTACKKHELYVSFQDLGWQDWIIAPKGYAANYCDGECSFPLNAHMNATNHAIVQTLVHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMVVRACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	54	MHVRSLRAAAPHSFVALWAPLFLLRSALADFSLDNEVHSSFIHRRLRSQERREMQREILSILGLPHRPRPHLQGKHNSAPMFMLDLYNAMAVEESGPDGQGFSYPYKAVFSTQGPPLASLQDSHFLTDADMVMSFVNLVEHDKEFFHPRYHHREFRFDLSKIPEGEAVTAAEFRIYKDYIRERFDNETFQITVYQVLQEHSGRESDLFLLDSRTIWASEEGWLVFDITATSNHWVVNPRHNLGLQLSVETLDGQSINPKLAGLIGRHGPQNKQPFMVAFFKATEVHLRSIRSTGGKQRSQNRSKTPKNQEALRMASVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPDTVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP8A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	399	61	MAMRPGPLWLLGLALCALGGGHGPRPPHTCPQRRLGARERRDMQREILAVLGLPGRPRPRAQPAAARQPASAPLFMLDLYHAMTDDDDGGPPQAHLGRADLVMSFVNMVERDRTLGYQEPHWKEFHFDLTQIPAGEAVTAAEFRIYKEPSTHPLNTTLHISMFEVVQEHSNRESDLFFLDLQTLRSGDEGWLVLDITAASDRWLLNHHKDLGLRLYVETADGHSMDPGLAGLLGRQAPRSRQPFMVTFFRASQSPVRAPRAARPLKRRQPKKTNELPHPNKLPGIFDDGHGSRGREVCRRHELYVSFRDLGWLDWVIAPQGYSAYYCEGECAFPLDSCMNATNHAILQSLVHLMKPDVVPKACCAPTKLSATSVLYYDSSNNVILRKHRNMVVKACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_BMP8B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	680	50	MAARPGLLWLLGLALCVLGGGHLSHPPHVFPQRRLGVREPRDMQREIREVLGLPGRPRSRAPVGAAQQPASAPLFMLDLYRAMTDDSGGGTPQPHLDRADLIMSFVNIVERDRTLGYQEPHWKEFHFDLTQIPAGEAVTAAEFRIYKEPSTHPLNTTLHISMFEVVQEHSNRESDLFFLDLQTLRSGDEGWLVLDITAASDRWLLNHHKDLGLRLYVETEDGHSIDPGLAGLLGRQAPRSRQPFMVGFFRANQSPVRAPRTARPLKKKQLNQINQLPHSNKHLGILDDGHGSHGREVCRRHELYVSFRDLGWLDSVIAPQGYSAYYCAGECIYPLNSCMNSTNHATMQALVHLMKPDIIPKVCCVPTELSAISLLYYDRNNNVILRRERNMVVQACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_C1QT4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	44	MLLLLLGFLGPAACWALGPAGPGSSELRSAFSAARTTPLEGTSEMAVTFDKVYVNIGGDFDAATGRFRCRVPGAYFFSFTAGKAPHKSLSVMLVRNRDEVQALAFDEQRRPGARRAASQSAMLQLDYGDTVWLRLHGAPQYALGAPGATFSGYLVYADADADAPARGPAAPEPRSAFSAARTRSLVGSDAAPGPRHRPLAFDTELVNIGGDFDAAAGVFRCRLPGAYFFSFTLGKLPRKTLSVKLMKNRDEVQAMIYDDGASRRREMQSQSVMLPLRRGDAVWLLSHDHDGYGAYSNHGKYITFSGFLVYPDLAAAGPPALKPPEL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CC21A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	58	18	MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIPAILFSPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSKGCKRTEQTQPSRG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CC21B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	65	18	MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIPAILFLPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSKGCKRTEQTQPSRG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CC21C_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	65	18	MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIPAILFLPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSKGCKRTEQTQPSRG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	84	23	MKPTAMALMCLLLAAVWIQDVDSKSMLTVSNSCCLNTLKKELPLKFIQCYRKMGSSCPDPPAVVFRLNKGRESCASTNKTWVQNHLKKVNPC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	160	28	MQSSTALLFLLLTVTSFTSQVLAHPGSIPTSCCFIMTSKKIPNTLLKSYKRITNNRCTLKAIVFKTRLGKEICADPKKKWVQDATKHLDQKLQTPKP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL12_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	207	33	MKISTLLCLLLIATTISPQVLAGPDAVSTPVTCCYNVVKQKIHVRKLKSYRRITSSQCPREAVIFRTILDKEICADPKEKWVKNSINHLDKTSQTFILEPSCLG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL17_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	422	79	MRSLQMLLLAALLLGTFLQHARAARATNVGRECCLDYFKGAIPIRKLVSWYKTSVECSRDAIVFLTVQGKLICADPKDKHVKKAIRLVKNPRP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL19_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	36	MAPRVTPLLAFSLLVLWTFPAPTLGGANDAEDCCLSVTQRPIPGNIVKAFRYLLNEDGCRVPAVVFTTLRGYQLCAPPDQPWVDRIIRRLKKSSAKNKGNSTRRSPVS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	83	MQVPVMLLGLLFTVAGWSIHVLAQPDAVNAPLTCCYSFTSKMIPMSRLESYKRITSSRCPKEAVVFVTKLKREVCADPKKEWVQTYIKNLDRNQMRSEPTTLFKTASALRSSAPLNVKLTRKSEANASTTFSTTTSSTSVGVTSVTVN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL20_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	224	46	MACGGKRLLFLALAWVLLAHLCSQAEAASNYDCCLSYIQTPLPSRAIVGFTRQMADEACDINAIIFHTKKRKSVCADPKQNWVKRAVNLLSLRVKKM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL22_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	111	15	MATLRVPLLVALVLLAVAIQTSDAGPYGANVEDSICCQDYIRHPLPSRLVKEFFWTSKSCRKPGVVLITVKNRDICADPRQVWVKKLLHKLS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL24_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	155	20	MAGSATIVAGLLLLVACACCIFPIDSVTIPSSCCTSFISKKIPENRVVSYQLANGSICPKAGVIFITKKGHKICTDPKLLWVQRHIQKLDAKKNQPSKGAKAVRTKFAVQRRRGNSTEV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL25_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	68	MKLWLFACLVACFVGAWMPVVHAQGAFEDCCLGYQHRIKWNVLRHARNYHQQEVSGSCNLRAVRFYFRQKVVCGNPEDMNVKRAMRILTARKRLVHWKSASDSQTERKKSNHMKSKVENPNSTSVRSATLGHPRMVMMPRKTNN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL27_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	468	42	MMEGLSPASSLPLLLLLLSPAPEAALPLPSSTSCCTQLYRQPLPSRLLRRIVHMELQEADGDCHLQAVVLHLARRSVCVHPQNRSLARWLERQGKRLQGTVPSLNLVLQKKMYSHPQQQN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL28_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	16	MQQAGLTLMAVAVCVAFQTSEAILPMASSCCTEVSHHVSGRLLERVSSCSIQRADGDCDLAAVILHVKRRRICISPHNRTLKQWMRASEVKKNGRENVCSGKKQPSRKDRKGHTTRKHRTRGTHRHEASR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	22	MKVSTTALAVLLCTMTLCNQVFSAPYGADTPTACCFSYSRKIPRQFIVDYFETSSLCSQPGVIFLTKRNRQICADSKETWVQEYITDLELNA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	163	20	MKLCVSALSLLLLVAAFCAPGFSAPMGSDPPTSCCFSYTSRQLHRSFVMDYYETSSLCSKPAVVFLTKRGRQICANPSEPWVTEYMSDLELN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	306	60	MKISAAALTIILTAAALCTPAPASPYGSDTTPCCFAYLSLALPRAHVKEYFYTSSKCSNLAVVFVTRRNRQVCANPEKKWVQEYINYLEMS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	27	MRNSKTAISFFILVAVLGSQAGLIQEMEKEDRRYNPPIIHQGFQDTSSDCCFSYATQIPCKRFIYYFPTSGGCIKPGIIFISRRGTQVCADPSDRRVQRCLSTLKQGPRSGNKVIA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	13	MRISATLLCLLLIAAAFSIQVWAQPDGPNASTCCYVKKQKIPKRNLKSYRRITSSRCPWEAVIFKTKKGMEVCAEAHQKWVEEAIAYLDMKTPTPKP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	53	MKIYAVLLCLLLIAVPVSPEKLTGPDKAPVTCCFHVLKLKIPLRVLKSYERINNIQCPMEAVVFQTKQGMSLCVDPTQKWVSEYMEILDQKSQILQP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CCL9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	191	35	MKPFHTALSFLILTTALGIWAQITHATETKEVQSSLKAQQGLEIEMFHMGFQDSSDCCLSYNSRIQCSRFIGYFPTSGGCTRPGIIFISKRGFQVCANPSDRRVQRCIERLEQNSQPRTYKQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CD40L_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	605	75	MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVLFAVYLHRRLDKVEEEVNLHEDFVFIKKLKRCNKGEGSLSLLNCEEMRRQFEDLVKDITLNKEEKKENSFEMQRGDEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKSNLVMLENGKQLTVKREGLYYVYTQVTFCSNREPSSQRPFIVGLWLKPSSGSERILLKAANTHSSSQLCEQQSVHLGGVFELQAGASVFVNVTEASQVIHRVGFSSFGLLKL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CER1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	343	34	MHLLLVQLLVLLPLGKADLCVDGCQSQGSLSFPLLERGRRDLHVANHEEAEDKPDLFVAVPHLMGTSLAGEGQRQRGKMLSRLGRFWKKPETEFYPPRDVESDHVSSGMQAVTQPADGRKVERSPLQEEAKRFWHRFMFRKGPAFQGVILPIKSHEVHWETCRTVPFNQTIAHEDCQKVVVQNNLCFGKCSSIRFPGEGADAHSFCSHCSPTKFTTVHLMLNCTSPTPVVKMVMQVEECQCMVKTERGEERLLLAGSQGSFIPGLPASKTNP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CKLF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	239	36	METPRPVVSRRPFCCTLKCFVKFLRLVVTVTSMIFFIVGQAPEPYIVITGFEVTVIFCFLVLYTCGLDKIMRSFFWPLLDVINSMVTALCMLIVSVLALIPETSTKTILGGVFGFLTVTCTIADCALMCQKLRFRPRQPYQKKSTNDIDDRE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CKLF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	460	49	MWPPDAEPEPDPESAHGPRSGRTVPGLRALLPARAFLCSLKGRLLLAESGLSFITFICYVVSSASAFLTVPLLEFLLAVYFLFADAMQLNDKWQGLCWPMMDFLRCVTAALIYFVISITAVAKYSDGAYKAAGVFGFFATIVFAIDFYLIFNEVAKFLKQGDSGNETTAHRTEEENSNSDSDSD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CKLF5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	47	MFSAWDRRERPPEEGAAAGLQGFGVDKTFLSSLKGILLETELALTFIIFICFTASISAYMAAALLEFLITLAFLFLCATQYYQRFDRLNWPCLDFLRCLSAIVIFLVVSFAAVTSREGAAIAAFVFGIILVSVFAYDAFKIYRTELMPSTTEGDQQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CKLF7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	195	21	MSHGSGLVRTTCSSGGALGPGQPSEGLLDRVYPLTHGALFKVAQMVTLLIAFICVRSSVPIDYGAHSFFEVVTMCDLIMILIFYLVHLFRFYRVLTCISWPLSELLHYLIGTLLLLIASIVIASKSYNQSGLVAGAIFGFLASFLCLASLWLSYKITCITQSSDASA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CKLF8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	54	MEEQQRARSHTVTTTTSSFAENFSTTSSSFAYDREFLRTPPGLLIVAEIVLGLLVWTLIAGTEYFRVPAFGWVMFVAVFYWVLTVFFLIVYITLTYTRIPQVPWTTVGLCFNGSAFVLYFSAAIVDASSVSPEKEGHNFNSWAASSFFAFLVTICYAGNTYFSFIAWRSRTAQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CLCF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	24	MDLRAGDSWGMLACLCTVLWHLPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLAGTYLNYLGPPFNEPDFNPPRLGAETLPRATVNLEVWRSLNDRLRLTQNYEAYSHLLCYLRGLNRQAATAELRRSLAHFCTSLQGLLGSIAGVMATLGYPLPQPLPGTEPAWAPGPAHSDFLQKMDDFWLLKELQTWLWRSAKDFNRLKKKMQPPAASVTLHLEAHGF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CLF2A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	904	83	MAAPIKFPFRPRGGQPREDTTPKRGLRRYLLELKESNKEFWLSGHAVFKLLSLGCMISALDYFETMLPHPVLILLICMEAAICIFFIFLNTLAINRYIPFVFWPMADIFNSLFSCVFLGGGIYFAFKARRLLPKPYLTAMILMGAAAICSFIDMLLQFQHFRGLRLRKW	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CLF2B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	796	56	MAAPAPRARTGGKKKDERRGFKGYKWEFRDSNKDFWAQGHAECKSLIMILLIAAMVCFQRVATHPIVILLLTMELSICAFFFFLYSLAINRYIPFVFWPMMDLMNDLACSTFLIGGIFFALEARRELPVPYLTGMILMGVTAFISIIDLCLQRRQFKSRKLRKFILLTPDRKGKKQDPKLLLMLAAKEDEEERQRELAEKAKRESMDPGW	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CSF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	561	43	MTARGAAGRCPSSTWLGSRLLLVCLLMSRSIAKEVSEHCSHMIGNGHLKVLQQLIDSQMETSCQIAFEFVDQEQLDDPVCYLKKAFFLVQDIIDETMRFKDNTPNANATERLQELSNNLNSCFTKDYEEQNKACVRTFHETPLQLLEKIKNFFNETKNLLEKDWNIFTKNCNNSFAKCSSRDVVTKPDCNCLYPKATPSSDPASASPHQPPAPSMAPLAGLAWDDSQRTEGSSLLPSELPLRIEDPGSAKQRPPRSTCQTLESTEQPNHGDRLTEDSQPHPSAGGPVPGVEDILESSLGTNWVLEEASGEASEGFLTQEAKFSPSTPVGGSIQAETDRPRALSASPFPKSTEDQKPVDITDRPLTEVNPMRPIGQTQNNTPEKTDGTSTLREDHQEPGSPHIATPNPQRVSNSATPVAQLLLPKSHSWGIVLPLGELEGKRSTRDRRSPAELEGGSASEGAARPVARFNSIPLTDTGHVEQHEGSSDPQIPESVFHLLVPGIILVLLTVGGLLFYKWKWRSHRDPQTLDSSVGRPEDSSLTQDEDRQVELPV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CSF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	384	70	MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALNLLDDMPVTLNEEVEVVSNEFSFKKLTCVQTRLKIFEQGLRGNFTKLKGALNMTASYYQTYCPPTPETDCETQVTTYADFIDSLKTFLTDIPFECKKPGQK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CSF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	68	MAQLSAQRRMKLMALQLLLWQSALWSGREAVPLVTVSALPPSLPLPRSFLLKSLEQVRKIQASGSVLLEQLCATYKLCHPEELVLLGHSLGIPKASLSGCSSQALQQTQCLSQLHSGLCLYQGLLQALSGISPALAPTLDLLQLDVANFATTIWQQMENLGVAPTVQPTQSAMPAFTSAFQRRAGGVLAISYLQGFLETARLALHHLA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CTF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	588	40	MSQREGSLEDHQTDSSISFLPHLEAKIRQTHNLARLLTKYAEQLLEEYVQQQGEPFGLPGFSPPRLPLAGLSGPAPSHAGLPVSERLRQDAAALSVLPALLDAVRRRQAELNPRAPRLLRSLEDAARQVRALGAAVETVLAALGAAARGPGPEPVTVATLFTANSTAGIFSAKVLGFHVCGLYGEWVSRTEGDLGQLVPGGVA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CTF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	784	62	MYCLLATPLCLLSLLLPPLSPAAPISPSEPIGQAYSLALYMQKNTSALLQTYLQHQGSPFSDPGFSAPELQLSTLPSAAVSFKTWHAMEDAERLSRAQGAFLALTQHLQLVGDDQSYLNPGSPILLAQLGAARLRAQGLLGNMAAIMTALGLPIPPEEDTLGFVPFGASAFERKCRGYIVTREYGHWTDRAVRDLALLKAKYSA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXCL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	269	49	MAPPTCRLLSAALVLLLLLATNHQATGAVVASELRCQCLKTLPRVDFKNIQSLSVTPPGPHCAQTEVIATLKGGQKVCLDPEAPLVQKIIQKILNKGKAN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXCL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	270	42	MAPPTCRLLSAALVLLLLLATNHQATGAVVASELRCQCLNTLPRVDFETIQSLTVTPPGPHCTQTEVIATLKDGQEVCLNPQGPRLQIIIKKILKSGKSS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXCL5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	461	50	MSLQLRSSARIPSGSISPFMRMAPLAFLLLFTLPQHLAEAAPSSVIAATELRCVCLTVTPKINPKLIANLEVIPAGPQCPTVEVIAKLKNQKEVCLDPEAPVIKKIIQKILGSDKKKAKRNALAVERTASVQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXCL9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	35	10	MKSAVLFLLGIIFLEQCGVRGTLVIRNARCSCISTSRGTIHYKSLKDLKQFAPSPNCNKTEIIATLKNGDQTCLDPDSANVKKLMKEWEKKISQKKKQKRGKKHQKNMKNRKPKTPQSRRRSRKTT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	33	MNPSAAVIFCLILLGLSGTQGIPLARTVRCNCIHIDDGPVRMRAIGKLEIIPASLSCPRVEIIATMKKNDEQRCLNPESKTIKNLMKAFSQKRSKRAP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	300	36	MNRKVTAIALAAIIWATAAQGFLMFKQGRCLCIGPGMKAVKMAEIEKASVIYPSNGCDKVEVIVTMKAHKRQRCLDPRSKQARLIMQAIEKKNFLRRQNM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL13_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	205	36	MRLSTATLLLLLASCLSPGHGILEAHYTNLKCRCSGVISTVVGLNIIDRIQVTPPGNGCPKTEVVIWTKMKKVICVNPRAKWLQRLLRHVQSKSLSSTPQAPVSKRRAA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL14_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	151	40	MRLLAAALLLLLLALCASRVDGSKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVIVTTKSMSRYRGQEHCLHPKLQSTKRFIKWYNAWNEKRRVYEE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	64	MAAQGWSMLLLAVLNLGIFVRPCDTQELRCLCIQEHSEFIPLKLIKNIMVIFETIYCNRKEVIAVPKNGSMICLDPDAPWVKATVGPITNRFLPEDLKQKEFPPAMKLLYSVEHEKPLYLSFGRPENKRIFPFPIRETSRHFADLAHNSDRNFLRDSSEVSLTGSDA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_CXL16_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	295	36	MRRGFGPLSLAFFLFLLALLTLPGDGNQGSVAGSCSCDRTISSGTQIPQGTLDHIRKYLKAFHRCPFFIRFQLQSKSVCGGSQDQWVRELVDCFERKECGTGHGKSFHHQKHLPQASTQTPEAAEGTPSDTSTPAHSQSTQHSTLPSGALSLNKEHTQPWEMTTLPSGYGLEARPEAEANEKQQDDRQQEAPGAGASTPAWVPVLSLLAIVFFLTAAMAYVLCNRRATQQNSAGLQLWYTPVEPRP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_EDA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	25	8	MGYPEVERREPLPAAAPRERGSQGCGCRGAPARAGEGNSCRLFLGFFGLSLALHLLTLCCYLELRSELRRERGTESRLGGPGAPGTSGTLSSPGSLDPVGPITRHLGQPSFQQQPLEPGEDPLPPDSQDRHQMALLNFFFPDEKAYSEEESRRVRRNKRSKSGEGADGPVKNKKKGKKAGPPGPNGPPGPPGPPGPQGPPGIPGIPGIPGTTVMGPPGPPGPPGPQGPPGLQGPSGAADKTGTRENQPAVVHLQGQGSAIQVKNDLSGGVLNDWSRITMNPKVFKLHPRSGELEVLVDGTYFIYSQVEVYYINFTDFASYEVVVDEKPFLQCTRSIETGKTNYNTCYTAGVCLLKARQKIAVKMVHADISINMSKHTTFFGAIRLGEAPAS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_FAM3B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	517	88	MRPVATGIFKALVFIFSSLCAWYSGYLLAELIPDVPLSSTLYNIRSIGERPVLKAPAPKRQKCDHWSPCPPDTYAYRLLSGGGRDKYAKICFEDEVLIGEKTGNVARGINIAVVNYETGKVIATKYFDMYEGDNSGPMAKFIQSTPSKSLLFMVTHDDGSSKLKAQAKDAIEALGSKEIKNMKFRSSWVFVAAKGFELPSEIEREKINHSDQSRNRYAGWPAEIQIEGCIPKGLR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_FLT3L_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	388	42	MTVLAPAWSPNSSLLLLLLLLSPCLRGTPDCYFSHSPISSNFKVKFRELTDHLLKDYPVTVAVNLQDEKHCKALWSLFLAQRWIEQLKTVAGSKMQTLLEDVNTEIHFVTSCTFQPLPECLRFVQTNISHLLKDTCTQLLALKPCIGKACQNFSRCLEVQCQPDSSTLLPPRSPIALEATELPEPRPRQLLLLLLLLLPLTLVLLAAAWGLRWQRARRRGELHPGVPLPSHP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_G6PI_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	639	65	MAALTRNPQFQKLLEWHRANSANLKLRELFEADPERFNNFSLNLNTNHGHILVDYSKNLVNKEVMQMLVELAKSRGVEAARDNMFSGSKINYTENRAVLHVALRNRSNTPIKVDGKDVMPEVNRVLDKMKSFCQRVRSGDWKGYTGKSITDIINIGIGGSDLGPLMVTEALKPYSKGGPRVWFVSNIDGTHIAKTLASLSPETSLFIIASKTFTTQETITNAETAKEWFLEAAKDPSAVAKHFVALSTNTAKVKEFGIDPQNMFEFWDWVGGRYSLWSAIGLSIALHVGFDHFEQLLSGAHWMDQHFLKTPLEKNAPVLLALLGIWYINCYGCETHALLPYDQYMHRFAAYFQQGDMESNGKYITKSGARVDHQTGPIVWGEPGTNGQHAFYQLIHQGTKMIPCDFLIPVQTQHPIRKGLHHKILLANFLAQTEALMKGKLPEEARKELQAAGKSPEDLEKLLPHKVFEGNRPTNSIVFTKLTPFILGALIAMYEHKIFVQGIMWDINSFDQWGVELGKQLAKKIEPELEGSSAVTSHDSSTNGLISFIKQQRDTKLE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	403	36	MLPVCHRFCDHLLLLLLLPSTTLAPAPASMGPAAALLQVLGLPEAPRSVPTHRPVPPVMWRLFRRRDPQEARVGRPLRPCHVEELGVAGNIVRHIPDSGLSSRPAQPARTSGLCPEWTVVFDLSNVEPTERPTRARLELRLEAESEDTGGWELSVALWADAEHPGPELLRVPAPPGVLLRADLLGTAVAANASVPCTVRLALSLHPGATAACGRLAEASLLLVTLDPRLCPLPRLRRHTEPRVEVGPVGTCRTRRLHVSFREVGWHRWVIAPRGFLANFCQGTCALPETLRGPGGPPALNHAVLRALMHAAAPTPGAGSPCCVPERLSPISVLFFDNSDNVVLRHYEDMVVDECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	727	48	MAPGPARISLGSQLLPMVPLLLLLRGAGCGHRGPSWSSLPSAAAGLQGDRDSQQSPGDAAAALGPGAQDMVAIHMLRLYEKYNRRGAPPGGGNTVRSFRARLEMIDQKPVYFFNLTSMQDSEMILTAAFHFYSEPPRWPRAREVFCKPRAKNASCRLLTPGLPARLHLIFRSLSQNTATQGLLRGAMALTPPPRGLWQAKDISSIIKAARRDGELLLSAQLDTGEKDPGVPRPSSHMPYILVYANDLAISEPNSVAVSLQRYDPFPAGDFEPGAAPNSSADPRVRRAAQVSKPLQDNELPGLDERPAPALHAQNFHKHEFWSSPFRALKPRTGRKDRKKKDQDTFTAASSQVLDFDEKTMQKARRRQWDEPRVCSRRYLKVDFADIGWNEWIISPKSFDAYYCAGACEFPMPKIVRPSNHATIQSIVRAVGIVPGIPEPCCVPDKMNSLGVLFLDENRNAVLKVYPNMSVETCACR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MVLAAPLLLGFLLLALELRPRGEAAEGPAAAAAAAAAAAGVGGERSSRPAPSAPPEPDGCPVCVWRQHSRELRLESIKSQILSKLRLKEAPNISREVVKQLLPKAPPLQQILDLHDFQGDALQPEDFLEEDEYHATTETVISMAQETDPAVQTDGSPLCCHFHFSPKVMFTKVLKAQLWVYLRPVPRPATVYLQILRLKPLTGEGTAGGGGGGRRHIRIRSLKIELHSRSGHWQSIDFKQVLHSWFRQPQSNWGIEINAFDPSGTDLAVTSLGPGAEGLHPFMELRVLENTKRSRRNLGLDCDEHSSESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGQCEYMFMQKYPHTHLVQQANPRGSAGPCCTPTKMSPINMLYFNDKQQIIYGKIPGMVVDRCGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	664	79	MAPPALQAQPPGGSQLRFLLFLLLLLLLLSWPSQGDALAMPEQRPSGPESQLNADELRGRFQDLLSRLHANQSREDSNSEPSPDPAVRILSPEVRLGSHGQLLLRVNRASLSQGLPEAYRVHRALLLLTPTARPWDITRPLKRALSLRGPRAPALRLRLTPPPDLAMLPSGGTQLELRLRVAAGRGRRSAHAHPRDSCPLGPGRCCHLETVQATLEDLGWSDWVLSPRQLQLSMCVGECPHLYRSANTHAQIKARLHGLQPDKVPAPCCVPSSYTPVVLMHRTDSGVSLQTYDDLVARGCHCA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	49	MSPGAFRVALLPLFLLVCVTQQKPLQNWEQASPGENAHSSLGLSGAGEEGVFDLQMFLENMKVDFLRSLNLSGIPSQDKTRAEPPQYMIDLYNRYTTDKSSTPASNIVRSFSVEDAISTAATEDFPFQKHILIFNISIPRHEQITRAELRLYVSCQNDVDSTHGLEGSMVVYDVLEDSETWDQATGTKTFLVSQDIRDEGWETLEVSSAVKRWVRADSTTNKNKLEVTVQSHRESCDTLDISVPPGSKNLPFFVVFSNDRSNGTKETRLELKEMIGHEQETMLVKTAKNAYQVAGESQEEEGLDGYTAVGPLLARRKRSTGASSHCQKTSLRVNFEDIGWDSWIIAPKEYDAYECKGGCFFPLADDVTPTKHAIVQTLVHLKFPTKVGKACCVPTKLSPISILYKDDMGVPTLKYHYEGMSVAECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	971	73	MQPYQRLLALGFLLLTLPWGQTSEFQDSDLLQFLGLEKAPSPHRFQPVPRVLRKIIRAREAAAASGASQDLCYVKELGVRGNLLQLLPDQGFFLNTQKPFQDGSCLQKVLYFNLSAIKEKAKLTMAQLTLDLGPRSYYNLRPELVVALSVVQDRGVWGRSHPKVGRLLFLRSVPGPQGQLQFNLQGALKDWSSNRLKNLDLHLEILVKEDRYSRVTVQPENPCDRLLRSLHASLLVVTLNPKHCHPSSRKRRAAISVPKGFCRNFCHRHQLFINFQDLGWHKWVIAPKGFMANYCHGECPFSMTTYLNSSNYAFMQALMHMADPKVPKAVCVPTKLSPISMLYQDSDKNVILRHYEDMVVDECGCG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	29	MRLPKLLTLLLWHLAWLDLELICTVLGAPDLGQRTPGAKPGLTKAEAKERPPLARNVFRPGGHIYGVGATNARAKGSSGQTQAKKDEPRKMPPRSGGPETKPGPSSQTRQAAARTVTPKGQLPGGKASSKAGSAPSSFLLKKTREPGTPREPKEPFRPPPITPHEYMLSLYRTLSDADRKGGNSSVKLEAGLANTITSFIDKGQDDRGPAVRKQRYVFDISALEKDGLLGAELRILRKKPLDVAKPAVPSSGRVAQLKLSSCPSGRQPAALLDVRSVPGLDGSGWEVFDIWKLFRNFKNSAQLCLELEAWERGRAVDLRGLGFERTARQVHEKALFLVFGRTKKRDLFFNEIKARSGQDDKTVYEYLFSQRRKRRAPLANRQGKRPSKNLKARCSRKALHVNFKDMGWDDWIIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISILFIDSANNVVYKQYEDMVVESCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	30	MDTPRVLLWAIFLISFLWDLPGFQQASISSSSSSSTELDSTKDVGNRKEGKMQRTPQESAEGRTPPEHGLRQKDLRRRPPGQHQGQEPPGRGLRVVPHEYMLSIYKTYSIAEKLGINASFFQSSKSANTITSFVDRGLDDLSHTPLRRQKYLFDVSTLSDKEELVGAELRLYRQAPPTPWGLPARPLHLQLFPCLSPLLLDARTLDPQGPTQAGWEVFDVWQGLRPQPWKQLCLELRAAWGELDAGDTGARARGPQQPPPLDLRSLGFGRRVRPPQERALLVVFTRSQRKNLFTEMHEQLGSAEAAGAEGSWPAPSGSPDAGSWLPSPGRRRRRTAFASRHGKRHGKKSRLRCSRKPLHVNFKELGWDDWIIAPLEYEAYHCEGVCDFPLRSHLEPTNHAIIQTLMNSMDPGSTPPSCCVPTKLTPISILYIDAGNNVVYKQYEDMVVESCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	577	44	MDLSAAAALCLWLLSACRPRDGLEAAAVLRAAGAGPAWSPGGGGGGRTLARAPGPSALQAAAVPGPRAVRRAAGSGFRNGSVVPHHFMMSLYRSLAGRAPVAAASGHGRVDTITGFTDQATQDETAAAEPGQSFLFDVSSLSEADEVVNAELRVLRRRSPEPDRDSATLLPRLLLSTCPDEAGTAHLLHSRAAEPLGGARWEAFDVTDAVQSHRRWPRASRKFCLVLRAVTASESSPLALRRLGFGWPGGGDGGGTAAEERALLVISSRTQRKESLFREIRAQARALRAAAEPPPDPGPGAGSRKANLGGRRRRRTALAGTRGAQGSGGGGGGGGGGGGGGGGGGGGAGRGHGRRGRSRCSRKSLHVDFKELGWDDWIIAPLDYEAYHCEGVCDFPLRSHLEPTNHAIIQTLLNSMAPDAAPASCCVPARLSPISILYIDAANNVVYKQYEDMVVEACGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	68	MMQKLQMYVYIYLFMLIAAGPVDLNEGSEREENVEKEGLCNACAWRQNTRYSRIEAIKIQILSKLRLETAPNISKDAIRQLLPRAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQADGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVKTPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMSPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GDF9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	623	50	MALPSNFLLGVCCFAWLCFLSSLSSQASTEESQSGASENVESEADPWSLLLPVDGTDRSGLLPPLFKVLSDRRGETPKLQPDSRALYYMKKLYKTYATKEGVPKPSRSHLYNTVRLFSPCAQQEQAPSNQVTGPLPMVDLLFNLDRVTAMEHLLKSVLLYTLNNSASSSSTVTCMCDLVVKEAMSSGRAPPRAPYSFTLKKHRWIEIDVTSLLQPLVTSSERSIHLSVNFTCTKDQVPEDGVFSMPLSVPPSLILYLNDTSTQAYHSWQSLQSTWRPLQHPGQAGVAARPVKEEAIEVERSPRRRRGQKAIRSEAKGPLLTASFNLSEYFKQFLFPQNECELHDFRLSFSQLKWDNWIVAPHRYNPRYCKGDCPRAVRHRYGSPVHTMVQNIIYEKLDPSVPRPSCVPGKYSPLSVLTIEPDGSIAYKEYEDMIATRCTCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GP15L_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	29	8	MRLLALSGLLCMLLLCFCIFSSEGRRHPAKSLKLRRCCHLSPRSKLTTWKGNHTRPCRLCRNKLPVKSWVVPGALPQI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GREM1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	4	MNRTAYTVGALLLLLGTLLPTAEGKKKGSQGAIPPPDKAQHNDSEQTQSPPQPGSRTRGRGQGRGTAMPGEEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGCNSRTIINRFCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKKFTTMMVTLNCPELQPPTKKKRVTRVKQCRCISIDLD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GREM2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	19	MFWKLSLTLLLVAVLVKVAETRKNRPAGAIPSPYKDGSSNNSERWHHQIKEVLASSQEALVVTERKYLKSDWCKTQPLRQTVSEEGCRSRTILNRFCYGQCNSFYIPRHVKKEEDSFQSCAFCKPQRVTSVIVELECPGLDPPFRIKKIQKVKHCRCMSVNLSDSDKQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GRN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	23	MWVLMSWLAFAAGLVAGTQCPDGQFCPVACCLDQGGANYSCCNPLLDTWPRITSHHLDGSCQTHGHCPAGYSCLLTVSGTSSCCPFSKGVSCGDGYHCCPQGFHCSADGKSCFQMSDNPLGAVQCPGSQFECPDSATCCIMVDGSWGCCPMPQASCCEDRVHCCPHGASCDLVHTRCVSPTGTHTLLKKFPAQKTNRAVSLPFSVVCPDAKTQCPDDSTCCELPTGKYGCCPMPNAICCSDHLHCCPQDTVCDLIQSKCLSKNYTTDLLTKLPGYPVKEVKCDMEVSCPEGYTCCRLNTGAWGCCPFAKAVCCEDHIHCCPAGFQCHTEKGTCEMGILQVPWMKKVIAPLRLPDPQILKSDTPCDDFTRCPTNNTCCKLNSGDWGCCPIPEAVCCSDNQHCCPQGFTCLAQGYCQKGDTMVAGLEKIPARQTTPLQIGDIGCDQHTSCPVGQTCCPSLKGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARTCEKDVDFIQPPVLLTLGPKVGNVECGEGHFCHDNQTCCKDSAGVWACCPYLKGVCCRDGRHCCPGGFHCSARGTKCLRKKIPRWDMFLRDPVPRPLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_GROA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	368	67	MIPATRSLLCAALLLLATSRLATGAPIANELRCQCLQTMAGIHLKNIQSLKVLPSGPHCTQTEVIATLKNGREACLDPEAPLVQKIVQKMLKGVPK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_I36RA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	101	28	MMVLSGALCFRMKDSALKVLYLHNNQLLAGGLHAEKVIKGEEISVVPNRALDASLSPVILGVQGGSQCLSCGTEKGPILKLEPVNIMELYLGAKESKSFTFYRRDMGLTSSFESAAYPGWFLCTSPEADQPVRLTQIPEDPAWDAPITDFYFQQCD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	653	64	MARLCAFLMVLAVLSYWPTCSLGCDLPQTHNLRNKRALTLLVQMRRLSPLSCLKDRKDFGFPQEKVDAQQIKKAQAIPVLSELTQQILNIFTSKDSSAAWNTTLLDSFCNDLHQQLNDLQGCLMQQVGVQEFPLTQEDALLAVRKYFHRITVYLREKKHSPCAWEVVRAEVWRALSSSANVLGRLREEK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	714	64	MARLCAFLVMLIVMSYWSICSLGCDLPHTYNLRNKRALKVLAQMRRLPFLSCLKDRQDFGFPLEKVDNQQIQKAQAIPVLRDLTQQTLNLFTSKASSAAWNATLLDSFCNDLHQQLNDLQTCLMQQVGVQEPPLTQEDALLAVRKYFHRITVYLREKKHSPCAWEVVRAEVWRALSSSVNLLPRLSEEKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	547	69	MARLCAFLMILVMMSYYWSACSLGCDLPHTYNLGNKRALTVLEEMRRLPPLSCLKDRKDFGFPLEKVDNQQIQKAQAILVLRDLTQQILNLFTSKDLSATWNATLLDSFCNDLHQQLNDLKACVMQEPPLTQEDSLLAVRTYFHRITVYLRKKKHSLCAWEVIRAEVWRALSSSTNLLARLSEEKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	720	64	MARLCAFLMVLPVLSYWPTCSLGCDLPQTHNLRNKRALTLLVKMRRLSPLSCLKDRKDFGFPQEKVGAQQIQEAQAIPVLSELTQQVLNIFTSKDSSAAWNATLLDSFCNEVHQQLNDLKACVMQQVGVQESPLTQEDSLLAVRKYFHRITVYLREKKHSPCAWEVVRAEVWRALSSSVNLLARLSKEE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	728	68	MARLCAFLMVLAVLSYWPTCSLGCDLPQTHNLRNKRALTLLVKMRRLSPLSCLKDRKDFGFPQEKVGAQQIQEAQAIPVLTELTQQILTLFTSKDSSAAWNATLLDSFCNDLHQLLNDLQGCLMQQVEIQALPLTQEDSLLAVRTYFHRITVFLREKKHSPCAWEVVRAEVWRALSSSAKLLARLNEDE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	731	71	MARLCAFLMVLAVMSYWPTCCLGCDLPQTHNLRNKRALTLLVKMRRLSPLSCLKDRKDFGFPQAKVDAQQIQEAQAIPVLSELTQQILNIFTSKDSSAAWNATLLDSVCNDLHQQLNDLQGCLMQEVGVQELSLTQEDSLLAVRKYFHRITVFLREKKHSPCAWEVVRAEIWRALSSSANLLARLSEKKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNA9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	648	65	MARPFAFLMVLVVISYWSTCSLGCDLPQTHNLRNKKILTLLAQMRRLSPLSCLKDRKDFGFPQEKVDAQQIQEAQAIPVLSELTQQILTLFTSKDSSAAWNATLLDSFCTGLHQLLNDLQGCLMQLVGMKELPLTQEDSQLAMKKYFHRITVYLREKKHSPCAWEVVRAEVWRALSSSVNLLARLSEEKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNAB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	678	69	MARLCAFLMILIVMSYWSTCSLGCDLPHTYNLRNKRALKVLAQMRRLTPLSCLKDRKDFGFPLEKVDAQQIQKAQSIPVLRDLTQQILNLFASKDSSAAWNATLLDSFCNDLHQQLNDLQGCLMQQVGVQESPLTQEDSLLAVRIYFHRITVFLREKKHSPCAWEVVRAEVWRALSSSANVLGRLREEKA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNAC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	649	64	MARLCAFLMTLLVMSYWSTCSLGCDLPQTHNLRNKRALTLLAQMRRLSPLSCLKDRKNFRFPQEKVDAQQIKKAQVIPVLSELTQQILTLFTSKDSSAAWNTTLLDSFCNDLHQQLNDLQGCLMQQVGVQEPPLTQEDSLLAVRKYFHRITVYLREKKHSPCAWEVVRAEVWRTLSSSAKLLARLSEKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNAD_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	570	84	MARPCAFLMVLVVLSYWSACSLGCDLPQTHNLRNKRALTLLEQMRRLSPLSCLKDRKDFGFPQEKVDAQQIKKAQAIPFVHELTQQILTLFTSNDSSAAWNATLLDSFCNDLHQQLNDLKACLMQQVGVQEFPLTQEDSLLAVRKYFHSITVYLREKKHSPCAWEVVRAEVQRTLSSSANLLARLSKEE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	893	49	MNNRWILHAAFLLCFSTTALSINYKQLQLQERTNIRKCQELLEQLNGKINLTYRADFKIPMEMTEKMQKSYTAFAIQEMLQNVFLVFRNNFSSTGWNETIVVRLLDELHQQTVFLKTVLEEKQEERLTWEMSSTALHLKSYYWRVQRYLKLMKYNSYAWMVVRAEIFRNFLIIRRLTRNFQN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNE_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	614	61	MVHRQLPETVLLLLVSSTIFSLEPKRIPFQLWMNRESLQLLKPLPSSSVQQCLAHRKNFLLPQQPVSPHQYQEGQVLAVVHEILQQIFTLLQTHGTMGIWEENHIEKVLAALHRQLEYVESLGGLNAAQKSGGSSAQNLRLQIKAYFRRIHDYLENQRYSSCAWIIVQTEIHRCMFFVFRFTTWLSRQDPDP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	466	34	MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNK_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	73	MTPKFLWLVALVALYIPPIQSLNCVYLDDSILENVKLLGSTMTGFPLRCLKDITDFKFPKEILPYIQHMKREINAVSYRISSLALTIFNLKGSIPPVTEEHWERIRSGLFKQVRQAQECFMDEEKENREHPHSEDFLTVYLELGKYFFRIKKFLINKKYSFCAWKIVTVEIRRCFIIFSKSRKLLKMISESPTFKQELK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	252	25	MLLLLLPLLLAAVLTRTQADPVPRATRLPVEAKDCHIAQFKSLSPKELQAFKKAKDAIEKRLLEKDLRCSSHLFPRAWDLKQLQVQERPKALQAEVALTLKVWENMTDSALATILGQPLHTLSHIHSQLQTCTQLQATAEPRSPSRRLSRWLHRLQEAQSKETPGCLEASVTSNLFRLLTRDLKCVANGDQCV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IFNL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	284	36	MLLLLLPLLLAAVLTRTQADPVPRATRLPVEAKDCHIAQFKSLSPKELQAFKKAKGAIEKRLLEKDMRCSSHLISRAWDLKQLQVQERPKALQAEVALTLKVWENINDSALTTILGQPLHTLSHIHSQLQTCTQLQATAEPKPPSRRLSRWLHRLQEAQSKETPGCLEDSVTSNLFQLLLRDLKCVASGDQCV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	485	50	MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQTKDQLDNILLTDSLMQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLRMRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	41	MNCVCRLVLVVLSLWPDRVVAPGPPAGSPRVSSDPRADLDSAVLLTRSLLADTRQLAAQMRDKFPADGDHSLDSLPTLAMSAGTLGSLQLPGVLTRLRVDLMSYLRHVQWLRRAGGPSLKTLEPELGALQARLERLLRRLQLLMSRLALPQAAPDQPVIPLGPPASAWGSIRAAHAILGGLHLTLDWAVRGLLLLKTRL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL12A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	701	80	MCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL12B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	423	37	MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL13_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	257	25	MALWVTAVLALACLGGLAAPGPVPRSVSLPLTLKELIEELSNITQDQTPLCNGSMVWSVDLAAGGFCVALDSLTNISNCNAIYRTQRILHGLCNRKAPTTVSSLPDTKIEVAHFITKLLSYTKQLFRHGPF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	370	51	MKILKPYMRNTSISCYLCFLLNSHFLTEAGIHVFILGCVSVGLPKTEANWIDVRYDLEKIESLIQSIHIDTTLYTDSDFHPSCKVTAMNCFLLELQVILHEYSNMTLNETVRNVLYLANSTLSSNKNVAESGCKECEELEEKTFTEFLQSFIRIVQMFINTS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL16_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1143	61	MEPHGHSGKSRKSTKFRSISRSLILCNAKTSDDGSSPDEKYPDPFETSLCQGKEGFFHSSMQLADTFEAGLSNIPDLALASDSAQLAAAGSDRGKHCRKMFFMKESSSTSSKEKSGKPEAQSSSFLFPKACHQRTRSNSTSVNPYSAGEIDFPMTKKSAAPTDRQPYSLCSNRKSLSQQLDYPILGTARPTRSLSTAQLGQLSGGLQASVISNIVLMKGQAKGLGFSIVGGKDSIYGPIGIYVKSIFAGGAAAADGRLQEGDEILELNGESMAGLTHQDALQKFKQAKKGLLTLTVRTRLTTPPSLCSHLSPPLCRSLSSSTCGAQDSSPFSLESPASPASTAKPNYRIMVEVSLKKEAGVGLGIGLCSIPYFQCISGIFVHTLSPGSVAHLDGRLRCGDEIVEINDSPVHCLTLNEVYTILSHCDPGPVPIIVSRHPDPQVSEQQLKEAVAQAVEGVKFGKDRHQWSLEGVKRLESSWHGRPTLEKEREKHSAPPHRRAQKIMVRSSSDSSYMSGSPGGSPCSAGAEPQPSEREGSTHSPSLSPGEEQEPCPGVPSRPQQESPPLPESLERESHPPLRLKKSFEILVRKPTSSKPKPPPRKYFKNDSEPQKKLEEKEKVTDPSGHTLPTCSQETRELLPLLLQEDTAGRAPCTAACCPGPAASTQTSSSTEGESRRSASPETPASPGKHPLLKRQARMDYSFDITAEDPWVRISDCIKNLFSPIMSENHSHTPLQPNTSLGEEDGTQGCPEGGLSKMDAANGAPRVYKSADGSTVKKGPPVAPKPAWFRQSLKGLRNRAPDPRRPPEVASAIQPTPVSRDPPGPQPQASSSIRQRISSFENFGSSQLPDRGVQRLSLQPSSGETTKFPGKQDGGRFSGLLGQGATVTAKHRQTEVESMSTTFPNSSEVRDPGLPESPPPGQRPSTKALSPDPLLRLLTTQSEDTQGPGLKMPSQRARSFPLTRTQSCETKLLDEKASKLYSISSQLSSAVMKSLLCLPSSVSCGQITCIPKERVSPKSPCNNSSAAEGFGEAMASDTGFSLNLSELREYSEGLTEPGETEDRNHCSSQAGQSVISLLSAEELEKLIEEVRVLDEATLKQLDSIHVTILHKEEGAGLGFSLAGGADLENKVITVHRVFPNGLASQEGTIQKGNEVLSINGKSLKGATHNDALAILRQARDPRQAVIVTRRTTVEATHDLNSSTDSAASASAASDISVESKEATVCTVTLEKTSAGLGFSLEGGKGSLHGDKPLTINRIFKGTEQGEMVQPGDEILQLAGTAVQGLTRFEAWNVIKALPDGPVTIVIRRTSLQCKQTTASADS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL17_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	438	60	MSPGRASSVSLMLLLLLSLAATVKAAAIIPQSSACPNTEAKDFLQNVKVNLKVFNSLGAKVSSRRPSDYLNRSTSPWTLHRNEDPDRYPSVIWEAQCRHQRCVNAEGKLDHHMNSVLIQQEILVLKREPESCPFTFRVEKMLVGVGCTCVASIVRQAA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL17B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	41	MDWPHSLLFLLAISIFLAPSHPRNTKGKRKGQGRPSPLAPGPHQVPLDLVSRVKPYARMEEYERNLGEMVAQLRNSSEPAKKKCEVNLQLWLSNKRSLSPWGYSINHDPSRIPADLPEARCLCLGCVNPFTMQEDRSMVSVPVFSQVPVRRRLCPQPPRPGPCRQRVVMETIAVGCTCIF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL17C_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	190	31	MSLLLLGWLPTGMTHQDPPSWGKPRSHRTLRCYSAEELSHGQAPPHLLTRSARWEQALPVALVASLEATGHRRQHEGPLAGTQCPVLRPEEVLEADTHERSISPWRYRIDTDENRYPQKLAVAECLCRGCINAKTGRETAALNSVQLLQSLLVLRRQPCSRDGTADPTPGSFAFHTEFIRVPVGCTCVLPRSTQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL17F_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	218	36	MKCTRETAMVKSLLLLMLGLAILREVAARKNPKAGVPALQKAGNCPPLEDNTVRVDIRIFNQNQGISVPREFQNRSSSPWDYNITRDPHRFPSEIAEAQCRHSGCINAQGQEDSTMNSVAIQQEILVLRREPQGCSNSFRLEKMLLKVGCTCVKPIVHQAA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL18_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	332	39	MAAMSEDSCVNFKEMMFIDNTLYFIPEENGDLESDNFGRLHCTTAVIRNINDQVLFVDKRQPVFEDMTDIDQSASEPQTRLIIYMYKDSEVRGLAVTLSVKDSKMSTLSCKNKIISFEEMDPPENIDDIQSDLIFFQKRVPGHNKMEFESSLYEGHFLACQKEDDAFKLILKKKDENGDKSVMFTLTNLHQS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL19_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	55	MKTQCASTWLLGMTLILCSVHIYSLRRCLISVDMRLIEKSFHEIKRAMQTKDTFKNVTILSLENLRSIKPGDVCCMTNNLLTFYRDRVFQDHQERSLEVLRRISSIANSFLCVQKSLERCQVHRQCNCSQEATNATRIIHDNYNQLEVSSAALKSLGELNILLAWIDRNHLETPAA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL1A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	693	56	MAKVPDLFEDLKNCYSENEDYSSAIDHLSLNQKSFYDASYGSLHETCTDQFVSLRTSETSKMSNFTFKESRVTVSATSSNGKILKKRRLSFSETFTEDDLQSITHDLEETIQPRSAPYTYQSDLRYKLMKLVRQKFVMNDSLNQTIYQDVDKHYLSTTWLNDLQQEVKFDMYAYSSGGDDSKYPVTLKISDSQLFVSAQGEDQPVLLKELPETPKLITGSETDLIFFWKSINSKNYFTSAAYPELFIATKEQSRVHLARGLPSMTDFQIS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL1B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	436	83	MATVPELNCEMPPFDSDENDLFFEVDGPQKMKGCFQTFDLGCPDESIQLQISQQHINKSFRQAVSLIVAVEKLWQLPVSFPWTFQDEDMSTFFSFIFEEEPILCDSWDDDDNLLVCDVPIRQLHYRLRDEQQKSLVLSDPYELKALHLNGQNINQQVIFSMSFVQGEPSNDKIPVALGLKGKNLYLSCVMKDGTPTLQLESVDPKQYPKKKMEKRFVFNKIEVKSKVEFESAEFPNWYISTSQAEHKPVFLGNNSGQDIIDFTMESVSS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL1FA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	282	50	MCSLPMARYYIIKDAHQKALYTRNGQLLLGDPDSDNYSPEKVCILPNRGLDRSKVPIFLGMQGGSCCLACVKTREGPLLQLEDVNIEDLYKGGEQTTRFTFFQRSLGSAFRLEAAACPGWFLCGPAEPQQPVQLTKESEPSTHTEFYFEMSR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	35	MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKLPRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFECQFDDESATVVDFLRRWIAFCQSIISTSPQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL20_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	710	68	MKGFGLAFGLFSAVGFLLWTPLTGLKTLHLGSCVITANLQAIQKEFSEIRDSVQAEDTNIDIRILRTTESLKDIKSLDRCCFLRHLVRFYLDRVFKVYQTPDHHTLRKISSLANSFLIIKKDLSVCHSHMACHCGEEAMEKYNQILSHFIELELQAAVVKALGELGILLRWMEEML	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL21_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	421	62	MERTLVCLVVIFLGTVAHKSSPQGPDRLLIRLRHLIDIVEQLKIYENDLDPELLSAPQDVKGHCEHAAFACFQKAKLKPSNPGNNKTFIIDLVAQLRRRLPARRGGKKQKHIAKCPSCDSYEKRTPKEFLERLKWLLQKMIHQHLS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL22_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	396	70	MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPVNTRCKLEVSNFQQPYIVNRTFMLAKEASLADNNTDVRLIGEKLFRGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVPFLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL22B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	465	70	MAVLQKSMSFSLMGTLAASCLLLIALWAQEANALPINTRCKLEVSNFQQPYIVNRTFMLAKEVSLADNNTDVWLIGEKLFRGVSAKDQCYLMKQVLNFTLEDVLLPQSDRFQPYMQEVVPFLTKLSNQLSSCHISGDDQNIQKNVRRLKETVKKLGESGEIKAIGELDLLFMSLRNACV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL23A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	669	90	MLDCRAVIMLWLLPWVTQGLAVPRSSSPDWAQCQQLSRNLCMLAWNAHAPAGHMNLLREEEDEETKNNVPRIQCEDGCDPQGLKDNSQFCLQRIRQGLAFYKHLLDSDIFKGEPALLPDSPMEQLHTSLLGLSQLLQPEDHPRETQQMPSLSSSQQWQRPLLRSKILRSLQAFLAIAARVFAHGAATLTEPLVPTA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL24_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	926	80	MSWGLQILPCLSLILLLWNQVPGLEGQEFRSGSCQVTGVVLPELWEAFWTVKNTVQTQDDITSIRLLKPQVLRNVSGAESCYLAHSLLKFYLNTVFKNYHSKIAKFKVLRSFSTLANNFIVIMSQLQPSKDNSMLPISESAHQRFLLFRRAFKQLDTEVALVKAFGEVDILLTWMQKFYHL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL25_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	46	MYQAVAFLAMIVGTHTVSLRIQEGCSHLPSCCPSKEQEPPEEWLKWSSASVSPPEPLSHTHHAESCRASKDGPLNSRAISPWSYELDRDLNRVPQDLYHARCLCPHCVSLQTGSHMDPLGNSVPLYHNQTVFYRRPCHGEEGTHRRYCLERRLYRVSLACVCVRPRVMA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL27A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	682	61	MGQVTGDLGWRLSLLLLPLLLVQAGSWGFPTDPLSLQELRREFTVSLYLARKLLSEVQGYVHSFAESRLPGVNLDLLPLGYHLPNVSLTFQAWHHLSDSERLCFLATTLRPFPAMLGGLGTQGTWTSSEREQLWAMRLDLRDLHRHLRFQVLAAGFKCSKEEEDKEEEEEEEEEEKKLPLGALGGPNQVSSQVSWPQLLYTYQLLHSLELVLSRAVRDLLLLSLPRRPGSAWDS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL27B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	682	79	MSKLLFLSLALWASRSPGYTETALVALSQPRVQCHASRYPVAVDCSWTPLQAPNSTRSTSFIATYRLGVATQQQSQPCLQRSPQASRCTIPDVHLFSTVPYMLNVTAVHPGGASSSLLAFVAERIIKPDPPEGVRLRTAGQRLQVLWHPPASWPFPDIFSLKYRLRYRRRGASHFRQVGPIEATTFTLRNSKPHAKYCIQVSAQDLTDYGKPSDWSLPGQVESAPHKP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	359	67	MVLASSTTSIHTMLLLLLMLFHLGLQASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL31_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	248	35	MIFHTGTTKPTLVLLCCIGTWLATCSLSFGAPISKEDLRTTIDLLKQESQDLYNNYSIKQASGMSADESIQLPCFSLDREALTNISVIIAHLEKVKVLSENTVDTSWVIRWLTNISCFNPLNLNISVPGNTDESYDCKVFVLTVLKQFSNCMAELQAKDNTTC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL33_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	385	42	MRPRMKYSNSKISPAKFSSTAGEALVPPCKIRRSQQKTKEFCHVYCMRLRSGLTIRKETSYFRKEPTKRYSLKSGTKHEENFSAYPRDSRKRSLLGSIQAFAASVDTLSIQGTSLLTQSPASLSTYNDQSVSFVLENGCYVINVDDSGKDQEQDQVLLRYYESPCPASQSGDGVDGKKLMVNMSPIKDTDIWLHANDKDYSVELQRGDVSPPEQAFFVLHKKSSDFVSFECKNLPGTYIGVKDNQLALVEEKDESCNNIMFKLSKI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL34_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	475	50	MPWGLAWLYCLGILLDVALGNENLEIWTLTQDKECDLTGYLRGKLQYKNRLQYMKHYFPINYRIAVPYEGVLRVANITRLQKAHVSERELRYLWVLVSLNATESVMDVLLEGHPSWKYLQEVQTLLENVQRSLMDVEIGPHVEAVLSLLSTPGLSLKLVRPKALLDNCFRVMELLYCSCCKQSPILKWQDCELPRLHPHSPGSLMQCTATNVYPLSRQTPTSLPGSPSSSHGSLP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL36A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	254	32	MNKEKELRAASPSLRHVQDLSSRVWILQNNILTAVPRKEQTVPVTITLLPCQYLDTLETNRGDPTYMGVQRPMSCLFCTKDGEQPVLQLGEGNIMEMYNKKEPVKASLFYHKKSGTTSTFESAAFPGWFIAVCSKGSCPLILTQELGEIFITDFEMIVVH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL36B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	438	45	MMAFPPQSCVHVLPPKSIQMWEPNHNTMHGSSQSPRNYRVHDSQQMVWVLTGNTLTAVPASNNVKPVILSLIACRDTEFQDVKKGNLVFLGIKNRNLCFCCVEMEGKPTLQLKEVDIMNLYKERKAQKAFLFYHGIEGSTSVFQSVLYPGWFIATSSIERQTIILTHQRGKLVNTNFYIESEK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL36G_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	249	39	MFSKHPFSTHISGRETPDFGEVFDLDQQVWIFRNQALVTVPRSHRVTPVSVTILPCKYPESLEQDKGIAIYLGIQNPDKCLFCKEVNGHPTLLLKEEKILDLYHHPEPMKPFLFYHTRTGGTSTFESVAFPGHYIASSKTGNPIFLTSKKGEYYNINFNLDIKS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	452	56	MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCRASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL40_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	656	82	MALLQLLLFAMLAACGFSEEQTEGITIAYKVLEVYPQSRRVLITCDAPEASQPITYSLLASRGILVAKKVVHDSVPASFNINITIKSSPDLLTYSCQATSNSGTYGPSSRLQMYQELWAKPVSQLQADFVLRHGDSGPTVELSCLASSGSPPITYRLVGNGGRVLAQQRPLHGKPANFSLPLSQTTGWFQCEAENDVGVDSSARIPLPRAEARAKLVTTLAGELPLTPTCILAGSLVSIAVIASRMLSSTGL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	41	MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGLDILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	411	32	MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELCNGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKARVLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	67	MFHVSFRYIFGIPPLILVLLPVTSSECHIKDKEGKAYESVLMISIDELDKMTGTDSNCPNNEPNFFRKHVCDDTKEAAFLNRAARKLKQFLKMNISEEFNVHLLTVSQGTQTLVNCTSKEEKNVKEQKKNDACFLKRLLREIKTCWNKILKGSI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_IL9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	38	MLVTYILASVLLFSSVLGQRCSTTWGIRDTNYLIENLKDDPPSKCSCSGNVTSCLCLSVPTDDCTTPCYREGLLQLTNATQKSRLLPVFHRVKRIVEVLKNITCPSFSCEKPCNQTMAGNTLSFLKSLLGTFQKTEMQRQKSRP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_LFTY1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	43	MPFLWLCWALWALSLVSLREALTGEQILGSLLQQLQLDQPPVLDKADVEGMVIPSHVRTQYVALLQHSHASRSRGKRFSQNLREVAGRFLVSETSTHLLVFGMEQRLPPNSELVQAVLRLFQEPVPRTALRRQKRLSPHSARARVTIEWLRFRDDGSNRTALIDSRLVSIHESGWKAFDVTEAVNFWQQLSRPRQPLLLQVSVQREHLGPGTWSSHKLVRFAAQGTPDGKGQGEPQLELHTLDLKDYGAQGNCDPEAPVTEGTRCCRQEMYLDLQGMKWAENWILEPPGFLTYECVGSCLQLPESLTSRWPFLGPRQCVASEMTSLPMIVSVKEGGRTRPQVVSLPNMRVQTCSCASDGALIPRRLQP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_LFTY2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	435	37	MKSLWLCWALWVLPLAGPGAAMTEEQVLSSLLQQLQLSQAPTLDSADVEEMAIPTHVRSQYVALLQGSHADRSRGKRFSQNFREVAGRFLMSETSTHLLVFGMEQRLPPNSELVQAVLRLFQEPVPRTALRRFERLSPHSARARVTIEWLRVREDGSNRTALIDSRLVSIHESGWKAFDVTEAVNFWQQLSRPRQPLLLQVSVQREHLGPGTWSAHKLVRFAAQGTPDGKGQGEPQLELHTLDLKDYGAQGNCDPEVPVTEGTRCCRQEMYLDLQGMKWAENWILEPPGFLTYECVGSCLQLPESLTIGWPFLGPRQCVASEMTSLPMIVSVKEGGRTRPQVVSLPNMRVQTCSCASDGALIPRGIDL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_LIF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	418	41	MKVLAAGIVPLLLLVLHWKHGAGSPLPITPVNATCAIRHPCHGNLMNQIKNQLAQLNGSANALFISYYTAQGEPFPNNVEKLCAPNMTDFPSFHGNGTEKTKLVELYRMVAYLSASLTNITRDQKVLNPTAVSLQVKLNATIDVMRGLLSNVLCRLCNKYRVGHVDVPPVPDHSDKEAFQRKKLGCQLLGTYKQVISVVVQAF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_MIF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	26	8	MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTNDPCALCSLHSIGKIGGAQNRNYSKLLCGLLSDRLHISPDRVYINYYDMNAANVGWNGSTFA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_MSMP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	53	12	MALRMLWAGQAKGILGGWRTICLVVSLFLQHPGVSSKCYFQAQAPCHYEGKYFTLGESWLRKDCFHCTCLHPVGVGCCDTAQHPIDFPAECEVLQEAGTCQFSLVQKADPRLPCKGGGPDLEWGSANTPAPGASAPHSS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_NAMPT_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	48	MNAAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKVRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKEVYREHFQDDVFNERGWNYILEKYDGHLPIEVKAVPEGSVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGIALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTEAPLIIRPDSGNPLDTVLKVLDILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKKWSIENVSFGSGGALLQKLTRDLLNCSFKCSYVVTNGLGVNVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGHDLLHTVFKNGKVTKSYSFDEVRKNAQLNIEQDVAPH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_NODAL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	65	MSAHSLRILLLQACWALLHPRAPTAAALPLWTRGQPSSPSPLAYMLSLYRDPLPRADIIRSLQAQDVDVTGQNWTFTFDFSFLSQEEDLVWAELRLQLPGPMDIPTEGPLTIDIFHQAKGDPERDPADCLERIWMETFTVIPSQVTFASGSTVLEVTKPLSKWLKDPRALEKQVSSRAEKCWHQPYTPPVPVASTNVLMLYSNRPQEQRQLGGATLLWEAESSWRAQEGQLSVERGGWGRRQRRHHLPDRSQLCRRVKFQVDFNLIGWGSWIIYPKQYNAYRCEGECPNPVGEEFHPTNHAYIQSLLKRYQPHRVPSTCCAPVKTKPLSMLYVDNGRVLLEHHKDMIVEECGCL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_ONCM_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	788	46	MQTRLLRTLLSLTLSLLILSMALANRGCSNSSSQLLSQLQNQANLTGNTESLLEPYIRLQNLNTPDLRAACTQHSVAFPSEDTLRQLSKPHFLSTVYTTLDRVLYQLDALRQKFLKTPAFPKLDSARHNILGIRNNVFCMARLLNHSLEIPEPTQTDSGASRSTTTPDVFNTKIGSCGFLWGYHRFMGSVGRVFREWDDGSTRSRRQSPLRARRKGTRRIRVRHKGTRRIRVRRKGTRRIWVRRKGSRKIRPSRSTQSPTTRA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_OSTP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	261	77	MRLAVICFCLFGIASSLPVKVTDSGSSEEKLYSLHPDPIATWLVPDPSQKQNLLAPQNAVSSEEKDDFKQETLPSNSNESHDHMDDDDDDDDDDGDHAESEDSVDSDESDESHHSDESDETVTASTQADTFTPIVPTVDVPNGRGDSLAYGLRSKSRSFQVSDEQYPDATDEDLTSHMKSGESKESLDVIPVAQLLSMPSDQDNNGKGSHESSQLDEPSLETHRLEHSKESQESADQSDVIDSQASSKASLEHQSHKFHSHKDKLVLDPKSKEDDRYLKFRISHELESSSSEVN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_PGRP1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	321	37	MLFACALLALLGLATSCSFIVPRSEWRALPSECSSRLGHPVRYVVISHTAGSFCNSPDSCEQQARNVQHYHKNELGWCDVAYNFLIGEDGHVYEGRGWNIKGDHTGPIWNPMSIGITFMGNFMDRVPAKRALRAALNLLECGVSRGFLRSNYEVKGHRDVQSTLSPGDQLYQVIQSWEHYRE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_PLF4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	66	MSVAAVFRGLRPSPELLLLGLLFLPAVVAVTSAGPEESDGDLSCVCVKTISSGIHLKHITSLEVIKAGRHCAVPQLIATLKNGRKICLDRQAPLYKKVIKKILES	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_SDF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	124	39	MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRLKM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_SG3A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	59	MKLTTTFLVLCVALLSDSGVAFFMDSLAKPAVEPVAALAPAAEAVAGAVPSLPLSHLAILRFILASMGIPLDPLIEGSRKCVTELGPEAVGAVKSLLGVLTMFG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_SLUR1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	34	7	MTLRWAMWLLLLAAWSMGYGEAFRCYTCEQPTAINSCKNIAQCKMEDTACKTVLETVEAAFPFNHSPMVTRSCSSSCLATDPDGIGVAHPVFCCFRDLCNSGFPGFVAGL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TAFA5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MAPSPRTSSRQDATALPSMSSTFWAFMILASLLIAYCSQLAAGTCEIVTLDRDSSQPRRTIARQTARCACRKGQIAGTTRARPACVDARIIKTKQWCDMLPCLEGEGCDLLINRSGWTCTQPGGRIKTTTVS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TN13B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	617	42	MDESAKTLPPPCLCFCSEKGEDMKVGYDPITPQKEEGAWFGICRDGRLLAATLLLALLSSSFTAMSLYQLAALQADLMNLRMELQSYRGSATPAAAGAPELTAGVKLLTPAAPRPHNSSRGHRNRRAFQGPEETEQDVDLSAPPAPCLPGCRHSQHDDNGMNLRNIIQDCLQLIADSDTPTIRKGTYTFVPWLLSFKRGNALEEKENKIVVRQTGYFFIYSQVLYTDPIFAMGHVIQRKKVHVFGDELSLVTLFRCIQNMPKTLPNNSCYSAGIARLEEGDEIQLAIPRENAQISRNGDDTFFGALKLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	490	55	MPSSGALKDLSFSQHFRMMVICIVLLQVLLQAVSVAVTYMYFTNEMKQLQDNYSKIGLACFSKTDEDFWDSTDGEILNRPCLQVKRQLYQLIEEVTLRTFQDTISTVPEKQLSTPPLPRGGRPQKVAAHITGITRRSNSALIPISKDGKTLGQKIESWESSRKGHSFLNHVLFRNGELVIEQEGLYYIYSQTYFRFQEAEDASKMVSKDKVRTKQLVQYIYKYTSYPDPIVLMKSARNSCWSRDAEYGLYSIYQGGLFELKKNDRIFVSVTNEHLMDLDQEASFFGAFLIN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	507	69	MRRASRDYGKYLRSSEEMGSGPGVPHEGPLHPAPSAPAPAPPPAASRSMFLALLGLGLGQVVCSIALFLYFRAQMDPNRISEDSTHCFYRILRLHENADLQDSTLESEDTLPDSCRRMKQAFQGAVQKELQHIVGPQRFSGAPAMMEGSWLDVAQRGKPEAQPFAHLTINAASIPSGSHKVTLSSWYHDRGWAKISNMTLSNGKLRVNQDGFYYLYANICFRHHETSGSVPTDYLQLMVYVVKTSIKIPSSHNLMKGGSTKNWSGNSEFHFYSINVGGFFKLRAGEEISIQVSNPSLLDPDQDATYFGAFKVQDID	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF12_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	278	58	MAARRSQRRRGRRGEPGTALLAPLVLSLGLALACLGLLLVVVSLGSWATLSAQEPSQEELTAEDRREPPELNPQTEESQDVVPFLEQLVRPRRSAPKGRKARPRRAIAAHYEVHPRPGQDGAQAGVDGTVSGWEETKINSSSPLRYDRQIGEFTVIRAGLYYLYCQVHFDEGKAVYLKLDLLVNGVLALRCLEEFSATAASSPGPQLRLCQVSGLLPLRPGSSLRIRTLPWAHLKAAPFLTYFGLFQVH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF13_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	372	44	MPASSPGHMGGSVREPALSVALWLSWGAVLGAVTCAVALLIQQTELQSLRREVSRLQRSGGPSQKQGERPWQSLWEQSPDVLEAWKDGAKSRRRRAVLTQKHKKKHSVLHLVPVNITSKADSDVTEVMWQPVLRRGRGLEAQGDIVRVWDTGIYLLYSQVLFHDVTFTMGQVVSREGQGRRETLFRCIRSMPSDPDRAYNSCYSAGVFHLHQGDIITVKIPRANAKLSLSPHGTFLGFVKL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF14_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	424	51	MESVVQPSVFVVDGQTDIPFRRLEQNHRRRRCGTVQVSLALVLLLGAGLATQGWFLLRLHQRLGDIVAHLPDGGKGSWEKLIQDQRSHQANPAAHLTGANASLIGIGGPLLWETRLGLAFLRGLTYHDGALVTMEPGYYYVYSKVQLSGVGCPQGLANGLPITHGLYKRTSRYPKELELLVSRRSPCGRANSSRVWWDSSFLGGVVHLEAGEEVVVRVPGNRLVRPRDGTRSYFGAFMV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	367	33	MAEELGLGFGEGVPVEVLPEGCRHRPEARAGLAARSKACLALTCCLLSFPILAGLSTLLMAGQLRVPGKDCMLRAITEERSEPSPQQVYSPPRGKPRAHLTIKKQTPAPHLKNQLSALHWEHDLGMAFTKNGMKYINKSLVIPESGDYFIYSQITFRGTTSVCGDISRGRRPNKPDSITVVITKVADSYPEPARLLTGSKSVCEISNNWFQSLYLGAMFSLEEGDRLMVNVSDISLVDYTKEDKTFFGAFLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNF18_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	68	MEEMPLRESSPQRAERCKKSWLLCIVALLLMLLCSLGTLIYTSLKPTAIESCMVKFELSSSKWHMTSPKPHCVNTTSDGKLKILQSGTYLIYGQVIPVDKKYIKDNAPFVVQIYKKNDVLQTLMNDFQILPIGGVYELHAGDNIYLKFNSKDHIQKTNTYWGIILMPDLPFIS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	394	49	MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQRDEKFPNGLPLISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGMDLKDNQLVVPADGLYLVYSQVLFKGQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPWYEPIYLGGVFQLEKGDQLSAEVNLPKYLDFAESGQVYFGVIAL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	573	68	MTLLGRLHLLRVLGTPPVFLLGLLLALPLGAQGLSGVRFSAARTAHPLPQKHLTHGILKPAAHLVGYPSKQNSLLWRASTDRAFLRHGFSLSNNSLLIPTSGLYFVYSQVVFSGESCSPRAIPTPIYLAHEVQLFSSQYPFHVPLLSAQKSVYPGLQGPWVRSMYQGAVFLLSKGDQLSTHTDGISHLHFSPSSVFFGAFAL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	327	31	MGTRGLQGLGGRPQGRGCLLLAVAGATSLVTLLLAVPITVLAVLALVPQDQGRRVEKIIGSGAQAQKRLDDSKPSCILPSPSSLSETPDPRLHPQRSNASRNLASTSQGPVAQSSREASAWMTILSPAADSTPDPGVQQLPKGEPETDLNPELPAAHLIGAWMSGQGLSWEASQEEAFLRSGAQFSPTHGLALPQDGVYYLYCHVGYRGRTPPAGRSRARSLTLRSALYRAGGAYGRGSPELLLEGAETVTPVVDPIGYGSLWYTSVGFGGLAQLRSGERVYVNISHPDMVDYRRGKTFFGAVMVG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFL4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	67	MEGEGVQPLDENLENGSRPRFKWKKTLRLVVSGIKGAGMLLCFIYVCLQLSSSPAKDPPIQRLRGAVTRCEDGQLFISSYKNEYQTMEVQNNSVVIKCDGLYIIYLKGSFFQEVKIDLHFREDHNPISIPMLNDGRRIVFTVVASLAFKDKVYLTVNAPDTLCEHLQINDGELIVVQLTPGYCAPEGSYHSTVNQVPL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFL6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	214	20	MQQPMNYPCPQIFWVDSSATSSWAPPGSVFPCPSCGPRGPDQRRPPPPPPPVSPLPPPSQPLPLPPLTPLKKKDHNTNLWLPVVFFMVLVALVGMGLGMYQLFHLQKELAELREFTNQSLKVSSFEKQIANPSTPSEKKEPRSVAHLTGNPHSRSIPLEWEDTYGTALISGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNQPLNHKVYMRNSKYPEDLVLMEEKRLNYCTTGQIWAHSSYLGAVFNLTSADHLYVNISQLSLINFEESKTFFGLYKL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFL8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	708	44	MEPGLQQAGSCGAPSPDPAMQVQPGSVASPWRSTRPWRSTSRSYFYLSTTALVCLVVAVAIILVLVVQKKDSTPNTTEKAPLKGGNCSEDLFCTLKSTPSKKSWAYLQVSKHLNNTKLSWNEDGTIHGLIYQDGNLIVQFPGLYFIVCQLQFLVQCSNHSVDLTLQLLINSKIKKQTLVTVCESGVQSKNIYQNLSQFLLHYLQVNSTISVRVDNFQYVDTNTFPLDNVLSVFLYSSSD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TNFL9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	537	41	MDQHTLDVEDTADARHPAGTSCPSDAALLRDTGLLADAALLSDTVRPTNAALPTDAAYPAVNVRDREAAWPPALNFCSRHPKLYGLVALVLLLLIAACVPIFTRTEPRPALTITTSPNLGTRENNADQVTPVSHIGCPNTTQQGSPVFAKLLAKNQASLCNTTLNWHSQDGAGSSYLSQGLRYEEDKKELVVDSPGLYYVFLELKLSPTFTNTGHKVQGWVSLVLQAKPQVDDFDNLALTVELFPCSMENKLVDRSWSQLLLLKAGHRLSVGLRAYLHGAQDAYRDWELSYPNTTSFGLFLVKPDNPWE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TPO_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	643	40	MELTDLLLAAMLLAVARLTLSSPVAPACDPRLLNKLLRDSHLLHSRLSQCPDVDPLSIPVLLPAVDFSLGEWKTQTEQSKAQDILGAVSLLLEGVMAARGQLEPSCLSSLLGQLSGQVRLLLGALQGLLGTQLPLQGRTTAHKDPNALFLSLQQLLRGKVRFLLLVEGPTLCVRRTLPTTAVPSSTSQLLTLNKFPNRTSGLLETNFSVTARTAGPGLLSRLQGFRVKITPGQLNQTSRSPVQISGYLNRTHGPVNGTHGLFAGTSLQTLEASDISPGAFNKGSLAFNLQGGLPPSPSLAPDGHTPFPPSPALPTTHGSPPQLHPLFPDPSTTMPNSTAPHPVTMYPHPRNLSQET	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_TSLP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	195	30	MVLLRSLFILQVLVRMGLTYNFSNCNFTSITKIYCNIIFHDLTGDLKGAKFEQIEDCESKPACLLKIEYYTLNPIPGCPSLPDKTFARRTREALNDHCPGYPETERNDGTQEMAQEVQNICLNQTSQILRLWYSFMQSPE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_X3CL1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	339	32	MAPSPLAWLLRLAAFFHLCTLLPGQHLGMTKCEIMCDKMTSRIPVALLIRYQLNQESCGKRAIVLETTQHRRFCADPKEKWVQDAMKHLDHQAAALTKNGGKFEKRVDNVTPGITLATRGLSPSALTKPESATLEDLALELTTISQEARGTMGTSQEPPAAVTGSSLSTSEAQDAGLTAKPQSIGSFEAADISTTVWPSPAVYQSGSSSWAEEKATESPSTTAPSPQVSTTSPSTPEENVGSEGQPPWVQGQDLSPEKSLGSEEINPVHTDNFQERGPGNTVHPSVAPISSEETPSPELVASGSQAPKIEEPIHATADPQKLSVLITPVPDTQAATRRQAVGLLAFLGLLFCLGVAMFAYQSLQGCPRKMAGEMVEGLRYVPRSCGSNSYVLVPV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineCytokines_XCL1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	317	57	MRLLLLTFLGVCCLTPWVVEGVGTEVLEESSCVNLQTQRLPVQKIKTYIIWEGAMRAVIFVTKRGLKICADPEAKWVKAAIKTVDGRASTRKNMAETVPTGAQRSTSTAITLTG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_ALR_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	222	73	MAAPSEPAGFPRGSRFSFLPGGARSEMTDDLVTDARGRGARHRDDTTPAAAPAPQGLEHGKRPCRACVDFKSWMRTQQKRDIKFREDCPQDREELGRHTWAFLHTLAAYYPDRPTPEQQQDMAQFIHIFSKFYPCEECAEDIRKRIGRNQPDTSTRVSFSQWLCRLHNEVNRKLGKPDFDCSRVDERWRDGWKDGSCD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_AREG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	37	MRTPLLPLARSVLLLLVLGSGHYAAALELNDPSSGKGESLSGDHSAGGLELSVGREVSTISEMPSGSELSTGDYDYSEEYDNEPQISGYIIDDSVRVEQVIKPKKNKTEGEKSTEKPKRKKKGGKNGKGRRNKKKKNPCTAKFQNFCIHGECRYIENLEVVTCNCHQDYFGERCGEKSMKTHSEDDKDLSKIAVVAVTIFVSAIILAAIGIGIVITVHLWKRYFREYEGETEERRRLRQENGTVHAIA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_ARTN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	240	59	MELGLAEPTALSHCLRPRWQSAWWPTLAVLALLSCVTEASLDPMSRSPAARDGPSPVLAPPTDHLPGGHTAHLCSERTLRPPPQSPQPAPPPPGPALQSPPAALRGARAARAGTRSSRARTTDARGCRLRSQLVPVSALGLGHSSDELIRFRFCSGSCRRARSQHDLSLASLLGAGALRSPPGSRPISQPCCRPTRYEAVSFMDVNSTWRTVDHLSATACGCLG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BDNF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	5	5	MTILFLTMVISYFGCMKAAPMKEVNVHGQGNLAYPGVRTHGTLESVNGPRAGSRGLTTTSLADTFEHVIEELLDEDQKVRPNEENHKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	478	78	MPGVARPPLPLLSLPLLLLLLLLPRAGRPLDLADYTYDLGEEDAPELLNYKDPCKAAAFLGDIALDEEDLRAFQVQQAAVLRQQTARRPSIKAAGNSSALGGQGTSGQPQRESRGRWRGRPRSRRAATSRPERVWPDGVIPFVIGGNFTGSQRAVFRQAMRHWEKHTCVTFLERTDEDSYIVFTYRPCGCCSYVGRRGGGPQAISIGKNCDKFGIVVHELGHVIGFWHEHTRPDRDRHVSIVRENIQPGQEYNFLKMEVQEVESLGETYDFDSIMHYARNTFSRGIFLDTIVPKYEVNGVKPSIGQRTRLSKGDIAQARKLYKCPACGETLQDSTGNFSSPEYPNGYSAHMHCVWRISVTPGEKIILNFTSMDLYRSRLCWYDYVEVRDGFWRKAPLRGRFCGGKLPEPIVSTDSRLWVEFRSSSNWVGKGFFAVYEAICGGDVKKDNGHIQSPNYPDDYRPSKVCIWRIQVSEGFHVGLTFQSFEIERHDSCAYDYLEVRDGHSESSNLIGRYCGYEKPDDIKSTSSRLWLKFVSDGSINKAGFAVNFFKEVDECSRPNRGGCEQRCLNTLGSYKCSCDPGYELAPDKRRCEAACGGFLTKLNGSITSPGWPKEYPPNKNCIWQLVAPTQYRISLQFDFFETEGNDVCKYDFVEVRSGLTADSKLHGKFCGSEKPEVITSQYNNMRVEFKSDNTVSKKGFKAHFFSDKDECSKDNGGCQQDCVNTFGSYECQCRSGFVLHDNKHDCKEAGCEHKVTSTSGTITSPNWPDKYPSKKECTWAISSTPGHRVKLTFVEMDIESQPECAYDHLEVFDGRDAKAPVLGRFCGSKKPEPVLATGNRMFLRFYSDNSVQRKGFQASHSTECGGQVRADVKTKDLYSHAQFGDNNYPGGVDCEWVIVAEEGYGVELVFQTFEVEEETDCGYDYIELFDGYDSTAPRLGRYCGSGPPEEVYSAGDSVLVKFHSDDTISKKGFHLRYTSTKFQDTLHSRK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	MGSLVLPLSAVFCLVAHSASGSPIMGLEQSPLEEDMPFFDDIFTEQDGIDFNTLLQSMKNEFLKTLNLSDIPVQDTGRVDPPEYMLELYNKFATDRTSMPSANIIRSFKNEDLFSQPVTFNGLRKYPLLFNVSIPHHEEVVMAELRLYTLVQRDRMMYDGVDRKITIFEVLESADGSEEERSMLVLVSTEIYGTNSEWETFDVTDATRRWQKSGPSTHQLEIHIESRQNQAEDTGRGQLEIDMSAQNKHDPLLVVFSDDQSNDKEQKEELNELITHEQDLDLDSDAFFSGPDEEALLQMRSNMIDDSSARIRRNAKGNYCKKTPLYIDFKEIGWDSWIIAPPGYEAYECRGVCNYPLAEHLTPTKHAIIQALVHLKNSQKASKACCVPTKLDPISILYLDKGVVTYKFKYEGMAVSECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1047	83	MALLTILRILLWGVVLFMEQRVQMAKPGWPSTALLADDPTLPSILDLAKEAPGKEMKQWPQGYPLRYMLKLYHRSADPHGHPRENRTIGAKMVRLVKPSANTVRPPRGSWHVQTLDFPLASNQVAYELIRATVVYRHQLHLVNYHLSCHVETWVPKCRTKHLPSSKSGSSKPSPMSKAWTEIDITHCIQQKLWNRKGRSVLRLRFMCQQQKGNETREFRWHGMTSLDVAFLLLYFNDTDDRVQGKLLARGQEELTDRESSFLMRSVRQACSIESDASCPSQEHDGSVNNQCSLHPYKVSFHQLGWDHWIIAPRLYTPNYCKGICTRVLPYGLNSPNHAIIQSLVNELVNHSVPQPSCVPYNFLPMSILLIETNGSILYKEYEGMIAQSCTCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	432	81	MVAGTRCLLVLLLPQVLLGGAAGLIPELGRKKFAAASSRPLSRPSEDVLSEFELRLLSMFGLKQRPTPSKDVVVPPYMLDLYRRHSGQPGAPAPDHRLERAASRANTVRSFHHEEAVEELPEMSGKTARRFFFNLSSVPSDEFLTSAELQIFREQIQEALGNSSFQHRINIYEIIKPAAANLKFPVTRLLDTRLVNQNTSQWESFDVTPAVMRWTTQGHTNHGFVVEVAHLEENPGVSKRHVRISRSLHQDEHSWSQIRPLLVTFGHDGKGHPLHKREKRQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	39	MAGARGLLCLWLGYFCLNLAQGQRPNLHLPGLRETEPSDRATGGSPSPDLRPHDKVSEHMLWLYDRYSGSSRVQATRTPGSQLPGPQPLRGGNTVRSFRAAAAGTPQTKGLHTFNLTSLTKSENILSATLYFYVGELVNISLSCPEPQGCSHHTQRQHIQIDLSAWILKSNQSQLLGHLSVDVVRPYRDSVSWLSKDITQLLRKAKQNEEFLIGFNITSRAHELPKRMLFFPEPYILVYANDAAISEPESVVSSLQRHRDFTAGTGPRLDSHVREALSVERRKKRSTGILLPLQNNELPGAEYQYKEEGAWEERKPYKSLQTQPPEKSRNKKKQRKGSHQKGQTLQFDEQTLKKARRKQWVEPRNCARRYLKVDFADIGWSEWIISPKSFDAFYCSGACQFPMPKSLKPSNHATIQSIVRAVGVVSGIPEPCCVPEKMSSLSILFFDENKNVVLKVYPNMTVDSCACR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	5	MIPGNRMLMVVLLCQVLLGGASHASLIPETGKKKVAEIQGHAGGRRSGQSHELLRDFEATLLQMFGLRRRPQPSKSAVIPDYMRDLYRLQSGEEEEEEQSQGTGLEYPERPASRANTVRSFHHEEHLENIPGTSESSAFRFLFNLSSIPENEVISSAELRLFREQVDQGPDWEQGFHRINIYEVMKPPAEMVPGHLITRLLDTRLVHHNVTRWETFDVSPAVLRWTREKQPNYGLAIEVTHLHQTRTHQGQHVRISRSLPQGSGDWAQLRPLLVTFGHDGRGHTLTRRRAKRSPKHHPQRSRKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFPLADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKVVLKNYQEMVVEGCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	197	40	MHWTVFLLRGIVGFLWSGWVQVGYAKGGLGDNHVHSSFIYRRLRNHERREIQREILSILGLPHRPRPFSPGKQASSAPLFMLDLYNAMASEDNPEEYLVRVSLAGEAKETRKGYPASPNGYAHRLHLPPRTPLTTQSPPLASLHDTNFLNDADMVMSFVNLVERDKDFSHQRRHYKEFRFDLTQIPHGEAVTAAEFRIYKDKGNHRFENETIKISIYQIIKEYTNRDADLFLLDTRKTQALDVGWLVFDITVTSNHWVINPQNNLGLQLCAETGDGRSINVKSAGLVGRHGPQSKQPFMVAFFKASEVLLRSVRAASKRKNQNRNKSNSHQDPSRMPSAGDYNTSEQKQACKKHELYVSFRDLGWQDWIIAPEGYAAFYCDGECSFPLNAHMNATNHAIVQTLVHLMFPDHVPKPCCAPTKLNAISVLYFDDSSNVILKKYRNMVVRSCGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	130	16	MPGLGRRAQWLCWWWGLLCSCGPPPLRPPLPVAAAAAGGQLLGAGGSPVRAEQPPPQSSSSGFLYRRLKTHEKREMQKEILSVLGLPHRPRPLHGLQQPQPPVLPPQQQQQQQQQQTAREEPPPGRLKSAPLFMLDLYNALSNDDEEDGASEGVGQEPGSHGGASSSQLRQPSPGAAHSLNRKSLLAPGPGGGASPLTSAQDSAFLNDADMVMSFVNLVEYDKEFSPHQRHHKEFKFNLSQIPEGEAVTAAEFRVYKDCVVGSFKNQTFLISIYQVLQEHQHRDSDLFLLDTRVVWASEEGWLEFDITATSNLWVVTPQHNMGLQLSVVTRDGLHVNPRAAGLVGRDGPYDKQPFMVAFFKVSEVHVRTTRSASSRRRQQSRNRSTQSQDVSRGSGSSDYNGSELKTACKKHELYVSFQDLGWQDWIIAPKGYAANYCDGECSFPLNAHMNATNHAIVQTLVHLMNPEYVPKPCCAPTKLNAISVLYFDDNSNVILKKYRNMVVRACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	54	MHVRSLRAAAPHSFVALWAPLFLLRSALADFSLDNEVHSSFIHRRLRSQERREMQREILSILGLPHRPRPHLQGKHNSAPMFMLDLYNAMAVEESGPDGQGFSYPYKAVFSTQGPPLASLQDSHFLTDADMVMSFVNLVEHDKEFFHPRYHHREFRFDLSKIPEGEAVTAAEFRIYKDYIRERFDNETFQITVYQVLQEHSGRESDLFLLDSRTIWASEEGWLVFDITATSNHWVVNPRHNLGLQLSVETLDGQSINPKLAGLIGRHGPQNKQPFMVAFFKATEVHLRSIRSTGGKQRSQNRSKTPKNQEALRMASVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPDTVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BMP8B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	680	50	MAARPGLLWLLGLALCVLGGGHLSHPPHVFPQRRLGVREPRDMQREIREVLGLPGRPRSRAPVGAAQQPASAPLFMLDLYRAMTDDSGGGTPQPHLDRADLIMSFVNIVERDRTLGYQEPHWKEFHFDLTQIPAGEAVTAAEFRIYKEPSTHPLNTTLHISMFEVVQEHSNRESDLFFLDLQTLRSGDEGWLVLDITAASDRWLLNHHKDLGLRLYVETEDGHSIDPGLAGLLGRQAPRSRQPFMVGFFRANQSPVRAPRTARPLKKKQLNQINQLPHSNKHLGILDDGHGSHGREVCRRHELYVSFRDLGWLDSVIAPQGYSAYYCAGECIYPLNSCMNSTNHATMQALVHLMKPDIIPKVCCVPTELSAISLLYYDRNNNVILRRERNMVVQACGCH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_BTC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	90	19	MDPTAPGSSVSSLPLLLVLALGLAILHCVVADGNTTRTPETNGSLCGAPGENCTGTTPRQKVKTHFSRCPKQYKHYCIHGRCRFVVDEQTPSCICEKGYFGARCERVDLFYLQQDRGQILVVCLIVVMVVFIILVIGVCTCCHPLRKHRKKKKEEKMETLDKDKTPISEDIQETNIA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CCN3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	28	MSLFLRKRCLCLGFLLFHLLSQVSASLRCPSRCPPKCPSISPTCAPGVRSVLDGCSCCPVCARQRGESCSEMRPCDQSSGLYCDRSADPNNQTGICMVPEGDNCVFDGVIYRNGEKFEPNCQYFCTCRDGQIGCLPRCQLDVLLPGPDCPAPRKVAVPGECCEKWTCGSDEQGTQGTLGGLALPAYRPEATVGVEVSDSSINCIEQTTEWSACSKSCGMGVSTRVTNRNRQCEMVKQTRLCIVRPCEQEPEEVTDKKGKKCLRTKKSLKAIHLQFENCTSLYTYKPRFCGVCSDGRCCTPHNTKTIQVEFQCLPGEIIKKPVMVIGTCTCYSNCPQNNEAFLQDLELKTSRGEI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CCN6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	141	44	MRRLLFCTLLMTGLTQLCCRTQGSAPQDSTPGGRPGAALEVYQRTEVCRWPCRCPPQRPTCPPGVSLVRDGCGCCKVCAKQPGDTCNEAEICDPHKGLYCDYSGDTPRYETGVCAYLVAVGCEFNRVYYQNGQVFQPHPLFSCLCVSGAIGCTPLFIPKLAGSNCSAAKGRRKTDPPNCGRGTLQQQNSASYKTMSAYRNLPLTWRKKCLVQATKWTPCSRTCGMGISNRVTNDNANCEMRKERRLCYIQPCSRNTSQAVKIPRGETCQPTFQLPKAEKFVFSGCSSTQSYRPTFCGICLDKRCCVPNKSKMITVRFDCPSEGSFKWQMLWVTSCVCQRDCREPGDIFSELRIL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CD320_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	313	29	MARGGAGRAVALGLVLRLLFGLRTGLEAAPAPAHTRVQVSGSRADSCPTDTFQCLTSGYCVPLSWRCDGDQDCSDGSDEEDCRIESCAQNGQCQPQSALPCSCDNISGCSDVSDKNLNCSRPPCQESELHCILDDVCIPHTWRCDGHPDCLDSSDELSCDTDTEIDKIFQEENATTTRISTTMENETSFRNVTFTSAGDSSRNPSAYGVIAAAGVLSAILVSATLLILLRLRGQGYLPPPGLLVAVKESLLLSERKTSLI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CDNF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	308	45	MRCISPTALVTFCAGFCISNPVLAQGLEAGVGPRADCEVCKEFLDRFYNSLLSRGIDFSADTIEKELLNFCSDAKGKENRLCYYLGATTDAATKILGEVTRPMSVHIPAVKICEKLKKMDSQICELKYGKKLDLASVDLWKMRVAELKQILQRWGEECRACAEKSDYVNLIRELAPKYVEIYPQTEL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CLC11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	407	56	MQAAWLLGALVVPQLLSFGHGARGPGREWEGGWGGALEEERERESQMLKNLQEALGLPTGVGNEDNLAENPEDKEVWETTETQGEEEEEEITTAPSSSPNPFPSPSPTPEDTVTYILGRLASLDAGLHQLHVRLHVLDTRVVELTQGLRQLRDAASDTRDSVQALKEVQDRAEQEHGRLEGCLKGLRLGHKCFLLSRDFETQAAAQARCKARGGSLAQPADRQQMDALSRYLRAALAPYNWPVWLGVHDRRSEGLYLFENGQRVSFFAWHRAFSLESGAQPSAATHPLSPDQPNGGVLENCVAQASDDGSWWDHDCERRLYFVCEFPF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CNTF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	437	48	MAFAEQSPLTLHRRDLCSRSIWLARKIRSDLTALMESYVKHQGLNKNISLDSVDGVPVASTDRWSEMTEAERLQENLQAYRTFQGMLTKLLEDQRVHFTPTEGDFHQAIHTLTLQVSAFAYQLEELMALLEQKVPEKEADGMPVTIGDGGLFEKKLWGLKVLQELSQWTVRSIHDLRVISSHHMGISAHESHYGAKQM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CSF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	561	43	MTARGAAGRCPSSTWLGSRLLLVCLLMSRSIAKEVSEHCSHMIGNGHLKVLQQLIDSQMETSCQIAFEFVDQEQLDDPVCYLKKAFFLVQDIIDETMRFKDNTPNANATERLQELSNNLNSCFTKDYEEQNKACVRTFHETPLQLLEKIKNFFNETKNLLEKDWNIFTKNCNNSFAKCSSRDVVTKPDCNCLYPKATPSSDPASASPHQPPAPSMAPLAGLAWDDSQRTEGSSLLPSELPLRIEDPGSAKQRPPRSTCQTLESTEQPNHGDRLTEDSQPHPSAGGPVPGVEDILESSLGTNWVLEEASGEASEGFLTQEAKFSPSTPVGGSIQAETDRPRALSASPFPKSTEDQKPVDITDRPLTEVNPMRPIGQTQNNTPEKTDGTSTLREDHQEPGSPHIATPNPQRVSNSATPVAQLLLPKSHSWGIVLPLGELEGKRSTRDRRSPAELEGGSASEGAARPVARFNSIPLTDTGHVEQHEGSSDPQIPESVFHLLVPGIILVLLTVGGLLFYKWKWRSHRDPQTLDSSVGRPEDSSLTQDEDRQVELPV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CSF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	384	70	MWLQNLLFLGIVVYSLSAPTRSPITVTRPWKHVEAIKEALNLLDDMPVTLNEEVEVVSNEFSFKKLTCVQTRLKIFEQGLRGNFTKLKGALNMTASYYQTYCPPTPETDCETQVTTYADFIDSLKTFLTDIPFECKKPGQK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_CSF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	68	MAQLSAQRRMKLMALQLLLWQSALWSGREAVPLVTVSALPPSLPLPRSFLLKSLEQVRKIQASGSVLLEQLCATYKLCHPEELVLLGHSLGIPKASLSGCSSQALQQTQCLSQLHSGLCLYQGLLQALSGISPALAPTLDLLQLDVANFATTIWQQMENLGVAPTVQPTQSAMPAFTSAFQRRAGGVLAISYLQGFLETARLALHHLA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_EGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1742	63	MPWGRRPTWLLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAGPAPFLVFSQGKSISRIDPDGTNHQQLVVDAGISADMDIHYKKERLYWVDVERQVLLRVFLNGTGLEKVCNVERKVSGLAIDWIDDEVLWVDQQNGVITVTDMTGKNSRVLLSSLKHPSNIAVDPIERLMFWSSEVTGSLHRAHLKGVDVKTLLETGGISVLTLDVLDKRLFWVQDSGEGSHAYIHSCDYEGGSVRLIRHQARHSLSSMAFFGDRIFYSVLKSKAIWIANKHTGKDTVRINLHPSFVTPGKLMVVHPRAQPRTEDAAKDPDPELLKQRGRPCRFGLCERDPKSHSSACAEGYTLSRDRKYCEDVNECATQNHGCTLGCENTPGSYHCTCPTGFVLLPDGKQCHELVSCPGNVSKCSHGCVLTSDGPRCICPAGSVLGRDGKTCTGCSSPDNGGCSQICLPLRPGSWECDCFPGYDLQSDRKSCAASGPQPLLLFANSQDIRHMHFDGTDYKVLLSRQMGMVFALDYDPVESKIYFAQTALKWIERANMDGSQRERLITEGVDTLEGLALDWIGRRIYWTDSGKSVVGGSDLSGKHHRIIIQERISRPRGIAVHPRARRLFWTDVGMSPRIESASLQGSDRVLIASSNLLEPSGITIDYLTDTLYWCDTKRSVIEMANLDGSKRRRLIQNDVGHPFSLAVFEDHLWVSDWAIPSVIRVNKRTGQNRVRLQGSMLKPSSLVVVHPLAKPGADPCLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCLPQDYPILSGENADLSKEVTSLSNSTQAEVPDDDGTESSTLVAEIMVSGMNYEDDCGPGGCGSHARCVSDGETAECQCLKGFARDGNLCSDIDECVLARSDCPSTSSRCINTEGGYVCRCSEGYEGDGISCFDIDECQRGAHNCGENAACTNTEGGYNCTCAGRPSSPGLSCPDSTAPSLLGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIESLDSYTCNCVIGYSGDRCQTRDLRWWELRHAGYGQKHDIMVVAVCMVALVLLLVLGMWGTYYYRTRKQLSNPPKNPCDEPSGSVSSSGPNSSSGAAVASCPQPWFVVLEKHQDPKNGSLPADGTNGAVVDAGLSPSLQLGSVHLTSWRQKPHIDGMGTGQSCWIPPSSDRGPQEIEGNSHLPSYRPVGPEKLHSLQSANGSCHERAPDLPRQTEPVQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_EPGN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	314	77	MALGVLIAVCLLFKAMKAALSEEAEVIPPSTAQQSNWTFNNTEADYIEEPVALKFSHPCLEDHNSYCINGACAFHHELKQAICRCFTGYTGQRCEHLTLTSYAVDSYEKYIAIGIGVGLLISAFLAVFYCYIRKRCINLKSPYIICSGGSPL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_EREG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	150	20	METLPASWVLTLLCLGSHLLQAVISTTVIPSCIPGESEDNCTALVQMEDDPRVAQVQITKCSSDMDGYCLHGQCIYLVDMREKFCRCEVGYTGLRCEHFFLTVHQPLSKEYVALTVILIFLFLIITAGCIYYFCRWYKNRKSKKSREEYERVTSGDPVLPQV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FBLN3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	405	40	MLQTLFLTMLTLALVKSQYTEETITYTQCTDGYEWDPIRQQCKDIDECDIVPDACKGGMKCVNHYGGYLCLPKTAQIIVNNEHPQQETPAAEASSGATTGTVAARSMATSGVVPGGGFMASATAVAGPEVQTGRNNFVIRRNPADPQRIPSNPSHRIQCAAGYEQSEHNVCQDIDECTSGTHNCRTDQVCINLRGSFTCQCLPGYQKRGEQCVDIDECTVPPYCHQRCVNTPGSFYCQCSPGFQLAANNYTCVDINECDASNQCAQQCYNILGSFICQCNQGYELSSDRLNCEDIDECRTSSYLCQYQCVNEPGKFSCMCPQGYEVVRSRTCQDINECETTNECREDEMCWNYHGGFRCYPRNPCQDHYVLTSENRCVCPVSNTMCRELPQSIVYKYMSIRSDRSVPSDIFQIQATMIYANTINTFRIKSGNENGEFYLRQTSPVSAMLVLVKSLSGPREYIVDLEMLTVSSIGTFRTSSVLRLTIIVGPFSF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	71	22	MAEGEITTFAALTERFNLPLGNYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESAGEVYIKGTETGQYLAMDTEGLLYGSQTPNEECLFLERLEENHYNTYTSKKHAEKNWFVGLKKNGSCKRGPRTHYGQKAILFLPLPVSSD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	157	28	MWKWILTHCASAFPHLPGCCCCFLLLFLVSSFPVTCQALGQDMVSQEATNCSSSSSSFSSPSSAGRHVRSYNHLQGDVRWRRLFSFTKYFLTIEKNGKVSGTKNEDCPYSVLEITSVEIGVVAVKAINSNYYLAMNKKGKLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRRGQKTRRKNTSAHFLPMTIQT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	47	15	MAALASSLIRQKREVREPGGSRPVSAQRRVCPRGTKSLCQKQLLILLSKVRLCGGRPTRQDRGPEPQLKGIVTKLFCRQGFYLQANPDGSIQGTPEDTSSFTHFNLIPVGLRVVTIQSAKLGHYMAMNAEGLLYSSPHFTAECRFKECVFENYYVLYASALYRQRRSGRAWYLGLDKEGRVMKGNRVKKTKAAAHFVPKLLEVAMYREPSLHSVPETSPSSPPAH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF12_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MAAAIASSLIRQKRQARESNSDRVSASKRRSSPSKDGRSLCERHVLGVFSKVRFCSGRKRPVRRRPEPQLKGIVTRLFSQQGYFLQMHPDGTIDGTKDENSDYTLFNLIPVGLRVVAIQGVKASLYVAMNGEGYLYSSDVFTPECKFKESVFENYYVIYSSTLYRQQESGRAWFLGLNKEGQIMKGNRVKKTKPSSHFVPKPIEVCMYREPSLHEIGEKQGRSRKSSGTPTMNGGKVVNQDST	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF14_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	10	10	MAAAIASGLIRQKRQAREQHWDRPSASRRRSSPSKNRGLFNGNLVDIFSKVRIFGLKKRRLRRQDPQLKGIVTRLYCRQGYYLQMHPDGALDGTKDDSTNSTLFNLIPVGLRVVAIQGVKTGLYIAMNGEGYLYPSELFTPECKFKESVFENYYVIYSSMLYRQQESGRAWFLGLNKEGQVMKGNRVKKTKPAAHFLPKPLEVAMYREPSLHDVGETVPKAGVTPSKSTSASAIMNGGKPVNKCKTT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	795	51	MARKWNGRAVARALVLATLWLAVSGRPLAQQSQSVSDEDPLFLYGWGKITRLQYLYSAGPYVSNCFLRIRSDGSVDCEEDQNERNLLEFRAVALKTIAIKDVSSVRYLCMSADGKIYGLIRYSEEDCTFREEMDCLGYNQYRSMKHHLHIIFIQAKPREQLQDQKPSNFIPVFHRSFFETGDQLRSKMFSLPLESDSMDPFRMVEDVDHLVKSPSFQK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF16_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MAEVGGVFASLDWDLHGFSSSLGNVPLADSPGFLNERLGQIEGKLQRGSPTDFAHLKGILRRRQLYCRTGFHLEIFPNGTVHGTRHDHSRFGILEFISLAVGLISIRGVDSGLYLGMNERGELYGSKKLTRECVFREQFEENWYNTYASTLYKHSDSERQYYVALNKDGSPREGYRTKRHQKFTHFLPRPVDPSKLPSMSRDLFRYR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF17_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MGAARLLPNLTLCLQLLILCCQTQGENHPSPNFNQYVRDQGAMTDQLSRRQIREYQLYSRTSGKHVQVTGRRISATAEDGNKFAKLIVETDTFGSRVRIKGAESEKYICMNKRGKLIGKPSGKSKDCVFTEIVLENNYTAFQNARHEGWFMAFTRQGRPRQASRSRQNQREAHFIKRLYQGQLPFPNHAERQKQFEFVGSAPTRRTKRTRRPQSQT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF18_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	8	MYSAPSACTCLCLHFLLLCFQVQVLAAEENVDFRIHVENQTRARDDVSRKQLRLYQLYSRTSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKGKETEFYLCMNRKGKLVGKPDGTSKECVFIEKVLENNYTALMSAKYSGWYVGFTKKGRPRKGPKTRENQQDVHFMKRYPKGQAELQKPFKYTTVTKRSRRIRPTHPG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	77	30	MAASGITSLPALPEDGGAAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHVKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTEECFFFERLESNNYNTYRSRKYSSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF20_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	15	10	MAPLTEVGAFLGGLEGLSQQVGSHFLLPPAGERPPLLGERRGALERGARGGPGSVELAHLHGILRRRQLYCRTGFHLQILPDGTVQGTRQDHSLFGILEFISVAVGLVSIRGVDSGLYLGMNDKGELYGSEKLTSECIFREQFEENWYNTYSSNIYKHGDTGRRYFVALNKDGTPRDGARSKRHQKFTHFLPRPVDPERVPELYKDLLMYT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF21_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	354	54	MEWMRSRVGTLGLWVRLLLAVFLLGVYQAYPIPDSSPLLQFGGQVRQRYLYTDDDQDTEAHLEIREDGTVVGAAHRSPESLLELKALKPGVIQILGVKASRFLCQQPDGALYGSPHFDPEACSFRELLLEDGYNVYQSEAHGLPLRLPQKDSPNQDATSWGPVRFLPMPGLLHEPQDQAGFLPPEPPDVGSSDPLSMVEPLQGRSPSYAS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF22_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	504	57	MRSRLWLGLAWLLLARAPGAPGGYPHLEGDVRWRRLFSSTHFFLRVDLGGRVQGTRWRHGQDSIVEIRSVRVGTVVIKAVYSGFYVAMNRRGRLYGSRVYSVDCRFRERIEENGYNTYASRRWRHRGRPMFLALDSQGIPRQGRRTRRHQLSTHFLPVLVSS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF23_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	572	47	MLGTCLRLLVGVLCTVCSLGTARAYPDTSPLLGSNWGSLTHLYTATARTSYHLQIHRDGHVDGTPHQTIYSALMITSEDAGSVVITGAMTRRFLCMDLHGNIFGSLHFSPENCKFRQWTLENGYDVYLSQKHHYLVSLGRAKRIFQPGTNPPPFSQFLARRNEVPLLHFYTVRPRRHTRSAEDPPERDPLNVLKPRPRATPVPVSCSRELPSAEEGGPAASDPLGVLRRGRGDARGGAGGADRCRPFPRFV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	28	MGLIWLLLLSLLEPSWPTTGPGTRLRRDAGGRGGVYEHLGGAPRRRKLYCATKYHLQLHPSGRVNGSLENSAYSILEITAVEVGVVAIKGLFSGRYLAMNKRGRLYASDHYNAECEFVERIHELGYNTYASRLYRTGSSGPGAQRQPGAQRPWYVSVNGKGRPRRGFKTRRTQKSSLFLPRVLGHKDHEMVRLLQSSQPRAPGEGSQPRQRRQKKQSPGDHGKMETLSTRATPSTQLHTGGLAVA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	488	62	MAKRGPTTGTLLPRVLLALVVALADRGTAAPNGTRHAELGHGWDGLVARSLARLPVAAQPPQAAVRSGAGDYLLGLKRLRRLYCNVGIGFHLQVLPDGRIGGVHADTRDSLLELSPVQRGVVSIFGVASRFFVAMSSRGKLFGVPFFTDECKFKEILLPNNYNAYESYAYPGMFMALSKNGRTKKGNRVSPTMKVTHFLPRL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	134	22	MSLSLLFLIFCSHLIHSAWAHGEKRLTPEGQPAPPRNPGDSSGSRGRSSATFSSSSASSPVAASPGSQGSGSEHSSFQWSPSGRRTGSLYCRVGIGFHLQIYPDGKVNGSHEASVLSILEIFAVSQGIVGIRGVFSNKFLAMSKKGKLHASAKFTDDCKFRERFQENSYNTYASAIHRTEKTGREWYVALNKRGKAKRGCSPRVKPQHVSTHFLPRFKQSEQPELSFTVTVPEKKKPPVKPKVPLSQPRRSPSPVKYRLKFRFG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	292	41	MALGQRLFITMSRGAGRVQGTLQALVFLGVLVGMVVPSPAGARANGTLLDSRGWGTLLSRSRAGLAGEISGVNWESGYLVGIKRQRRLYCNVGIGFHLQVPPDGRISGTHEENPYSLLEISTVERGVVSLFGVKSALFIAMNSKGRLYTTPSFHDECKFRETLLPNNYNAYESDLYRGTYIALSKYGRVKRGSKVSPIMTVTHFLPRI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	238	68	MRKWILTRILPTLLYRSCFHLVCLVGTISLACNDMSPEQTATSVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNSYNIMEIRTVAVGIVAIKGVESEYYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHSGGEMFVALNQKGIPVKGKKTKKEQKTAHFLPMAIT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	45	19	MGSPRSALSCLLLHLLVLCLQAQVRSAAQKRGPGAGNPADTLGQGHEDRPFGQRSRAGKNFTNPAPNYPEEGSKEQRDSVLPKVTQRHVREQSLVTDQLSRRLIRTYQLYSRTSGKHVQVLANKRINAMAEDGDPFAKLIVETDTFGSRVRVRGAETGLYICMNKKGKLIAKSNGKGKDCVFTEIVLENNYTALQNAKYEGWYMAFTRKGRPRKGSKTRQHQREVHFMKRLPRGHHTTEQSLRFEFLNYPPFTRSLRGSQRTWAPEPR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_FGF9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	7	5	MAPLGEVGSYFGVQDAVPFGNVPVLPVDSPVLLSDHLGQSEAGGLPRGPAVTDLDHLKGILRRRQLYCRTGFHLEIFPNGTIQGTRKDHSRFGILEFISIAVGLVSIRGVDSGLYLGMNEKGELYGSEKLTQECVFREQFEENWYNTYSSNLYKHVDTGRRYYVALNKDGTPREGTRTKRHQKFTHFLPRPVDPDKVPELYKDILSQS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_G6PI_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	639	65	MAALTRNPQFQKLLEWHRANSANLKLRELFEADPERFNNFSLNLNTNHGHILVDYSKNLVNKEVMQMLVELAKSRGVEAARDNMFSGSKINYTENRAVLHVALRNRSNTPIKVDGKDVMPEVNRVLDKMKSFCQRVRSGDWKGYTGKSITDIINIGIGGSDLGPLMVTEALKPYSKGGPRVWFVSNIDGTHIAKTLASLSPETSLFIIASKTFTTQETITNAETAKEWFLEAAKDPSAVAKHFVALSTNTAKVKEFGIDPQNMFEFWDWVGGRYSLWSAIGLSIALHVGFDHFEQLLSGAHWMDQHFLKTPLEKNAPVLLALLGIWYINCYGCETHALLPYDQYMHRFAAYFQQGDMESNGKYITKSGARVDHQTGPIVWGEPGTNGQHAFYQLIHQGTKMIPCDFLIPVQTQHPIRKGLHHKILLANFLAQTEALMKGKLPEEARKELQAAGKSPEDLEKLLPHKVFEGNRPTNSIVFTKLTPFILGALIAMYEHKIFVQGIMWDINSFDQWGVELGKQLAKKIEPELEGSSAVTSHDSSTNGLISFIKQQRDTKLE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	403	36	MLPVCHRFCDHLLLLLLLPSTTLAPAPASMGPAAALLQVLGLPEAPRSVPTHRPVPPVMWRLFRRRDPQEARVGRPLRPCHVEELGVAGNIVRHIPDSGLSSRPAQPARTSGLCPEWTVVFDLSNVEPTERPTRARLELRLEAESEDTGGWELSVALWADAEHPGPELLRVPAPPGVLLRADLLGTAVAANASVPCTVRLALSLHPGATAACGRLAEASLLLVTLDPRLCPLPRLRRHTEPRVEVGPVGTCRTRRLHVSFREVGWHRWVIAPRGFLANFCQGTCALPETLRGPGGPPALNHAVLRALMHAAAPTPGAGSPCCVPERLSPISVLFFDNSDNVVLRHYEDMVVDECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF10_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	727	48	MAPGPARISLGSQLLPMVPLLLLLRGAGCGHRGPSWSSLPSAAAGLQGDRDSQQSPGDAAAALGPGAQDMVAIHMLRLYEKYNRRGAPPGGGNTVRSFRARLEMIDQKPVYFFNLTSMQDSEMILTAAFHFYSEPPRWPRAREVFCKPRAKNASCRLLTPGLPARLHLIFRSLSQNTATQGLLRGAMALTPPPRGLWQAKDISSIIKAARRDGELLLSAQLDTGEKDPGVPRPSSHMPYILVYANDLAISEPNSVAVSLQRYDPFPAGDFEPGAAPNSSADPRVRRAAQVSKPLQDNELPGLDERPAPALHAQNFHKHEFWSSPFRALKPRTGRKDRKKKDQDTFTAASSQVLDFDEKTMQKARRRQWDEPRVCSRRYLKVDFADIGWNEWIISPKSFDAYYCAGACEFPMPKIVRPSNHATIQSIVRAVGIVPGIPEPCCVPDKMNSLGVLFLDENRNAVLKVYPNMSVETCACR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	0	0	MVLAAPLLLGFLLLALELRPRGEAAEGPAAAAAAAAAAAGVGGERSSRPAPSAPPEPDGCPVCVWRQHSRELRLESIKSQILSKLRLKEAPNISREVVKQLLPKAPPLQQILDLHDFQGDALQPEDFLEEDEYHATTETVISMAQETDPAVQTDGSPLCCHFHFSPKVMFTKVLKAQLWVYLRPVPRPATVYLQILRLKPLTGEGTAGGGGGGRRHIRIRSLKIELHSRSGHWQSIDFKQVLHSWFRQPQSNWGIEINAFDPSGTDLAVTSLGPGAEGLHPFMELRVLENTKRSRRNLGLDCDEHSSESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGQCEYMFMQKYPHTHLVQQANPRGSAGPCCTPTKMSPINMLYFNDKQQIIYGKIPGMVVDRCGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	509	49	MSPGAFRVALLPLFLLVCVTQQKPLQNWEQASPGENAHSSLGLSGAGEEGVFDLQMFLENMKVDFLRSLNLSGIPSQDKTRAEPPQYMIDLYNRYTTDKSSTPASNIVRSFSVEDAISTAATEDFPFQKHILIFNISIPRHEQITRAELRLYVSCQNDVDSTHGLEGSMVVYDVLEDSETWDQATGTKTFLVSQDIRDEGWETLEVSSAVKRWVRADSTTNKNKLEVTVQSHRESCDTLDISVPPGSKNLPFFVVFSNDRSNGTKETRLELKEMIGHEQETMLVKTAKNAYQVAGESQEEEGLDGYTAVGPLLARRKRSTGASSHCQKTSLRVNFEDIGWDSWIIAPKEYDAYECKGGCFFPLADDVTPTKHAIVQTLVHLKFPTKVGKACCVPTKLSPISILYKDDMGVPTLKYHYEGMSVAECGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	971	73	MQPYQRLLALGFLLLTLPWGQTSEFQDSDLLQFLGLEKAPSPHRFQPVPRVLRKIIRAREAAAASGASQDLCYVKELGVRGNLLQLLPDQGFFLNTQKPFQDGSCLQKVLYFNLSAIKEKAKLTMAQLTLDLGPRSYYNLRPELVVALSVVQDRGVWGRSHPKVGRLLFLRSVPGPQGQLQFNLQGALKDWSSNRLKNLDLHLEILVKEDRYSRVTVQPENPCDRLLRSLHASLLVVTLNPKHCHPSSRKRRAAISVPKGFCRNFCHRHQLFINFQDLGWHKWVIAPKGFMANYCHGECPFSMTTYLNSSNYAFMQALMHMADPKVPKAVCVPTKLSPISMLYQDSDKNVILRHYEDMVVDECGCG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	171	29	MRLPKLLTLLLWHLAWLDLELICTVLGAPDLGQRTPGAKPGLTKAEAKERPPLARNVFRPGGHIYGVGATNARAKGSSGQTQAKKDEPRKMPPRSGGPETKPGPSSQTRQAAARTVTPKGQLPGGKASSKAGSAPSSFLLKKTREPGTPREPKEPFRPPPITPHEYMLSLYRTLSDADRKGGNSSVKLEAGLANTITSFIDKGQDDRGPAVRKQRYVFDISALEKDGLLGAELRILRKKPLDVAKPAVPSSGRVAQLKLSSCPSGRQPAALLDVRSVPGLDGSGWEVFDIWKLFRNFKNSAQLCLELEAWERGRAVDLRGLGFERTARQVHEKALFLVFGRTKKRDLFFNEIKARSGQDDKTVYEYLFSQRRKRRAPLANRQGKRPSKNLKARCSRKALHVNFKDMGWDDWIIAPLEYEAFHCEGLCEFPLRSHLEPTNHAVIQTLMNSMDPESTPPTCCVPTRLSPISILFIDSANNVVYKQYEDMVVESCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	220	30	MDTPRVLLWAIFLISFLWDLPGFQQASISSSSSSSTELDSTKDVGNRKEGKMQRTPQESAEGRTPPEHGLRQKDLRRRPPGQHQGQEPPGRGLRVVPHEYMLSIYKTYSIAEKLGINASFFQSSKSANTITSFVDRGLDDLSHTPLRRQKYLFDVSTLSDKEELVGAELRLYRQAPPTPWGLPARPLHLQLFPCLSPLLLDARTLDPQGPTQAGWEVFDVWQGLRPQPWKQLCLELRAAWGELDAGDTGARARGPQQPPPLDLRSLGFGRRVRPPQERALLVVFTRSQRKNLFTEMHEQLGSAEAAGAEGSWPAPSGSPDAGSWLPSPGRRRRRTAFASRHGKRHGKKSRLRCSRKPLHVNFKELGWDDWIIAPLEYEAYHCEGVCDFPLRSHLEPTNHAIIQTLMNSMDPGSTPPSCCVPTKLTPISILYIDAGNNVVYKQYEDMVVESCGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	577	44	MDLSAAAALCLWLLSACRPRDGLEAAAVLRAAGAGPAWSPGGGGGGRTLARAPGPSALQAAAVPGPRAVRRAAGSGFRNGSVVPHHFMMSLYRSLAGRAPVAAASGHGRVDTITGFTDQATQDETAAAEPGQSFLFDVSSLSEADEVVNAELRVLRRRSPEPDRDSATLLPRLLLSTCPDEAGTAHLLHSRAAEPLGGARWEAFDVTDAVQSHRRWPRASRKFCLVLRAVTASESSPLALRRLGFGWPGGGDGGGTAAEERALLVISSRTQRKESLFREIRAQARALRAAAEPPPDPGPGAGSRKANLGGRRRRRTALAGTRGAQGSGGGGGGGGGGGGGGGGGGGGAGRGHGRRGRSRCSRKSLHVDFKELGWDDWIIAPLDYEAYHCEGVCDFPLRSHLEPTNHAIIQTLLNSMAPDAAPASCCVPARLSPISILYIDAANNVVYKQYEDMVVEACGCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	414	68	MMQKLQMYVYIYLFMLIAAGPVDLNEGSEREENVEKEGLCNACAWRQNTRYSRIEAIKIQILSKLRLETAPNISKDAIRQLLPRAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQADGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVKTPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMSPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDF9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	623	50	MALPSNFLLGVCCFAWLCFLSSLSSQASTEESQSGASENVESEADPWSLLLPVDGTDRSGLLPPLFKVLSDRRGETPKLQPDSRALYYMKKLYKTYATKEGVPKPSRSHLYNTVRLFSPCAQQEQAPSNQVTGPLPMVDLLFNLDRVTAMEHLLKSVLLYTLNNSASSSSTVTCMCDLVVKEAMSSGRAPPRAPYSFTLKKHRWIEIDVTSLLQPLVTSSERSIHLSVNFTCTKDQVPEDGVFSMPLSVPPSLILYLNDTSTQAYHSWQSLQSTWRPLQHPGQAGVAARPVKEEAIEVERSPRRRRGQKAIRSEAKGPLLTASFNLSEYFKQFLFPQNECELHDFRLSFSQLKWDNWIVAPHRYNPRYCKGDCPRAVRHRYGSPVHTMVQNIIYEKLDPSVPRPSCVPGKYSPLSVLTIEPDGSIAYKEYEDMIATRCTCR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GDNF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	120	35	MKLWDVVAVCLVLLHTASAFPLPAGKRLLEAPAEDHSLGHRRVPFALTSDSNMPEDYPDQFDDVMDFIQATIKRLKRSPDKQAAALPRRERNRQAAAASPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGSCESAETMYDKILKNLSRSRRLTSDKVGQACCRPVAFDDDLSFLDDNLVYHILRKHSAKRCGCI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GMFB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	89	20	MSESLVVCDVAEDLVEKLRKFRFRKETHNAAIIMKIDKDERLVVLDEELEGVSPDELKDELPERQPRFIVYSYKYQHDDGRVSYPLCFIFSSPVGCKPEQQMMYAGSKNKLVQTAELTKVFEIRNTEDLTEEWLREKLGFFH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GMFG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	18	MSDSLVVCEVDPELKETLRKFRFRKETNNAAIIMKVDKDRQMVVLEDELQNISPEELKLELPERQPRFVVYSYKYVHDDGRVSYPLCFIFSSPVGCKPEQQMMYAGSKNRLVQTAELTKVFEIRTTDDLTETWLKEKLAFFR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_GROA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	368	67	MIPATRSLLCAALLLLATSRLATGAPIANELRCQCLQTMAGIHLKNIQSLKVLPSGPHCTQTEVIATLKNGREACLDPEAPLVQKIVQKMLKGVPK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_HBEGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	217	35	MKLLPSVMLKLFLAAVLSALVTGESLERLRRGLAAATSNPDPPTGSTNQLLPTGGDRAQGVQDLEGTDLNLFKVAFSSKPQGLATPSKERNGKKKKKGKGLGKKRDPCLRKYKDYCIHGECRYLQEFRTPSCKCLPGYHGHRCHGLTLPVENPLYTYDHTTVLAVVAVVLSSVCLLVIVGLLMFRYHRRGGYDLESEEKVKLGVASSH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_HDGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	2	2	MSRSNRQKEYKCGDLVFAKMKGYPHWPARIDEMPEAAVKSTANKYQVFFFGTHETAFLGPKDLFPYEESKEKFGKPNKRKGFSEGLWEIENNPTVKASGYQSSQKKSCAAEPEVEPEAHEGDGDKKGSAEGSSDEEGKLVIDEPAKEKNEKGTLKRRAGDVLEDSPKRPKESGDHEEEDKEIAALEGERPLPVEVEKNSTPSEPDSGQGPPAEEEEGEEEAAKEEAEAQGVRDHESL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_HDGR3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	11	5	MARPRPREYKAGDLVFAKMKGYPHWPARIDELPEGAVKPPANKYPIFFFGTHETAFLGPKDLFPYKEYKDKFGKSNKRKGFNEGLWEIENNPGVKFTGYQTIQQQSSSETEGEGGNTADASSEEEGDRVEDGKGKRKNEKGGSKRKKSYTSKKSSKQSRKSPGDEDDKDCKEEENKSSSEGGDAGNDTRNTTADLQKAGEGT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_HGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	677	63	MMWGTKLLPVLLLQHVLLHLLLLHVAIPYAEGQKKRRNTLHEFKKSAKTTLTKEDPLLKIKTKKVNSADECANRCIRNRGFTFTCKAFVFDKSRKRCYWYPFNSMSSGVKKGFGHEFDLYENKDYIRNCIIGKGGSYKGTVSITKSGIKCQPWNSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGPMDHTESGKTCQRWDQQTPHRHKFLPERYPDKGFDDNYCRNPDGKPRPWCYTLDPDTPWEYCAIKTCAHSAVNETDVPMETTECIQGQGEGYRGTSNTIWNGIPCQRWDSQYPHKHDITPENFKCKDLRENYCRNPDGAESPWCFTTDPNIRVGYCSQIPKCDVSSGQDCYRGNGKNYMGNLSKTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNKNYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTQTTVGWMVSLKYRNKHICGGSLIKESWVLTARQCFPARNKDLKDYEAWLGIHDVHERGEEKRKQILNISQLVYGPEGSDLVLLKLARPAILDNFVSTIDLPSYGCTIPEKTTCSIYGWGYTGLINADGLLRVAHLYIMGNEKCSQHHQGKVTLNESELCAGAEKIGSGPCEGDYGGPLICEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKVILTYKL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IGF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	237	73	MGKISSLPTQLFKICLCDFLKIKIHIMSSSHLFYLALCLLTFTSSTTAGPETLCGAELVDALQFVCGPRGFYFNKPTGYGSSIRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPTKAARSIRAQRHTDMPKTQKEVHLKNTSRGSAGNKTYRM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IGF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	33	MGIPVGKSMLVLLISLAFALCCIAAYGPGETLCGGELVDTLQFVCSDRGFYFSRPSSRANRRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTSQAVLPDDFPRYPVGKFFQYDTWRQSAGRLRRGLPALLRARRGRMLAKELKEFREAKRHRPLIVLPPKDPAHGGASSEMSSNHQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL11_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	366	41	MNCVCRLVLVVLSLWPDRVVAPGPPAGSPRVSSDPRADLDSAVLLTRSLLADTRQLAAQMRDKFPADGDHSLDSLPTLAMSAGTLGSLQLPGVLTRLRVDLMSYLRHVQWLRRAGGPSLKTLEPELGALQARLERLLRRLQLLMSRLALPQAAPDQPVIPLGPPASAWGSIRAAHAILGGLHLTLDWAVRGLLLLKTRL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL12A_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	701	80	MCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	476	35	MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKLPRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFECQFDDESATVVDFLRRWIAFCQSIISTSPQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	359	67	MVLASSTTSIHTMLLLLLMLFHLGLQASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL34_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	475	50	MPWGLAWLYCLGILLDVALGNENLEIWTLTQDKECDLTGYLRGKLQYKNRLQYMKHYFPINYRIAVPYEGVLRVANITRLQKAHVSERELRYLWVLVSLNATESVMDVLLEGHPSWKYLQEVQTLLENVQRSLMDVEIGPHVEAVLSLLSTPGLSLKLVRPKALLDNCFRVMELLYCSCCKQSPILKWQDCELPRLHPHSPGSLMQCTATNVYPLSRQTPTSLPGSPSSSHGSLP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	452	56	MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCRASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	334	41	MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGLDILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	411	32	MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELCNGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKARVLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL7_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	67	MFHVSFRYIFGIPPLILVLLPVTSSECHIKDKEGKAYESVLMISIDELDKMTGTDSNCPNNEPNFFRKHVCDDTKEAAFLNRAARKLKQFLKMNISEEFNVHLLTVSQGTQTLVNCTSKEEKNVKEQKKNDACFLKRLLREIKTCWNKILKGSI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_IL9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	259	38	MLVTYILASVLLFSSVLGQRCSTTWGIRDTNYLIENLKDDPPSKCSCSGNVTSCLCLSVPTDDCTTPCYREGLLQLTNATQKSRLLPVFHRVKRIVEVLKNITCPSFSCEKPCNQTMAGNTLSFLKSLLGTFQKTEMQRQKSRP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_INHA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	863	56	MVSQRSLLLLLLLTLRDVDSCQGPELVRELVLAKVKALFLDALGPPAMDGEGGDPGIRRLPRRHAVGGFMHRTSEPEEEDVSQAILFPATGATCEDQPAARGLAQEAEEGLFTYVFRPSQHIRSHQVTSAQLWFHTGLGRKSTAAANSSAPLLDLLVLSSGGPMAVPVSLGQGPPRWAVLHLAASAFPLLTHPILVLLLRCPLCSCSGRPETTPFLVAHTRARAPSAGERARRSTPSVPWPWSPAALRLLQRPPEEPAAHAFCHRAALNISFQELGWDRWIVHPPSFIFHYCHGSCGMPTSDLPLPVPGVPPTPVQPLFLVPGAKPCCAALPGSMRSLRVRTTSDGGYSFKYEMVPNLITQHCACI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_INHBA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	28	MPLLWLRGFLLASCWIIVRSSPTPGSEGHGSAPDCPSCALATLPKDGPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGDEAEEMGLKGERSELLLSEKVVDARKSTWHIFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEVDGDGKKKDGSDGGLEEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_INHBB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	26	MDGLPGRALGAACLLLLVAGWLGPEAWGSPTPPPSPAAPPPPPPPGAPGGSQDTCTSCGGGGGGFRRPEELGRVDGDFLEAVKRHILSRLQLRGRPNITHAVPKAAMVTALRKLHAGKVREDGRVEIPHLDGHASPGADGQERVSEIISFAETDGLASSRVRLYFFVSNEGNQNLFVVQASLWLYLKLLPYVLEKGSRRKVRVKVYFQEQGHGDRWNVVEKKVDLKRSGWHTFPITEAIQALFERGERRLNLDVQCDSCQELAVVPVFVDPGEESHRPFVVVQARLGDSRHRIRKRGLECDGRTSLCCRQQFFIDFRLIGWNDWIIAPTGYYGNYCEGSCPAYLAGVPGSASSFHTAVVNQYRMRGLNPGPVNSCCIPTKLSSMSMLYFDDEYNIVKRDVPNMIVEECGCA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_INHBC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	54	MASSLLLALLFLTPTTVVNPKTEGPCPACWGAIFDLESQRELLLDLAKKSILDKLHLSQRPILSRPVSRGALKTALQRLRGPRRETLLEHDQRQEEYEIISFADTDLSSINQTRLEFHFSGRMASGMEVRQTRFMFFVQFPHNATQTMNIRVLVLRPYDTNLTLTSQYVVQVNASGWYQLLLGPEAQAACSQGHLTLELVPESQVAHSSLILGWFSHRPFVAAQVRVEGKHRVRRRGIDCQGASRMCCRQEFFVDFREIGWNDWIIQPEGYAMNFCTGQCPLHVAGMPGISASFHTAVLNLLKANAAAGTTGRGSCCVPTSRRPLSLLYYDRDSNIVKTDIPDMVVEACGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_INHBE_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	73	MKLPKAQLWLILLWALVWVQSTRSACPSCGGPTLAPQGERALVLELAKQQILEGLHLTSRPRITRPLPQAALTRALRRLQPKSMVPGNREKVISFATIIDKSTSTYRSMLTFQLSPLWSHHLYHARLWLHVPPSFPGTLYLRIFRCGTTRCRGFRTFLAEHQTTSSGWHALTLPSSGLRSEDSGVVKLQLEFRPLDLNSTAAGLPRLLLDTAGQQRPFLELKIRANEPGAGRARRRTPTCEPETPLCCRRDHYVDFQELGWRDWILQPEGYQLNYCSGQCPPHLAGSPGIAASFHSAVFSLLKANNPWPAGSSCCVPTARRPLSLLYLDHNGNVVKTDVPDMVVEACGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_K1KB3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	397	38	MWFLILFLALSLGGIDAAPPVQSRIVGGFKCEKNSQPWHVAVYRYTQYLCGGVLLDPNWVLTAAHCYDDNYKVWLGKNNLFKDEPSAQHRFVSKAIPHPGFNMSLMRKHIRFLEYDYSNDLMLLRLSKPADITDTVKPITLPTEEPKLGSTCLASGWGSITPTKFQFTDDLYCVNLKLLPNEDCAKAHIEKVTDAMLCAGEMDGGKDTCKGDSGGPLICDGVLQGITSWGHTPCGEPDMPGVYTKLNKFTSWIKDTMAKNP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_K1KB4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	281	43	MWFLILFLALSLGGIDAAPPVQSQVDCENSQPWHVAVYRFNKYQCGGVLLDRNWVLTAAHCYNDKYQVWLGKNNFLEDEPSDQHRLVSKAIPHPDFNMSLLNEHTPQPEDDYSNDLMLLRLSKPADITDVVKPITLPTEEPKLGSTCLASGWGSTTPIKFKYPDDLQCVNLKLLPNEDCDKAHEMKVTDAMLCAGEMDGGSYTCEHDSGGPLICDGILQGITSWGPEPCGEPTEPSVYTKLIKFSSWIRETMANNP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_LFTY1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	416	43	MPFLWLCWALWALSLVSLREALTGEQILGSLLQQLQLDQPPVLDKADVEGMVIPSHVRTQYVALLQHSHASRSRGKRFSQNLREVAGRFLVSETSTHLLVFGMEQRLPPNSELVQAVLRLFQEPVPRTALRRQKRLSPHSARARVTIEWLRFRDDGSNRTALIDSRLVSIHESGWKAFDVTEAVNFWQQLSRPRQPLLLQVSVQREHLGPGTWSSHKLVRFAAQGTPDGKGQGEPQLELHTLDLKDYGAQGNCDPEAPVTEGTRCCRQEMYLDLQGMKWAENWILEPPGFLTYECVGSCLQLPESLTSRWPFLGPRQCVASEMTSLPMIVSVKEGGRTRPQVVSLPNMRVQTCSCASDGALIPRRLQP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_LFTY2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	435	37	MKSLWLCWALWVLPLAGPGAAMTEEQVLSSLLQQLQLSQAPTLDSADVEEMAIPTHVRSQYVALLQGSHADRSRGKRFSQNFREVAGRFLMSETSTHLLVFGMEQRLPPNSELVQAVLRLFQEPVPRTALRRFERLSPHSARARVTIEWLRVREDGSNRTALIDSRLVSIHESGWKAFDVTEAVNFWQQLSRPRQPLLLQVSVQREHLGPGTWSAHKLVRFAAQGTPDGKGQGEPQLELHTLDLKDYGAQGNCDPEVPVTEGTRCCRQEMYLDLQGMKWAENWILEPPGFLTYECVGSCLQLPESLTIGWPFLGPRQCVASEMTSLPMIVSVKEGGRTRPQVVSLPNMRVQTCSCASDGALIPRGIDL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_LIF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	418	41	MKVLAAGIVPLLLLVLHWKHGAGSPLPITPVNATCAIRHPCHGNLMNQIKNQLAQLNGSANALFISYYTAQGEPFPNNVEKLCAPNMTDFPSFHGNGTEKTKLVELYRMVAYLSASLTNITRDQKVLNPTAVSLQVKLNATIDVMRGLLSNVLCRLCNKYRVGHVDVPPVPDHSDKEAFQRKKLGCQLLGTYKQVISVVVQAF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_MANF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	28	MWATRGLAVALALSVLPDSRALRPGDCEVCISYLGRFYQDLKDRDVTFSPATIEEELIKFCREARGKENRLCYYIGATDDAATKIINEVSKPLAHHIPVEKICEKLKKKDSQICELKYDKQIDLSTVDLKKLRVKELKKILDDWGEMCKGCAEKSDYIRKINELMPKYAPKAASARTDL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_MIA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	145	24	MVWSPVLLGIVVLSVFSGPSRADRAMPKLADWKLCADEECSHPISMAVALQDYVAPDCRFLTIYRGQVVYVFSKLKGRGRLFWGGSVQGGYYGDLAARLGYFPSSIVREDLTLKPGKIDMKTDQWDFYCQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_MIME_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	499	37	METVHSTFLLLLFVPLTQQAPQSQLDSHVNYEYATGNSEETKFSQDYEDKYLDGKSIKEKETMIIPDEKSLQLQKDEVIPSLPTKKENDEMPTCLLCVCLSGSVYCEEVDIDAVPPLPKESAYLYARFNKIKKLTAKDFADMPNLRRLDFTGNLIEDIEDGTFSKLSLLEELTLAENQLLRLPVLPPKLTLLNAKHNKIKSKGIKANTFKKLNKLSFLYLDHNDLESVPPNLPESLRVIHLQFNSISSLTDDTFCKANDTRYIRERIEEIRLEGNPIALGKHPNSFICLKRLPIGSYF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_MIS_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	1072	56	MQGPHLSPLVLLLATMGAVLQPEAVENLATNTRGLIFLEDELWPPSSPPEPLCLVTVRGEGNTSRASLRVVGGLNSYEYAFLEAVQESRWGPQDLATFGVCSTDSQATLPALQRLGAWLGETGEQQLLVLHLAEVIWEPELLLKFQEPPPGGASRWEQALLVLYPGPGPQVTVTGTGLRGTQNLCPTRDTRYLVLTVDFPAGAWSGSGLILTLQPSREGATLSIDQLQAFLFGSDSRCFTRMTPTLVVLPPAEPSPQPAHGQLDTMPFPQPGLSLEPEALPHSADPFLETLTRLVRALRGPLTQASNTQLALDPGALASFPQGLVNLSDPAALGRLLDWEEPLLLLLSPAAATEREPMPLHGPASAPWAAGLQRRVAVELQAAASELRDLPGLPPTAPPLLARLLALCPNDSRSSGDPLRALLLLKALQGLRAEWHGREGRGRTGRSAGTGTDGPCALRELSVDLRAERSVLIPETYQANNCQGACAWPQSDRNPRYGNHVVLLLKMQARGAALGRLPCCVPTAYAGKLLISLSEERISAHHVPNMVATECGCV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_MK_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	93	22	MQHRGFFLLALLALLVVTSAVAKKKEKVKKGSECSEWTWGPCTPSSKDCGMGFREGTCGAQTQRVHCKVPCNWKKEFGADCKYKFESWGACDGSTGTKARQGTLKKARYNAQCQETIRVTKPCTSKTKSKTKAKKGKGKD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	35	MSMLFYTLITAFLIGVQAEPYTDSNVPEGDSVPEAHWTKLQHSLDTALRRARSAPTAPIAARVTGQTRNITVDPRLFKKRRLHSPRVLFSTQPPPTSSDTLDLDFQAHGTIPFNRTHRSKRSSTHPVFHMGEFSVCDSVSVWVGDKTTATDIKGKEVTVLAEVNINNSVFRQYFFETKCRASNPVESGCRGIDSKHWNSYCTTTHTFVKALTTDEKQAAWRFIRIDTACVCVLSRKATRRG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NODAL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	516	65	MSAHSLRILLLQACWALLHPRAPTAAALPLWTRGQPSSPSPLAYMLSLYRDPLPRADIIRSLQAQDVDVTGQNWTFTFDFSFLSQEEDLVWAELRLQLPGPMDIPTEGPLTIDIFHQAKGDPERDPADCLERIWMETFTVIPSQVTFASGSTVLEVTKPLSKWLKDPRALEKQVSSRAEKCWHQPYTPPVPVASTNVLMLYSNRPQEQRQLGGATLLWEAESSWRAQEGQLSVERGGWGRRQRRHHLPDRSQLCRRVKFQVDFNLIGWGSWIIYPKQYNAYRCEGECPNPVGEEFHPTNHAYIQSLLKRYQPHRVPSTCCAPVKTKPLSMLYVDNGRVLLEHHKDMIVEECGCL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NRG1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	513	39	MSERKEGRGKGKGKKKDRGSRGKPAPAEGDPSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRRNKPQNVKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNDLTTGMSASTERPYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLIKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKHLGIEFMEAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRQKLHDRLRQSLRSERNNMVNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREVETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESIISESHSVIMMSSVENSRHSSPAGGPRGRLHGLGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSVAVSPFVEEERPLLLVTPPRLREKKYDHHPQQLNSFHHNPAHQSTSLPPSPLRIVEDEEYETTQEYEPIQEPIKKVTNSRRAKRTKPNGHIANRLEMDSNPSSVSSNSESETEDERVGEDTPFLGIQNPLAASLEVAPAFRLAESRTNPAGRFSTQEELQARLSSVIANQDPIAV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NRG2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	232	47	MRRDPAPGFSMLLFGVSLACYSPSLKSVQDQAYKAPVVVEGKVQGLAPAGGSSSNSTREPPASGRVALVKVLDKWPLRSGGLQREQVISVGSCAPLERNQRYIFFLEPTEQPLVFKTAFAPVDPNGKNIKKEVGKILCTDCATRPKLKKMKSQTGEVGEKQSLKCEAAAGNPQPSYRWFKDGKELNRSRDIRIKYGNGRKNSRLQFNKVRVEDAGEYVCEAENILGKDTVRGRLHVNSVSTTLSSWSGHARKCNETAKSYCVNGGVCYYIEGINQLSCKCPVGYTGDRCQQFAMVNFSKHLGFELKEAEELYQKRVLTITGICVALLVVGIVCVVAYCKTKKQRRQMHHHLRQNMCPAHQNRSLANGPSHPRLDPEEIQMADYISKNVPATDHVIRREAETTFSGSHSCSPSHHCSTATPTSSHRHESHTWSLERSESLTSDSQSGIMLSSVGTSKCNSPACVEARARRAAAYSQEERRRAAMPPYHDSIDSLRDSPHSERYVSALTTPARLSPVDFHYSLATQVPTFEITSPNSAHAVSLPPAAPISYRLAEQQPLLRHPAPPGPGPGSGPGADMQRSYDSYYYPAAGPGPRRSACALGGSLGSLPASPFRIPEDDEYETTQECAPPPPPRPRTRGASRRTSAGPRRWRRSRLNGLAAQRARAARDSLSLSSGSGCGSASASDDDADDADGALAAESTPFLGLRAAHDALRSDSPPLCPAADSRTYYSLDSHSTRASSRHSRGPPTRAKQDSGPL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NRG3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	234	26	MSEGAAGASPPGAASAAAASAEEGTAAAAAAAAAGGGPDGGGEGAAEPPRELRCSDCIVWNRQQTWLCVVPLFIGFIGLGLSLMLLKWIVVGSVKEYVPTDLVDSKGMGQDPFFLSKPSSFPKAMETTTTTTSTTSPATPSAGGAASSRTPNRISTRLTTITRAPTRFPGHRVPIRASPRSTTARNTAAPPTVLSTTAPFFSSSTPGSRPPMPGAPSTQAMPSWPTAAYATSSYLHDSTPSWTLSPFQDAAAASSSSPSSTSSTTTTPETSTSPKFHTTTYSTERSEHFKPCRDKDLAYCLNDGECFVIETLTGSHKHCRCKEGYQGVRCDQFLPKTDSILSDPTDHLGIEFMESEDVYQRQVLSISCIIFGIVIVGMFCAAFYFKSKKQAKQIQEHLKESQNGKNYSLKASSTKSESLMKSHVHLQNYSKADRHPVTALEKIMESSFSAPQSFPEVTSPDRGSQPIKHHSPGQRSGMLHRNTFRRAPPSPRSRLGGIVGPAYQQLEESRIPDQDTIPCQGIEVRKTISHLPIQLWCVERPLDLKYVSNGLRTQQNASINMQLPSRETNPYFNSLDQKDLVGYLSPRANSVPIIPSMGLEETCMQMPGISDVKSIKWCKNSYSADIVNASMPVSDCLLEEQQEVKILLETVQEQIRILTDARRSEDFELASMETEDSASENTAFLPLSPTAKSEREAQFVLRNEIQRDSVLTK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NRG4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	109	42	MPTDHEQPCGPRHRSFCLNGGICYVIPTIPSPFCRCIENYTGARCEEVFLPSSSIPSESNLSAAFVVLAVLLTLTIAALCFLCRKGHLQRASSVQCEISLVETNNTRTRHSHREH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NRTN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	189	30	MRRWKAAALVSLICSSLLSVWMCQEGLLLGHRLGPALAPLRRPPRTLDARIARLAQYRALLQGAPDAVELRELSPWAARIPGPRRRAGPRRRRARPGARPCGLRELEVRVSELGLGYTSDETVLFRYCAGACEAAIRIYDLGLRRLRQRRRVRRERARAHPCCRPTAYEDEVSFLDVHSRYHTLQELSARECACV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NTF3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	73	23	MSILFYVIFLAYLRGIQGNSMDQRSLPEDSLNSLIIKLIQADILKNKLSKQMVDVKENYQSTLPKAEAPREPEQGEATRSEFQPMIATDTELLRQQRRYNSPRVLLSDSTPLEPPPLYLMEDYVGNPVVANRTSPRRKRYAEHKSHRGEYSVCDSESLWVTDKSSAIDIRGHQVTVLGEIKTGNSPVKQYFYETRCKEARPVKNGCRGIDDKHWNSQCKTSQTYVRALTSENNKLVGWRWIRIDTSCVCALSRKIGRT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_NTF4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	245	62	MLPRHSCSLLLFLFLLPSVPMEPHPPSSTLPPFLAPEWDLLSPRVALSRGAPAGPPLLFLLEAGAYGEPAGAPANRSRRGVSETAPASRRGELAVCDAVSGWVTDRRTAVDLRGREVEVLGEVPAAGGSPLRQYFFETRCKAESAGEGGPGVGGGGCRGVDRRHWLSECKAKQSYVRALTADSQGRVGWRWIRIDTACVCTLLSRTGRA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PDGFA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	119	26	MRTWACLLLLGCGYLAHALAEEAEIPRELIERLARSQIHSIRDLQRLLEIDSVGAEDALETSLRAHGSHAINHVPEKRPVPIRRKRSIEEAIPAVCKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTGCCNTSSVKCQPSRVHHRSVKVAKVEYVRKKPKLKEVQVRLEEHLECACATSNLNPDHREEETGRRRESGKKRKRKRLKPT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PDGFB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	276	33	MNRCWALFLPLCCYLRLVSAEGDPIPEELYEMLSDHSIRSFDDLQRLLHRDSVDEDGAELDLNMTRAHSGVELESSSRGRRSLGSLAAAEPAVIAECKTRTEVFQISRNLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRASQVQMRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETIVTPRPVTRSPGTSREQRAKTPQARVTIRTVRIRRPPKGKHRKFKHTHDKAALKETLGA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PDGFC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	374	35	MLLLGLLLLTSALAGQRTGTRAESNLSSKLQLSSDKEQNGVQDPRHERVVTISGNGSIHSPKFPHTYPRNMVLVWRLVAVDENVRIQLTFDERFGLEDPEDDICKYDFVEVEEPSDGSVLGRWCGSGTVPGKQTSKGNHIRIRFVSDEYFPSEPGFCIHYSIIMPQVTETTSPSVLPPSSLSLDLLNNAVTAFSTLEELIRYLEPDRWQVDLDSLYKPTWQLLGKAFLYGKKSKVVNLNLLKEEVKLYSCTPRNFSVSIREELKRTDTIFWPGCLLVKRCGGNCACCLHNCNECQCVPRKVTKKYHEVLQLRPKTGVKGLHKSLTDVALEHHEECDCVCRGNAGG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PDGFD_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	324	28	MQRLVLVSILLCANFSCYPDTFATPQRASIKALRNANLRRDESNHLTDLYQREENIQVTSNGHVQSPRFPNSYPRNLLLTWWLRSQEKTRIQLSFDHQFGLEEAENDICRYDFVEVEEVSESSTVVRGRWCGHKEIPPRITSRTNQIKITFKSDDYFVAKPGFKIYYSFVEDFQPEAASETNWESVTSSFSGVSYHSPSITDPTLTADALDKTVAEFDTVEDLLKHFNPVSWQDDLENLYLDTPHYRGRSYHDRKSKVDLDRLNDDVKRYSCTPRNHSVNLREELKLTNAVFFPRCLLVQRCGGNCGCGTVNWKSCTCSSGKTVKKYHEVLKFEPGHFKRRGKAKNMALVDIQLDHHERCDCICSSRPPR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PLGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	230	21	MLVMKLFTCFLQVLAGLAVHSQGALSAGNNSTEVEVVPFNEVWGRSYCRPMEKLVYILDEYPDEVSHIFSPSCVLLSRCSGCCGDEGLHCVPIKTANITMQILKIPPNRDPHFYVEMTFSQDVLCECRPILETTKAERRKTKGKRKRSRNSQTEEPHP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PROK1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	56	16	MRGAVHIFIMLLLATASDCAVITGACERDIQCGAGTCCAISLWLRGLRLCTPLGREGEECHPGSHKIPFLRKRQHHTCPCSPSLLCSRFPDGRYRCFRDLKNANF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PSPN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	233	29	MAAGRLRILCLLLLSLHPSLGWVLDLQEASVADKLSFGKMAETRGTWTPHQGNNHVRLPRALAGSCRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLARLRGRGRAHGRPCCQPTSYADVTFLDDQHHWQQLPQLSAAACGCGG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_PTN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	63	48	MSSQQYQQQRRKFAAAFLALIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSGDCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTGSLKRALHNADCQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_SCF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	536	38	MKKTQTWIITCIYLQLLLFNPLVKTKEICGNPVTDNVKDITKLVANLPNDYMITLNYVAGMDVLPSHCWLRDMVIQLSLSLTTLLDKFSNISEGLSNYSIIDKLGKIVDDLVLCMEENAPKNIKESPKRPETRSFTPEEFFSIFNRSIDAFKDFMVASDTSDCVLSSTLGPEKDSRVSVTKPFMLPPVAASSLRNDSSSSNRKAAKAPEDSGLQWTAMALPALISLVIGFAFGALYWKKKQSSLTRAVENIQINEEDNEISMLQQKEREFQEV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_SDF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	124	39	MDAKVVAVLALVLAALCISDGKPVSLSYRCPCRFFESHIARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRLKM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TDGF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	203	65	MGYFSSSVVLLVAISSAFEFGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLNGGTCILGSFCACPPSFYGRNCEHDVRKEHCGSILHGTWLPKKCSLCRCWHGQLHCLPQTFLPGCDGHVMDQDLKASGTPCQTPSVTTTFMLAGACLFLDMKV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TFF1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	96	17	MEHKVICVLAVVLMLAFGSLAQAQAQAQAQEETCIMAPRERINCGFPGVTAQQCTERGCCFDDSVRGFPWCFHPMAIENTQEEECPF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TGFA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	17	5	MVPATGQLALLALGILLAVCQALENSTSPLSDSPVAAAVVSHFNKCPDSHTQYCFHGTCRFLVQEEKPACVCHSGYVGVRCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVLIHCCQLRKHCEWCRALVCRHEKPSALLKGRTACCHSETVV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TGFB1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	325	35	MPPSGLRLLPLLLPLPWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESADPEPEPEADYYAKEVTRVLMVDRNNAIYEKTKDISHSIYMFFNTSDIREAVPEPPLLSRAELRLQRLKSSVEQHVELYQKYSNNSWRYLGNRLLTPTDTPEWLSFDVTGVVRQWLNQGDGIQGFRFSAHCSCDSKDNKLHVEINGISPKRRGDLGTIHDMNRPFLLLMATPLERAQHLHSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASASPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TGFB2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	280	41	MHYCVLSTFLLLHLVPVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPDEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPSHLPSENAIPPTFYRPYFRIVRFDVSTMEKNASNLVKAEFRVFRLQNPKARVAEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVQEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYASGDQKTIKSTRKKTSGKTPHLLLMLLPSYRLESQQSSRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHTKVLSLYNTINPEASASPCCVSQDLEPLTILYYIGNTPKIEQLSNMIVKSCKCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TGFB3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	57	14	MHLQRALVVLALLNLATISLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPEPSVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQETSESEYYAKEIHKFDMIQGLAEHNELAVCPKGITSKVFRFNVSSVEKNGTNLFRAEFRVLRVPNPSSKRTEQRIELFQILRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILENVHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRLDSPGQGSQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANFCSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TIMP1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	534	65	MMAPFASLASGILLLLSLIASSKACSCAPPHPQTAFCNSDLVIRAKFMGSPEINETTLYQRYKIKMTKMLKGFKAVGNAADIRYAYTPVMESLCGYAHKSQNRSEEFLITGRLRNGNLHISACSFLVPWRTLSPAQQRAFSKTYSAGCGVCTVFPCLSIPCKLESDTHCLWTDQVLVGSEDYQSRHFACLPRNPGLCTWRSLGAR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_TSP4_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	448	41	MPAPRAAAAAFLLLHLVLQPWQRTSAQATPQVFDLLPSSSQRLNPSALQPVLTDPTLHEVYLISTFKLQSKSSATIFGLYSSSDNSKYFEFTVMGRLNKAILRYLKNDGKIHLVVFNNLQLADGRRHRVLLRLSNLQRGDGSVELYLDCAQADSVRNLPRAFSGLTQNPESIELRTFQRKPQDFLEELKLVVRGSLFQVASLQDCFLQQSEPLAATSTGDFNRQFLGQMTQLNQLLGEVKDLLRQQVKETSFLRNTIAECQACGPLSFQSPTPNTLVPIAPPAPPTRPTRHCDSSPCFRGVRCTDTRDGFQCGPCPDGYTGNGITCSDVDECKYHPCYPGVRCVNLAPGFRCDACPVGFTGPMVQGVGINFAKTNKQVCTDVDECQNGACVLNSICINTLGSYRCGPCKPGYTGDQTRGCKTERSCRNPEQNPCSVHAQCIEERQGDVTCVCGVGWAGDGYVCGKDVDIDSYPDEELPCSARNCKKDNCKYVPNSGQEDADRDGIGDACDEDADGDGILNEQDNCVLTHNIDQRNSDKDIFGDACDNCRMVLNNDQKDTDGDGRGDACDDDMDGDGIKNILDNCPRVPNRDQQDRDGDDVGDACDSCPDVSNPNQSDVDNDLVGDSCDTNQDSDGDGHQDSTDNCPTVINSSQLDTDKDGIGDECDDDDDNDGIPDLVPPGPDNCRLVPNPAQEDSNNDGVGDICEADFDQDQVIDHIDVCPENAEITLTDFRAYQTVVLDPEGDAQIDPNWVVLNQGMEIVQTMNSDPGLAVGYTAFNGVDFEGTFHVNTQTDDDYAGFIFGYQDSSSFYVVMWKQTEQTYWQATPFRAVAEPGIQLKAVKSKTGPGEHLRNSLWHTGDTSDQVRLLWKDSRNVGWKDKVSYRWFLQHRPQVGYIRVRFYEGSELVADSGVTIDTTMRGGRLGVFCFSQENIIWSNLKYRCNDTIPEDFQEFQTQSFDRLDN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_VEGFA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	341	44	MTDRQTDTAPSPSAHLLAGGLPTVDAAASREEPKPAPGGGVEGVGARGIARKLFVQLLGSSRSVVAVVCAAGDKPIGAGRSASSGLEKPGPEKRGEEEKEEERGPQWALGSQEPSSWTGEAAVCADSAPAARAPQAPARASVPEGRGARQGAQESGLPRSPSRRGSASRAGPGRASETMNFLLSWVHWTLALLLYLHHAKWSQAAPTTEGEQKSHEVIKFMDVYQRSYCRPIETLVDIFQEYPDEIEYIFKPSCVPLMRCAGCCNDEALECVPTSESNITMQIMRIKPHQSQHIGEMSFLQHSRCECRPKKDRTKPEKKSVRGKGKGQKRKRKKSRFKSWSVHCEPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_VEGFB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	253	17	MSPLLRRLLLVALLQLARTQAPVSQFDGPSHQKKVVPWIDVYARATCQPREVVVPLSMELMGNVVKQLVPSCVTVQRCGGCCPDDGLECVPTGQHQVRMQILMIQYPSSQLGEMSLEEHSQCECRPKKKESAVKPDRVAIPHHRPQPRSVPGWDSTPGASSPADIIHPTPAPGSSARLAPSAVNALTPGPAAAAADAAASSIAKGGA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_VEGFC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	138	29	MHLLCFLSLACSLLAAALIPSPREAPATVAAFESGLGFSEAEPDGGEVKAFEGKDLEEQLRSVSSVDELMSVLYPDYWKMYKCQLRKGGWQQPTLNTRTGDSVKFAAAHYNTEILKSIDNEWRKTQCMPREVCIDVGKEFGAATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTGYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLDVYRQVHSIIRRSLPATLPQCQAANKTCPTNYVWNNYMCRCLAQQDFIFYSNVEDDSTNGFHDVCGPNKELDEDTCQCVCKGGLRPSSCGPHKELDRDSCQCVCKNKLFPNSCGANREFDENTCQCVCKRTCPRNQPLNPGKCACECTENTQKCFLKGKKFHHQTCSCYRRPCANRLKHCDPGLSFSEEVCRCVPSYWKRPHLN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_VEGFD_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	297	40	MYGEWGMGNILMMFHVYLVQGFRSEHGPVKDFSFERSSRSMLERSEQQIRAASSLEELLQIAHSEDWKLWRCRLKLKSLASMDSRSASHRSTRFAATFYDTETLKVIDEEWQRTQCSPRETCVEVASELGKTTNTFFKPPCVNVFRCGGCCNEEGVMCMNTSTSYISKQLFEISVPLTSVPELVPVKIANHTGCKCLPTGPRHPYSIIRRSIQTPEEDECPHSKKLCPIDMLWDNTKCKCVLQDETPLPGTEDHSYLQEPTLCGPHMTFDEDRCECVCKAPCPGDLIQHPENCSCFECKESLESCCQKHKIFHPDTCSCEDRCPFHTRTCASRKPACGKHWRFPKETRAQGLYSQENP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineGrowthFactors_VGF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	168	31	MKTFTLPASVLFCFLLLIQGLGAAPPGRPDVFPPPLSSEHNGQVAEDAVSRPKDDGVPEVRAARNPEPQDQGELFQGVDPRALASVLLQALDRPASPPSVPGGSQQGTPEEAAEALLTESVRSQTHSLPAPEIQAPAVAPPRPQTQDRDPEEDDRSEELEALASLLQELRDFSPSNAKRQQETAAAETETRTHTLTRVNLESPGPERVWRASWGEFQARVPERAPLPPPVPSQFQARMSESAPLPETHQFGEGVSSPKTHLGETLTPLSKAYQSLGGPFPKVRRLEGSFLGGSEAGERLLQQGLAQVEAGRRQAEATRQAAAQEERLADLASDLLLQYLLQGGARQRDLGGRELQETQQERENEREEEAEQERRGGGEDDVGEEDEEAAEAEAEAEEAERARQNALLFAEEEDGEAGAEDKRSQEEAPGHRRKDAEGAEEGGEEDDDDEEMDPQTIDSLIELSTKLHLPADDVVSIIEEVEEKRKRKKNAPPEPVPPPRAAPAPTHVRSPQPPPPAPARDELPDWNEVLPPWDREEDEVFPPGPYHPFPNYIRPRTLQPPASSRRRHFHHALPPARHHPDLEAQARRAQEEADAEERRLQEQEELENYIEHVLLHRP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ADIPL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	499	27	MWAWGWAAAALLWLQTAGAGARQELKKSRQLFARVDSPNITTSNREGFPGSVKPPEASGPELSDAHMTWLNFVRRPDDGSSRKRCRGRDKKSRGLSGLPGPPGPPGPPGPPGSPGVGVTPEALLQEFQEILKEATELRFSGLPDTLLPQEPSQRLVVEAFYCRLKGPVLVDKKTLVELQGFQAPTTQGAFLRGSGLSLSLGRFTAPVSAIFQFSASLHVDHSELQGRGRLRTRDMVRVLICIESLCHRHTSLEAVSGLESNSRVFTVQVQGLLHLQSGQYVSVFVDNSSGAVLTIQNTSSFSGMLLGT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ADIPO_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	289	40	MLLLQALLFLLILPSHAEDDVTTTEELAPALVPPPKGTCAGWMAGIPGHPGHNGTPGRDGRDGTPGEKGEKGDAGLLGPKGETGDVGMTGAEGPRGFPGTPGRKGEPGEAAYVYRSAFSVGLETRVTVPNVPIRFTKIFYNQQNHYDGSTGKFYCNIPGLYYFSYHITVYMKDVKVSLFKKDKAVLFTYDQYQEKNVDQASGSVLLHLEVGDQVWLQVYGDGDHNGLYADNVNDSTFTGFLLYHDTN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ADM2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	104	26	MAQLLMVTVTLGCISLLYLLPGTLSGSLGKGLRHSRPREPPAKIPSSNLQPGHPSLQPVVWKSRRHAPQPQGRGNRALAMVHLPQGGGSRHPGPQRPTGSRRPHAQLLRVGCVLGTCQVQNLSHRLWQLVRPAGRRDSAPVDPSSPHSYG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ADML_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	204	49	MKLVSITLMLLGSLAFLGADTAGPDTPSQFRKKWNKWALSRGKRELQASSSYPTGLADETTVPTQTLDPFLDEQNTTGPLQASNQSEAHIRVKRYRQSMNQGSRSNGCRFGTCTFQKLAHQIYQLTDKDKDGMAPRNKISPQGYGRRRRRSLLEVLRSRTVESSQEQTHTAPGPWAHISRLFRI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ANF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	179	47	MGSFSITLGFFLVLAFWLPGHIGANPVYSAVSNTDLMDFKNLLDHLEEKMPVEDEVMPPQALSEQTEEAGAALSSLPEVPPWTGEVNPPLRDGSALGRSPWDPSDRSALLKSKLRALLAGPRSLRRSSCFGGRIDRIGAQSGLGCNSFRYRR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ANFB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	45	MDLLKVLSQMILFLLFLYLSPLGGHSYPLGSPSQSPEQFKMQKLLELIREKSEEMAQRQLLKDQGLTKEHPKRVLRSQGSTLRVQQRPQNSKVTHISSCFGHKIDRIGSVSRLGCNALKLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ANFC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	85	43	MHLSQLIACALLLALLSLRPSEAKPGTPPKVPRTPPGEELADSQAAGGNQKKGDKTPGSGGANLKGDRSRLLRDLRVDTKSRAAWARLLHEHPNARKYKGGNKKGLSKGCFGLKLDRIGSMSGLGC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ANGL8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	415	41	MAVLALCLLWTLASAVRPAPVAPLGGPEPAQYEELTLLFHGALQLGQALNGVYRATEARLTEAGHSLGLYDRALEFLGTEVRQGQDATQELRTSLSEIQVEEDALHLRAEATARSLGEVARAQQALRDTVRRLQVQLRGAWLGQAHQEFETLKARADKQSHLLWALTGHVQRQQREMAEQQQWLRQIQQRLHTAALPA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_APEL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	55	19	MNLRLCVQALLLLWLSLTAVCGVPLMLPPDGTGLEEGSMRYLVKPRTSRTGPGAWQGGRRKFRRQRPRLSHKGPMPF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_C1QT9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	29	MRIWWLLLVMGACTRSVFSQDTCRQGHSGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGHPGGPGKDGIRGEKGEPGADGRVEAKGIKGDPGSRGSPGKHGPKGSIGPTGEQGLPGETGPQGQKGDKGEVGPTGPEGLMGSTGPLGPKGLPGPMGPIGKPGPRGEAGPMGPQGEPGVRGMRGWKGDRGEKGKVGEAPLVPKSAFTVGLTVISKFPPPDAPIKFDKILYNELNHYNVATGKFTCHVAGVYYFTYHITVFSRNVQVSLVKNGVKVLHTKDSYMSSEDQASGGIVQELKLGDEVWMQVTGGERFNGLFADEDDDTTFTGFLLFSSS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CALC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	266	31	MGFLKFSPFLVVSILLLYQACSLQAVPLRSILESSPGMATLSEEEVRLLAALVQDYMQMKARELEQEEEQEAEGSSLDSPRSKRCGNLSTCMLGTYTQDLNKFHTFPQTSIGVEAPGKKRDVAKDLETNHQSHFGN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CALCA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	258	31	MGFLKFSPFLVVSILLLYQACSLQAVPLRSILESSPGMATLSEEEVRLLAALVQDYMQMKARELEQEEEQEAEGSSVTAQKRSCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSEAFGRRRRDLQA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CALCB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	236	25	MDFWKFFPFLALSTIWVLCLASSLQAAPFRSALESSLDLGTLGDQEKHLLLAALMQDYEQMKARKLEQEEQETKGSRVTAQKRSCNTATCVTHRLADLLSRSGGVLKDNFVPTDVGSEAFGRRRRRDLQA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CCKN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	262	39	MKSGVCLCVVMAVLAAGALAQPVVPAEATDPVEQRAQEAPRRQLRAVLRTDGEPRARLGALLARYIQQVRKAPSGRMSVLKNLQSLDPSHRISDRDYMGWMDFGRRSAEDYEYPS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_COLI_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	196	51	MPRFCYSRSGALLLALLLQTSIDVWSWCLESSQCQDLTTESNLLACIRACKLDLSLETPVFPGNGDEQPLTENPRKYVMGHFRWDRFGPRNSSSAGSAAQRRAEEEAVWGDGSPEPSPREGKRSYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEFKRELEGERPLGLEQVLESDAEKDDGPYRVEHFRWSNPPKDKRYGGFMTSEKSQTPLVTLFKNAIIKNAHKKGQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_COPA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	113	29	MLTKFETKSARVKGLSFHPKRPWILTSLHNGVIQLWDYRMCTLIDKFDEHDGPVRGIDFHKQQPLFVSGGDDYKIKVWNYKLRRCLFTLLGHLDYIRTTFFHHEYPWILSASDDQTIRVWNWQSRTCVCVLTGHNHYVMCAQFHPSEDLVVSASLDQTVRVWDISGLRKKNLSPGAVESDVRGITGVDLFGTTDAVVKHVLEGHDRGVNWAAFHPTMPLIVSGADDRQVKIWRMNESKAWEVDTCRGHYNNVSCAVFHPRQELILSNSEDKSIRVWDMSKRTGVQTFRRDHDRFWVLAAHPNLNLFAAGHDGGMIVFKLERERPAYAVHGNMLHYVKDRFLRQLDFNSSKDVAVMQLRSGSKFPVFNMSYNPAENAVLLCTRASNLENSTYDLYTIPKDADSQNPDAPEGKRSSGLTAVWVARNRFAVLDRMHSLLIKNLKNEITKKIQVPNCDEIFYAGTGNLLLRDADSITLFDVQQKRTLASVKISKVKYVIWSADMSHVALLAKHAIVICNRKLDALCNIHENIRVKSGAWDESGVFIYTTSNHIKYAVTTGDHGIIRTLDLPIYVTRVKGNNVYCLDRECRPRVLTIDPTEFKFKLALINRKYDEVLHMVRNAKLVGQSIIAYLQKKGYPEVALHFVKDEKTRFSLALECGNIEIALEAAKALDDKNCWEKLGEVALLQGNHQIVEMCYQRTKNFDKLSFLYLITGNLEKLRKMMKIAEIRKDMSGHYQNALYLGDVSERVRILKNCGQKSLAYLSAATHGLDEEAESLKETFDPEKETIPDIDPNAKLLQPPAPIMPLDTNWPLLTVSKGFFEGSIASKGKGGALAADIDIDTVGTEGWGEDAELQLDEDGFVEAPEGLGEDVLGKGQEEGGGWDVEEDLELPPELDVPSGVSGSAEDGFFVPPTKGTSPTQIWCNNSQLPVDHILAGSFETAMRLLHDQVGVIQFGPYKQLFLQTYARGRTTYQALPCLPSMYSYPNRNWKDAGLKNGVPAVGLKLNDLIQRLQLCYQLTTVGKFEEAVEKFRSILLSVPLLVVDNKQEIAEAQQLITICREYIVGLCMEIERKKLPKETLDQQKRICEMAAYFTHSNLQPVHMILVLRTALNLFFKLKNFKTAATFARRLLELGPKPEVAQQTRKILSACEKNPTDACQLNYDMHNPFDICAASYRPIYRGKPVEKCPLSGACYSPEFKGQICRVTTVTEIGKDVIGLRISPLQFR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CORT_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	159	27	MMGGRGTGGKWPSAFGLLLLWGVAASALPLESGPTGQDSVQEATEGRSGLLTFLAWWHEWASQASSSTPVGGGTPGLSKSQERPPPQQPPHLDKKPCKNFFWKTFSSCK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_CRF_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	213	33	MRLRLLVSAGMLLVALSSCLPCRALLSRGSVPRAPRAPQPLNFLQPEQPQQPQPVLIRMGEEYFLRLGNLNRSPAARLSPNSTPLTAGRGSRPSHDQAAANFFRVLLQQLQMPQRSLDSRAEPAERGAEDALGGHQGALERERRSEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEIIGK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ELA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	69	11	MRFQPLFWVFFIFAMSLLFISEQKPVNFPRRRKLYRHNCFRRRCIPLHSRVPFP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_EPO_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	518	65	MGVPERPTLLLLLSLLLIPLGLPVLCAPPRLICDSRVLERYILEAKEAENVTMGCAEGPRLSENITVPDTKVNFYAWKRMEVEEQAIEVWQGLSLLSEAILQAQALLANSSQPPETLQLHIDKAISGLRSLTSLLRVLGAQKELMSPPDTTPPAPLRTLTVDTFCKLFRVYANFLRGKLKLYTGEVCRRGDR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_ERFE_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	362	22	MASTRRPVGARTLLACASLLAAMGLGVPESAEPVGTHARPQPPGAELPAPPANSPPEPTIAHAHSVDPRDAWMLFVKQSDKGINSKRRSKARRLKLGLPGPPGPPGPQGPPGPFIPSEVLLKEFQLLLKGAVRQRESHLEHCTRDLTTPASGSPSRVPAAQELDSQDPGALLALLAATLAQGPRAPRVEAAFHCRLRRDVQVDRRALHELGIYYLPEVEGAFHRGPGLNLTSGQYTAPVAGFYALAATLHVALTEQPRKGPTRPRDRLRLLICIQSLCQHNASLETVMGLENSSELFTISVNGVLYLQAGHYTSVFLDNASGSSLTVRSGSHFSAILLGL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_FBN1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	388	38	MRRGGLLEVALAFALLLESYTSHGADANLEAGSLKETRANRAKRRGGGGHDALKGPNVCGSRYNAYCCPGWKTLPGGNQCIVPICRHSCGDGFCSRPNMCTCPSGQISPSCGSRSIQHCSIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVVSNQMCQGQLSGIVCTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGMCQGGNCINTVGSFECKCPAGHKFNEVSQKCEDIDECSTIPGVCDGGECTNTVSSYFCKCPPGFYTSPDGTRCVDVRPGYCYTALANGRCSNQLPQSITKMQCCCDLGRCWSPGVTVAPEMCPIRSTEDFNKLCSVPLVIPGRPEYPPPPIGPLPPVQPVPPGYPPGPVIPAPRPPPEYPYPSPSREPPRVLPFNVTDYCQLVRYLCQNGRCIPTPGSYRCECNKGFQLDIRGECIDVDECEKNPCTGGECINNQGSYTCHCRAGYQSTLTRTECRDIDECLQNGRICNNGRCINTDGSFHCVCNAGFHVTRDGKNCEDMDECSIRNMCLNGMCINEDGSFKCICKPGFQLASDGRYCKDINECETPGICMNGRCVNTDGSYRCECFPGLAVGLDGRVCVDTHMRSTCYGGYRRGQCVKPLFGAVTKSECCCASTEYAFGEPCQPCPAQNSAEYQALCSSGPGMTSAGTDINECALDPDICPNGICENLRGTYKCICNSGYEVDITGKNCVDINECVLNSLLCDNGQCRNTPGSFVCTCPKGFVYKPDLKTCEDIDECESSPCINGVCKNSPGSFICECSPESTLDPTKTICIETIKGTCWQTVIDGRCEININGATLKSECCSSLGAAWGSPCTICQLDPICGKGFSRIKGTQCEDINECEVFPGVCKNGLCVNSRGSFKCECPNGMTLDATGRICLDIRLETCFLKYDDEECTLPIAGRHRMDACCCSVGAAWGTEECEECPLRNSREYEELCPRGPGFATKDITNGKPFFKDINECKMIPSLCTHGKCRNTIGSFKCRCDSGFALDSEERNCTDIDECRISPDLCGRGQCVNTPGDFECKCDEGYESGFMMMKNCMDIDECQRDPLLCRGGICHNTEGSYRCECPPGHQLSPNISACIDINECELSANLCPHGRCVNLIGKYQCACNPGYHPTHDRLFCVDIDECSIMNGGCETFCTNSDGSYECSCQPGFALMPDQRSCTDIDECEDNPNICDGGQCTNIPGEYRCLCYDGFMASEDMKTCVDVNECDLNPNICLSGTCENTKGSFICHCDMGYSGKKGKTGCTDINECEIGAHNCGRHAVCTNTAGSFKCSCSPGWIGDGIKCTDLDECSNGTHMCSQHADCKNTMGSYRCLCKDGYTGDGFTCTDLDECSENLNLCGNGQCLNAPGGYRCECDMGFVPSADGKACEDIDECSLPNICVFGTCHNLPGLFRCECEIGYELDRSGGNCTDVNECLDPTTCISGNCVNTPGSYTCDCPPDFELNPTRVGCVDTRSGNCYLDIRPRGDNGDTACSNEIGVGVSKASCCCSLGKAWGTPCELCPSVNTSEYKILCPGGEGFRPNPITVILEDIDECQELPGLCQGGKCINTFGSFQCRCPTGYYLNEDTRVCDDVNECETPGICGPGTCYNTVGNYTCICPPDYMQVNGGNNCMDMRRSLCYRNYYADNQTCDGELLFNMTKKMCCCSYNIGRAWNKPCEQCPIPSTDEFATLCGSQRPGFVIDIYTGLPVDIDECREIPGVCENGVCINMVGSFRCECPVGFFYNDKLLVCEDIDECQNGPVCQRNAECINTAGSYRCDCKPGYRLTSTGQCNDRNECQEIPNICSHGQCIDTVGSFYCLCHTGFKTNVDQTMCLDINECERDACGNGTCRNTIGSFNCRCNHGFILSHNNDCIDVDECATGNGNLCRNGQCVNTVGSFQCRCNEGYEVAPDGRTCVDINECVLDPGKCAPGTCQNLDGSYRCICPPGYSLQNDKCEDIDECVEEPEICALGTCSNTEGSFKCLCPEGFSLSSTGRRCQDLRMSYCYAKFEGGKCSSPKSRNHSKQECCCALKGEGWGDPCELCPTEPDEAFRQICPFGSGIIVGPDDSAVDMDECKEPDVCRHGQCINTDGSYRCECPFGYILEGNECVDTDECSVGNPCGNGTCKNVIGGFECTCEEGFEPGPMMTCEDINECAQNPLLCAFRCVNTYGSYECKCPVGYVLREDRRMCKDEDECAEGKHDCTEKQMECKNLIGTYMCICGPGYQRRPDGEGCIDENECQTKPGICENGRCLNTLGSYTCECNDGFTASPTQDECLDNREGYCFSEVLQNMCQIGSSNRNPVTKSECCCDGGRGWGPHCEICPFEGTVAYKKLCPHGRGFMTNGADIDECKVIHDVCRNGECVNDRGSYHCICKTGYTPDITGTACVDLNECNQAPKPCNFICKNTEGSYQCSCPKGYILQEDGRSCKDLDECATKQHNCQFLCVNTIGGFTCKCPPGFTQHHTACIDNNECTSDINLCGSKGVCQNTPGSFTCECQRGFSLDQSGASCEDVDECEGNHRCQHGCQNIIGGYRCSCPQGYLQHYQWNQCVDENECLSAHVCGGASCHNTLGSYKCMCPTGFQYEQFSGGCQDINECGSSQAPCSYGCSNTEGGYLCGCPPGYFRIGQGHCVSGMGMGRGGPEPPASSEMDDNSLSPEACYECKINGYPKRGRKRRSTNETDASDIQDGSEMEANVSLASWDVEKPASFAFNISHVNNKVRILELLPALTTLMNHNRYLIESGNEDGFFKINQKEGVSYLHFTKKKPVAGTYSLQISSTPLYKKKELNQLEDRYDKDYLSGELGDNLKMKIQILLH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_FBN2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	305	47	MGRRRRLCLQPYFVWLGCVALWAQGTDGQPQPPPPKTLRPQPPPQQVRPAVAGSEGGFMGPEYRDEGAVAASRVRRRGQQEILRGPNVCGSRFHSYCCPGWKTLPGGNQCIVPICRNSCGDGFCSRPNMCTCSSGQISPTCGAKSIQQCSVRCMNGGTCADDHCQCQKGYIGTYCGQPVCENGCQNGGRCIGPNRCACVYGFTGPQCERDYRTGPCFTQVNNQMCQGQLTGIVCTKTLCCATIGRAWGHPCEMCPAQPQPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECRCPAGHKQSETTQKCEDIDECSVIPGVCETGDCSNTVGSYFCLCPRGFVTSTDGSRCIDQRAGTCFSGLVNGRCAQELPGRMAKAQCCCEPGRCWSIGTIPEACPVRGSEEYRRLCLDGLPMGGIPGSSVSRPGGTGSTGNGYGPGGTGFLPIPGDNGFSPGVGGAGVGAGGQGPIITGLTILNQTIDICKHHANLCLNGRCIPTVSSYRCECNMGYKQDANGDCIDVDECTSNPCSNGDCVNTPGSYYCKCHAGFQRTPTKQACIDIDECIQNGVLCKNGRCVNTDGSFQCICNAGFELTTDGKNCVDHDECTTTNMCLNGMCINEDGSFKCVCKPGFILAPNGRYCTDVDECQTPGICMNGHCINNEGSFRCDCPPGLAVGVDGRVCVDTHMRSTCYGEIKKGVCVRPFPGAVTKSECCCANPDYGFGEPCQPCPAKNSAEFHGLCSSGIGITVDGRDINECALDPDICANGICENLRGSYRCNCNSGYEPDASGRNCIDIDECLVNRLLCDNGLCRNTPGSYSCTCPPGYVFRTETETCEDVNECESNPCVNGACRNNLGSFHCECSPGSKLSSTGLICIDSLKGTCWLNIQDNRCEVNINGATLKSECCATLGAAWGSPCERCELDAACPRGFARIKGVTCEDVNECEVFPGVCPNGRCVNSKGSFHCECPEGLTLDGTGRVCLDIRMEHCFLKWDEDECIHPVPGKFRMDACCCAVGAAWGTECEECPKPGTKEYETLCPRGPGFANRGDILTGRPFYKDINECKAFPGMCTYGKCRNTIGSFKCRCNNGFALDMEERNCTDIDECRISPDLCGSGICVNTPGSFECECFEGYESGFMMMKNCMDIDECERNPLLCRGGTCVNTEGSFQCDCPLGHELSPSREDCVDINECSLSDNLCRNGKCVNMIGTYQCSCNPGYQATPDRQGCTDIDECMIMNGGCDTQCTNSEGSYECSCSEGYALMPDGRSCADIDECENNPDICDGGQCTNIPGEYRCLCYDGFMASMDMKTCIDVNECDLNPNICMFGECENTKGSFICHCQLGYSVKKGTTGCTDVDECEIGAHNCDMHASCLNVPGSFKCSCREGWVGNGIKCIDLDECANGTHQCSINAQCVNTPGSYRCACSEGFTGDGFTCSDVDECAENTNLCENGQCLNVPGAYRCECEMGFTPASDSRSCQDIDECSFQNICVFGTCNNLPGMFHCICDDGYELDRTGGNCTDIDECADPINCVNGLCVNTPGRYECNCPPDFQLNPTGVGCVDNRVGNCYLKFGPRGDGSLSCNTEVGVGVSRSSCCCSLGKAWGNPCETCPPVNSTEYYTLCPGGEGFRPNPITIILEDIDECQELPGLCQGGNCINTFGSFQCECPQGYYLSEETRICEDIDECFAHPGVCGPGTCYNTLGNYTCICPPEYMQVNGGHNCMDMRKSFCYRSYNGTTCENELPFNVTKRMCCCTYNVGKAWNKPCEPCPTPGTADFKTICGNIPGFTFDIHTGKAVDIDECKEIPGICANGVCINQIGSFRCECPTGFSYNDLLLVCEDIDECSNGDNLCQRNADCINSPGSYRCECAAGFKLSPNGACVDRNECLEIPNVCSHGLCVDLQGSYQCICNNGFKASQDQTMCMDVDECERHPCGNGTCKNTVGSYNCLCYPGFELTHNNDCLDIDECSSFFGQVCRNGRCFNEIGSFKCLCNEGYELTPDGKNCIDTNECVALPGSCSPGTCQNLEGSFRCICPPGYEVRSENCIDINECDEDPNICLFGSCTNTPGGFQCICPPGFVLSDNGRRCFDTRQSFCFTNFENGKCSVPKAFNTTKAKCCCSKMPGEGWGDPCELCPKDDEVAFQDLCPYGHGTVPSLHDTREDVNECLESPGICSNGQCINTDGSFRCECPMGYNLDYTGVRCVDTDECSIGNPCGNGTCTNVIGSFECTCNEGFEPGPMMNCEDINECAQNPLLCAFRCMNTFGSYECTCPVGYALREDQKMCKDLDECAEGLHDCESRGMMCKNLIGTFMCICPPGMARRPDGEGCVDENECRTKPGICENGRCVNIIGSYRCECNEGFQSSSSGTECLDNRQGLCFAEVLQTMCQMASSSRNLVTKSECCCDGGRGWGHQCELCPLPGTAQYKKICPHGPGYATDGRDIDECKVMPSLCTNGQCVNTMGSFRCFCKVGYTTDISGTACVDLDECSQSPKPCNFICKNTKGSYQCSCPRGYVLQEDGKTCKDLDECQTKQHNCQFLCVNTLGGFTCKCPPGFTQHHTACIDNNECGSQPSLCGAKGICQNTPGSFSCECQRGFSLDASGLNCEDVDECDGNHRCQHGCQNILGGYRCGCPQGYVQHYQWNQCVDENECSNPGACGSASCYNTLGSYKCACPSGFSFDQFSSACHDVNECSSSKNPCSYGCSNTEGGYLCGCPPGYFRVGQGHCVSGMGFNKGQYLSVDAEAEDDENALSPEACYECKINGYTKKDGRRKRSAQEPEPASAEEQISLESVAMDSPVNMKFNLSGLGSKEHILELVPAIEPLNNHIRYVISQGNEDGVFRIHQRNGLSYLHTAKKKLAPGTYTLEITSIPLYGKKELRKLEEHNEDDYLLGVLGEALRMRLQIQLY	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_FNDC5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	4	MPPGPCAWPPRAALRLWLGCVCFALVQADSPSAPVNVTVRHLKANSAVVSWDVLEDEVVIGFAISQQKKDVRMLRFIQEVNTTTRSCALWDLEEDTEYIVHVQAISIQGQSPASEPVLFKTPREAEKMASKNKDEVTMKEMGRNQQLRTGEVLIIVVVLFMWAGVIALFCRQYDIIKDNEPNNNKEKTKSASETSTPEHQGGGLLRSKI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_FSHB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	12	4	MMKLIQLCILFWCWRAICCHSCELTNITISVEKEECRFCISINTTWCAGYCYTRDLVYKDPARPNTQKVCTFKELVYETVRLPGCARHSDSLYTYPVATECHCGKCDSDSTDCTVRGLGPSYCSFSEMKE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GALA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	83	21	MARGSVILLGWLLLVVTLSATLGLGMPAKEKRGWTLNSAGYLLGPHAIDNHRSFSDKHGLTGKRELQLEVEERRPGSVDVPLPESNIVRTIMEFLSFLHLKEAGALDSLPGIPLATSSEDLEKS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GALP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	79	41	MACSVHLVLFLTILLSLAETPESAPAHRGRGGWTLNSAGYLLGPVLPVSSKADQGRKRDSALEILDLWKIIDGLPYSHSPRMTKRTMGETFVKANTGDMHILDKNVPKEEATLDSES	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GAST_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	59	23	MPRLCVYMLVLVLALATFSEASWKPRSQLQDASSGPGTNEDLEQRQFNKLGSASHHRRQLGPQGPQHFIADLSKKQRPRMEEEEEAYGWMDFGRRSAEEDQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GDF15_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	664	79	MAPPALQAQPPGGSQLRFLLFLLLLLLLLSWPSQGDALAMPEQRPSGPESQLNADELRGRFQDLLSRLHANQSREDSNSEPSPDPAVRILSPEVRLGSHGQLLLRVNRASLSQGLPEAYRVHRALLLLTPTARPWDITRPLKRALSLRGPRAPALRLRLTPPPDLAMLPSGGTQLELRLRVAAGRGRRSAHAHPRDSCPLGPGRCCHLETVQATLEDLGWSDWVLSPRQLQLSMCVGECPHLYRSANTHAQIKARLHGLQPDKVPAPCCVPSSYTPVVLMHRTDSGVSLQTYDDLVARGCHCA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GFRAL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	426	24	MLVFIFLAVTLSSENESSSQTNDCAHLIQKCLIDANGCEQSWRSMEDTCLTPGDSCKINNSLHCNLSIQALVEKNFQFKECLCMDDLHCTVNKLFGKKCTNKTDNMEKDNKDKWNLTTTPFYHGFKQMQSCLEVTEACVGDVVCNAQLALYLKACSANGNLCDVKHCQAAIRFFYQNMPFNTAQMLAFCDCAQSDIPCQQSKETLHSKPCALNIVPPPTCLSVIHTCRNDELCRTHYRTFQTECWPHITGKCHEDETCISMLGKQDLTCSGSESCRAAFLGTFGTVLQVPCACRGVTQAEEHVCMIFQHMLHSKSCFNYPTPNVKDISSYEKKNSKEITLTGFNSFFNGELLYVVVCMAVTCGILFLVMLKLRIQSEKRDPSSIEIAGGVIIQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GHRL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	114	17	MLSSGTICSLLLLSMLWMDMAMAGSSFLSPEHQKAQQRKESKKPPAKLQPRALEGWLHPEDRGQAEETEEELEIRFNAPFDVGIKLSGAQYQQHGRALGKFLQDILWEEVKEAPADK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GIP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	169	28	MVALKTCSLLLVLLFLAVGLGEKEEVEFRSHAKFAGPRPRGPRYAEGTFISDYSIAMDKIRQQDFVNWLLAQRGKKSDWKHNITQREARALVLAGQSQGKEDKEAQESSLPKSLSDDDVLRDLLIQELLAWMVDQTELCRLRSQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GLHA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	39	MDYYRKYAAVILVMLSMFLHILHSLPDGDFIIQGCPECKLKENKYFSKLGAPIYQCMGCCFSRAYPTPARSKKTMLVPKNITSEATCCVAKAFTKATVMGNARVENHTECHCSTCYYHKS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GLUC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	51	10	MKTIYFVAGLLIMLVQGSWQHALQDTEENPRSFPASQTEAHEDPDEMNEDKRHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIAKRHDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGRRDFPEEVAIAEELGRRHADGSFSDEMSTILDNLATRDFINWLIQTKITDKK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GON1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	20	12	MILKLMAGILLLTVCLEGCSSQHWSYGLRPGGKRNTEHLVESFQEMGKEVDQMAEPQHFECTVHWPRSPLRDLRGALESLIEEEARQKKM	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GPHA2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	82	30	MPMAPRVLLLCLLGLAVTEGHSPETAIPGCHLHPFNVTVRSDRLGTCQGSHVAQACVGHCESSAFPSRYSVLVASGYRHNITSSSQCCTISSLRKVRVWLQCVGNQRGELEIFTARACQCDMCRFSRY	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_GPHB5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	16	MKLVYLVLGAVALLLLGGPDSVLSSSSGNLHTFVGCAVREFTFMAKKPGCRGLRITTDACWGRCETWEKPILEPPYIEAYHRVCTYNETRQVTVKLPNCAPGVDPFYTYPMAVRCDCGACSTATTECETI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_HEPC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	17	MALSTRTQAACLLLLLLASLSSTTYLHQQMRQTTELQPLHGEESRADIAIPMQKRRKRDTNFPICIFCCKCCNNSQCGICCKT	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_HEPC2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	39	16	MALSTRTQAACLLLLLLASLSSTTYLQQQMRQTTELQPLHGEESRADIAIPMQKRRKRDINFPICRFCCQCCNKPSCGICCEE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_IAPP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	290	53	MMCISKLPAVLLILSVALNHLRATPVRSGSNPQMDKRKCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYGKRNAAGDPNRESLDFLLV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_IGF2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	186	33	MGIPVGKSMLVLLISLAFALCCIAAYGPGETLCGGELVDTLQFVCSDRGFYFSRPSSRANRRSRGIVEECCFRSCDLALLETYCATPAKSERDVSTSQAVLPDDFPRYPVGKFFQYDTWRQSAGRLRRGLPALLRARRGRMLAKELKEFREAKRHRPLIVLPPKDPAHGGASSEMSSNHQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INHA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	863	56	MVSQRSLLLLLLLTLRDVDSCQGPELVRELVLAKVKALFLDALGPPAMDGEGGDPGIRRLPRRHAVGGFMHRTSEPEEEDVSQAILFPATGATCEDQPAARGLAQEAEEGLFTYVFRPSQHIRSHQVTSAQLWFHTGLGRKSTAAANSSAPLLDLLVLSSGGPMAVPVSLGQGPPRWAVLHLAASAFPLLTHPILVLLLRCPLCSCSGRPETTPFLVAHTRARAPSAGERARRSTPSVPWPWSPAALRLLQRPPEEPAAHAFCHRAALNISFQELGWDRWIVHPPSFIFHYCHGSCGMPTSDLPLPVPGVPPTPVQPLFLVPGAKPCCAALPGSMRSLRVRTTSDGGYSFKYEMVPNLITQHCACI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INHBA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	54	28	MPLLWLRGFLLASCWIIVRSSPTPGSEGHGSAPDCPSCALATLPKDGPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGDEAEEMGLKGERSELLLSEKVVDARKSTWHIFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEVDGDGKKKDGSDGGLEEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INHBB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	177	26	MDGLPGRALGAACLLLLVAGWLGPEAWGSPTPPPSPAAPPPPPPPGAPGGSQDTCTSCGGGGGGFRRPEELGRVDGDFLEAVKRHILSRLQLRGRPNITHAVPKAAMVTALRKLHAGKVREDGRVEIPHLDGHASPGADGQERVSEIISFAETDGLASSRVRLYFFVSNEGNQNLFVVQASLWLYLKLLPYVLEKGSRRKVRVKVYFQEQGHGDRWNVVEKKVDLKRSGWHTFPITEAIQALFERGERRLNLDVQCDSCQELAVVPVFVDPGEESHRPFVVVQARLGDSRHRIRKRGLECDGRTSLCCRQQFFIDFRLIGWNDWIIAPTGYYGNYCEGSCPAYLAGVPGSASSFHTAVVNQYRMRGLNPGPVNSCCIPTKLSSMSMLYFDDEYNIVKRDVPNMIVEECGCA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INHBC_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	855	54	MASSLLLALLFLTPTTVVNPKTEGPCPACWGAIFDLESQRELLLDLAKKSILDKLHLSQRPILSRPVSRGALKTALQRLRGPRRETLLEHDQRQEEYEIISFADTDLSSINQTRLEFHFSGRMASGMEVRQTRFMFFVQFPHNATQTMNIRVLVLRPYDTNLTLTSQYVVQVNASGWYQLLLGPEAQAACSQGHLTLELVPESQVAHSSLILGWFSHRPFVAAQVRVEGKHRVRRRGIDCQGASRMCCRQEFFVDFREIGWNDWIIQPEGYAMNFCTGQCPLHVAGMPGISASFHTAVLNLLKANAAAGTTGRGSCCVPTSRRPLSLLYYDRDSNIVKTDIPDMVVEACGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INHBE_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	521	73	MKLPKAQLWLILLWALVWVQSTRSACPSCGGPTLAPQGERALVLELAKQQILEGLHLTSRPRITRPLPQAALTRALRRLQPKSMVPGNREKVISFATIIDKSTSTYRSMLTFQLSPLWSHHLYHARLWLHVPPSFPGTLYLRIFRCGTTRCRGFRTFLAEHQTTSSGWHALTLPSSGLRSEDSGVVKLQLEFRPLDLNSTAAGLPRLLLDTAGQQRPFLELKIRANEPGAGRARRRTPTCEPETPLCCRRDHYVDFQELGWRDWILQPEGYQLNYCSGQCPPHLAGSPGIAASFHSAVFSLLKANNPWPAGSSCCVPTARRPLSLLYLDHNGNVVKTDVPDMVVEACGCS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INS1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	85	17	MALLVHFLPLLALLALWEPKPTQAFVKQHLCGPHLVEALYLVCGERGFFYTPKSRREVEDPQVEQLELGGSPGDLQTLALEVARQKRGIVDQCCTSICSLYQLENYCN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INS2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	139	27	MALWMRFLPLLALLFLWESHPTQAFVKQHLCGSHLVEALYLVCGERGFFYTPMSRREVEDPQVAQLELGGGPGAGDLQTLALEVAQQKRGIVDQCCTSICSLYQLENYCN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INSL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	272	42	MRAPLLLMLLALGSALRSPQPPEARAKLCGHHLVRTLVRVCGGPRWSPEATQPVETRDRELLQWLEQRHLLHALVADVDPALDPQLPRQASQRQRRSAATNAVHRCCLTGCTQQDLLGLCPH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INSL5_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	86	13	MKGPTLALFLLLVLLAVVEVRSRQTVKLCGLDYVRTVIYICASSRWRRHLEGHFHSQQAETRNYLQLLDRHEPSKKTLEHSLPKTDLSGQELVRDPQAPKEGLWELKKHSVVSRRDLQALCCREGCSMKELSTLC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_INSL6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	132	13	MKQLCCSCLLWLGLLLTPFSREEEEESRPRKLCGRHLLIEVIKLCGQSDWSRFEMEEQSPMTQFFPHYSRKGKAFNPHPSSSAWRRFTNPVPAGVSQKKGTHTWEPQSLPDYQFEKTELLPKARVFSYHSGKPYVKSVQLQKKSTNKMNTFRSLFWGNHSQRKRRGFADKCCVIGCTKEEMAVACLPFVDF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_LSHB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	309	39	MERLQGLLLWLLLSPSVVWASRGPLRPLCRPVNATLAAENEFCPVCITFTTSICAGYCPSMVRVLPAALPPVPQPVCTYRELAFASVRLPGCPPGVDPIVSFPVALSCRCGPCRLSSSDCGGPRTQPMACDLPHLPGLLLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_MCH_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	276	39	MAKMTLSSYMLMLAFSLFSQGILLSASKSIRNLEDDIVFNTFRMGKAFQKEDTAERSVVAPSLEQYKNDESGFMNDDDNKNSKNTGSKQNLVTHGLPLSLAVKPYLALKGSVAFPAENGVQNAESTQEKREIGDEENSAKFPIGRRDFDMLRCMLGRVYRPCWQV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_METRL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	421	85	MRGAVWAARRRAGQQWPRSPGPGPGPPPPPPLLLLLLLLLGGASAQYSSDLCSWKGSGLTREARSKEVEQVYLRCSAGSVEWMYPTGALIVNLRPNTFSPAQNLTVCIKPFRDSSGANIYLEKTGELRLLVRDIRGEPGQVQCFSLEQGGLFVEATPQQDISRRTTGFQYELMSGQRGLDLHVLSAPCRPCSDTEVLLAICTSDFVVRGFIEDVTHVPEQQVSVIYLRVNRLHRQKSRVFQPAPEDSGHWLGHVTTLLQCGVRPGHGEFLFTGHVHFGEAQLGCAPRFSDFQRMYRKAEEMGINPCEINME	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_NEU1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	6	3	MACPSLACCLLGLLALTSACYIQNCPLGGKRAVLDLDMRKCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAATGICCSPDGCRTDPACDPESAFSER	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_NEU2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	131	24	MLARMLNTTLSACFLSLLAFSSACYFQNCPRGGKRAISDMELRQCLPCGPGGKGRCFGPSICCADELGCFVGTAEALRCQEENYLPSPCQSGQKPCGSGGRCAAVGICCSDESCVAEPECHDGFFRLTRAREPSNATQLDGPARALLLRLVQLAGTRESVDSAKPRVY	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_OSTC2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	123	18	MRTLSLLTLLALAALCLSDLTDAKPSGPESDKAFMSKQEGNKVVNRLRRYLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_OSTCN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	18	MRTIFLLTLLTLAALCLSDLTDAKPSGPESDKAFMSKQEGNKVVNRLRRYLGASVPSPDPLEPTREQCELNPACDELSDQYGLKTAYKRIYGITI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_OSTN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	174	35	MLDWRLASTHFILAMIVMLWGSGKAFSVDLASQEFGTASLQSPPTAREEKSATELSAKLLRLDDLVSLENDVFETKKKRSFSGFGSPLDRLSAGSVEHRGKQRKAVDHSKKRFGIPMDRIGRNRLSSSRG	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PACA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	198	54	MTMCSGARLALLVYGIIMHSSVSCSPAAGLSFPGIRPEDEAYDQDGNPLQDFYDWDPPGVGSPASALRDAYALYYPADRRDVAHEILNEAYRKVLDQLSARKYLQSVVARGAGENLGGSAVDDPAPLTKRHSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNKGRRIAYL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PAHO_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	137	33	MAVAYCCLSLFLVSTWVALLLQPLQGTWGAPLEPMYPGDYATPEQMAQYETQLRRYINTLTRPRYGKRAEEENTGGLPGVQLSPCTSPPVGLIPCSAPWS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR2A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	627	55	MQLSVTHPCCRTLILLLVSNLLLWESEAVLPICSVRNGRCFGSFEELLERAVSLSEEISKKAFELFTAFDSQYAQSHQLIVKSLKKCHTSSLDLPKPGSQAMQTHPVTLLKLASKLLRAWQVPLNHLVNNLPSLKNVSPSILSKAKEIEEKSNGLLEGVKSILIQMQNGDTEDENYPGWSGLASLKSETEDIRLFAYYNMIRCEGRDTQKVETALKMVKCKISNENNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR2B1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	586	48	MLLSLTQMLSSRASSRLFLVSYLLLWENVVSTSTCAEKDATIQDSLEKLLTLTTFMSQVVSSETAKLFTEFNNQYAQGKRYNDRIPGTCHTEFFDTPVNKEQSLVRTPETLLTLVHSLLNSWTNALNHLVNEMSTMQGDTSSLISKAREIQAKFDELTTGVKIVQSMIGERDIATYSAWSGLASLQSSNEDVRCFSFYTMIRCLLRDSRKVNTYLEVIKYKMVDQNNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR2C2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	559	41	MLPSLIQPCSWILLLLLVNSSLLWKNVASFPMCAMRNGRCFMSFEDTFELAGSLSHNISIEVSELFTEFEKHYSNVSGLRDKSPMRCNTSFLPTPENKEQARLTHYSALLKSGAMILDAWESPLDDLVSELSTIKNVPDIIISKATDIKKKINAVRNGVNALMSTMLQNGDEEKKNPAWFLQSDNEDARIHSLYGMISCLDNDFKKVDIYLNVLKCYMLKIDNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR2C3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	586	41	MLPSSIQPCSWILLLLLVNSSLLWKNVASFPMCAMRNGRCFMSFEDTFELAGSLSHNISIEVSELFNEFEKHYSNVSGLRDKSPMRCNTSFLPTPENKEQARLTHYAALLKSGAMILDAWESPLDDLVSELSTIKNVPDIIISKATDIKKKINAVRNGVNALMSTMLQNGDEEKKNPAWFLQSDNEDARIHSLYGMISCLDNDFKKVDIYLNVLKCYMLKIDNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR3B1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	774	77	MKLSLSQPCSFSGALLLLAVSNLLVWEKVTSLPNYRLPTESLYQRVIVVSHNAHDLASKAFMEFEMKFGRTAWTYGLMLSPCHTAAILTPENSEQVHQTTSEDLLKVSITILQAWEEPLKHMVAAVAALPHVPDTLLSRTKELEERIQGLLEGLKIIFNRVYPGAVASDYTFWSAWSDLQSSDESTKNSALRTLWRCVRRDTHKVDNYLKVLKCRDVHNNNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR3C1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	697	78	MQLSLTQARTWKGLFLLVSCMFLWVYVTATRYDRKSNEEIYDNLLSSSRHIHRVAKKMYKILDSKLTEGVCFRNKNTKMCQTISTHSVKKNEDLLKVIINVSNFWTYPLKMLIPAVLTHLDSDDGMMTRAVELNYGNKVVLEGAKALLSRIQPGIEENNEPDRWSDLRELRSSKKSKHLLAFCKFFYCLRKDTKMVTCYLRALKHGKIKTIC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR3D1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	632	55	MQLTLNLSGSAGMQLLLLVSSLLLWENVSSKPTAMVPTEDLYTRLAELLHNTFILAADVYREFDLDFFDKTWITDRTLPLCHTASIHTPENREEVHETKTEDLLKAMINVSISWKEPLKHLVSALTALPGASESMGKKAADIKGRNLVILEGLQTIYNRSQANIEENENFDYPAWSGLEELQSPNEDTHLFAVYNLCRCIKRDIHKIDSYIKVLRCRVVFQNEC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR4A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	609	41	MHLSLTPQWSSWTVLLLLVSNLLLWENTASAMRAKRLNVHDYTTFGNTWNQAIQLSQSMNHRISELSTHFKVFYAQGRGFEKRTTRCHTSSLSSPENKEQAQKIQLEVLLGLAHSLLQAWVNPLYHLWAEMCERLGSTPPILSKALEVKTLNRNLLETIEKIAFKGNFEINENGNYTAWSELELLQSPNRDTRYFAFHNLFHCLKKDSSHVEMYLKLLKCRLIQSNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR5A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	914	69	MRLSKIQPHQSGTLLLLLLSNLLMWENVASVPRCIMEDGGCQKVLNYIFNMTSTISENFNNLSSETLNDFDTEYDPHQKFQNRPTMTCHTSSRSVPNNKRKAERMRPVVLLNVTIRMLAAWKNLLHHVENNMADLDGTPYVIISKVKLIDRQIKKLTKNLQNIKTILSQVNPDLKKNEDYPAWSGEPYVQQSKRRVQLFGLHSLFFCLNNDAQKVSDFISILRDQIVPNQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR6A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	678	66	MLSLSQPCFSGTLLMLLASNFLLWKNVAPVPMYASLDEYGEMSIYDLLDHVTILSHNVSELTAEMHRIFMEDVRYKPGRWFSDRYLTACHTSTLTISVSKEGARQMPGVFLVKEMISMLTAWRYPLYHIITELSYMEQAPDEIISRARNIEEKIIVLIEALRGILSKIQPGPPENERYPVWNELASLQSPDEDLRHLTLFNLFQCLVKDSRKIDSSIRLLKCKLLYNRDC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR7A1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	486	31	MPLSFTQPCSSGALLLLVVSNLLLWENVACLPLSSNDTDDDPLSIKGLLDHAMILSKNITDLNMELRRIFTISEMSAKLIDKFLSSSSSSDSYDQFMLEFLGQQELLTKNLTYCHKYSIKVPEDIEEAQNVISLEDFPILILSRMQAWNETLKNRINLSEGTPGIDDDILPIYKNIETKIAELLEDSKSILSQAYGATENVADYTLWSGLEDLQSSDEETRFLALCKLSYCLHVDIHTANFYLQFLRCVALVNSDSCLSSKTGNDS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR7A2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	602	46	MSFSFSQPCPSGALLLVVVSSLLLWENVASVPLSSNETDGYPLSINGLFHNAMRLTWNIKNLNMELRKTYTVNQVSEKLYENYMLDFIEDMEYLVKALTCCHNYSIKTPENLDEAQQIPFNEFPKLILSRMWAWNETSKVLLTTLRSIPGMHDDVISLAKNIETKLAELFEYTQSILNSIYGTTTTGNVEYTVFSGLEDLKSSDEEFSLFDLCKFSYCLRVDIHMVELYLKLLECVVYVSSDVCLSKNIRDAS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR7B1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	827	66	MNTSLTQLCFWALQILLMSNLLLWEDVVSVPTIGSGSGVSEMLTEDLFDDAIILSQHINSLAIETRRIFLSNNFSSDMFITFTLQFNRHDEFVVNGLNSCHTLPLKSPKTEKEAKRISLPDFMNMILSILRAWDNPLHHMETELKSMPGAPFAILARVKDIEVKNKILLDRIMKIAKKVKYGFEENEVYPAWSELASLQSANEESRFFALYKLSYCLFVDTDKVEHYLKHLKCRYFDGYMCQDSVNQINLL	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR7C1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	898	55	MLLSLTHPSFLAMLPMLLMSNLLQWEGVTSASIHHIEDDYGEAYLKDLFDQAIKLSNDTMALTIEMRMIFFSDGFSSNMFRKIVLDFLKDHKHMIETLNSCHTFSLSVPETLEEARKISLEDFLKIIVSILNSWNKPLYHLETELHCMKGAPDAILIRANAIRTLNRELLETILMILSRVHPGMEENTDYPLWTDLASLQATNKERQFFALYKLFYCLRVDTFTVDHYLKYLMCMLYSDDICTSVKFYEDP	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR7D1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	759	53	MLPSLIQPCSSGTLLMLLMSNLFLWEKVSSAPINASEAVLSDLKDLFDNATVLSGEMSKLGVIMRKEFFMNSFSSETFNKIILDLHKSTENITKAFNSCHTVPINVPETVEDVRKTSFEEFLKMVLHMLLAWKEPLKHLVTELSALPECPYRILSKAEAIEAKNKDLLEYIIRIISKVNPAIKENEDYPTWSDLDSLKSADKETQFFALYMFSFCLRIDLETVDFLVNFLKCLLLYDDVCYSEF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR8A6_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	669	57	MALLLSQPHFSGPLLLLVVSNLLLWEKAASNLPCVAEEGGCWNPLLETFNSATQKAETLHNLADQLYVELYYNQFSSGQFWDFSSQIIRQDKTVVRAGSYCHSSLTNPPNTGVHINIEIASYLKTLINFVGSWISPLFHLVIELSATKDVPETILSKAKEIEENNRQILSDLRWILTKVSPAAEMTEEFPHWEYLSFLKSSDKNNKFLAMFNLSYCIDHDSKYILLQLRLLKCLITGKDC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR8A8_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	987	65	MELQFRQPHFSDALLLLLLSNLLLWEKASSIPACMAEKSGCWNPRMETFDSAIRKAETLRTVSKQFYVELYHNQFSSGKFATLTSKLVRRDEIVFRAASHCHSTLTNPPNKGIQYITIEIPEYLKTLINYVGAWISPLFHLVIELSAMKDVPETILSKAKEIEENNRQILRDLRWIITEVYPTSKKKEIFPSWELLSFLKSSSRNSKFLAMFNLSHCLEYDTQFFLFHLRILKCRITGKDC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PR8A9_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	813	87	MVLPLSQPHFSGALLLLVVSNLLLWEKASAIPACMAQKSGCWNPLVETFNSAMQTAGTLRTLADQFYVELYHNQFSSGQFLIFNSNLIRRDETVARAGTYCHSTLSNPPDRGTEHADAETEKYLKTLINYVGAWIGPLYHVVIELNVMQDVPETILSKVRQIEENKRKLLEDLRWILTKVYPTAEMKEEFPAWEHLSFLKSQGKHYKLLAMFNLSNCIYNETYHILFYLRELKCQITGEDC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PRL_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	527	38	MNSQGSAQKAGTLLLLLISNLLFCQNVQPLPICSAGDCQTSLRELFDRVVILSHYIHTLYTDMFIEFDKQYVQDREFMVKVINDCPTSSLATPEDKEQALKVPPEVLLNLILSLVQSSSDPLFQLITGVGGIQEAPEYILSRAKEIEEQNKQLLEGVEKIISQAYPEAKGNGIYFVWSQLPSLQGVDEESKILSLRNTIRCLRRDSHKVDNFLKVLRCQIAHQNNC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PTHR_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	267	75	MLRRLVQQWSVLVFLLSYSVPSRGRSVEGLGRRLKRAVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEIRATSEVSPNSKPAPNTKNHPVRFGSDDEGRYLTQETNKVETYKEQPLKTPGKKKKGKPGKRREQEKKKRRTRSAWPSTAASGLLEDPLPHTSRTSLEPSLRTH	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_PYY_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	48	18	MVAVRRPWPVTVAMLLILLACLGALVDAYPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRYGKRDVPAALFSKLLFTDDSDSENLPFRPEGLDQW	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_REL1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	275	40	MSSRFLLQLLGFWLLLSQPCRTRVSEEWMDGFIRMCGREYARELIKICGASVGRLALSQEEPALLARQATEVVPSFINKDAEPFDTTLKCLPNLSEELKAVLSEAQASLPELQHAPVLSDSVVSLEGFKKTLHDRLGEAEDGSPPGLKYLQSDTHSRKKRESGGLMSQQCCHVGCSRRSIAKLYC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_REL3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	119	37	MAMLGLLLLASWALLGALGLQAEARPAPYGVKLCGREFIRAVIFTCGGSRWRRADILAHESLGDFFADGEANTDHLASELDEAVGSSEWLALTKSPQAFYGGRASWQGSPGVVRGSRDVLAGLSSSCCEWGCSKSQISSLC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_RETN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	106	52	MKNLSFPLLFLFFLVPELLGSSMPLCPIDEAIDKKIKQDFNSLFPNAIKNIGLNCWTVSSRGKLASCPEGTAVLSCSCGSACGSWDIREEKVCHCQCARIDWTAARCCKLQVAS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_RETNA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	92	11	MKTTTCSLLICISLLQLMVPVNTDETIEIIVENKVKELLANPANYPSTVTKTLSCTSVKTMNRWASCPAGMTATGCACGFACGSWEIQSGDTCNCLCLLVDWTTARCCQLS	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_RETNB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	31	7	MKPTLCFLFILVSLFPLIVPGNAQCSFESLVDQRIKEALSRQEPKTISCTSVTSSGRLASCPAGMVVTGCACGYGCGSWDIRNGNTCHCQCSVMDWASARCCRMA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_RETNG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	38	10	MLTFNKMKTTTCSLLICISLLQLMVPVNTEGTLESIVEKKVKELLANRDDCPSTVTKTFSCTSITASGRLASCPSGMTVTGCACGYGCGSWDIRDGNTCHCQCSTMDWATARCCQLA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_SECR_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	200	76	MEPPLPTPMLLLLLLLLSSSAALPAPPRTPRHSDGMFTSELSRLQDSARLQRLLQGLVGKRSEQDTENIPENSLARSKPLEDQLCLLWSNTQTLQDWLLPRLSLDGSLSLWLPPGPRSAVDRSEWTETTRPPR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_SMS_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	68	35	MLSCRLQCALAALCIVLALGGVTGAPSDPRLRQFLQKSLAAATGKQELAKYFLAELLSEPNQTENDALEPEDLPQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_SOMA_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	519	45	MATDSRTSWLLTVSLLCLLWPQEASAFPAMPLSSLFSNAVLRAQHLHQLAADTYKEFERAYIPEGQRYSIQNAQAAFCFSETIPAPTGKEEAQQRTDMELLRFSLLLIQSWLGPVQFLSRIFTNSLMFGTSDRVYEKLKDLEEGIQALMQELEDGSPRVGQILKQTYDKFDANMRSDDALLKNYGLLSCFKKDLHKAETYLRVMKCRRFVESSCAF	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_SPXN_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	122	20	MKGPSVLAVTAVVLLLVLSALENSSGAPQRLSEKRNWTPQAMLYLKGAQGRRFLSDQSRRKELADRPPPERRNPDLELLTLPEAAALFLASLEKSQKDEGGNFDKSELLEDRLFNW	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_STC1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	235	56	MLQNSAVILALVISAAAAHEAEQNDSVSPRKSRVAAQNSAEVVRCLNSALQVGCGAFACLENSTCDTDGMYDICKSFLYSAAKFDTQGKAFVKESLKCIANGITSKVFLAIRRCSTFQRMIAEVQEDCYSKLNVCSIAKRNPEAITEVIQLPNHFSNRYYNRLVRSLLECDEDTVSTIRDSLMEKIGPNMASLFHILQTDHCAQTHPRADFNRRRTNEPQKLKVLLRNLRGEGDSPSHIKRTSQESA	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_STC2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	146	28	MCAERLGQFVTLALVFATLDPAQGTDSTNPPEGPQDRSSQQKGRLSLQNTAEIQHCLVNAGDVGCGVFECFENNSCEIQGLHGICMTFLHNAGKFDAQGKSFIKDALRCKAHALRHKFGCISRKCPAIREMVFQLQRECYLKHDLCSAAQENVGVIVEMIHFKDLLLHEPYVDLVNLLLTCGEDVKEAVTRSVQAQCEQSWGGLCSILSFCTSNIQRPPTAAPEHQPLADRAQLSRPHHRDTDHHLTANRGAKGERGSKSHPNAHARGRTGGQSAQGPSGSSEWEDEQSEYSDIRR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_THYG_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	4570	69	MTALVLWVSTLLSSVCLVAANIFEYQVDAQPLRPCELQREKAFLKQAEYVPQCSEDGSFQTVQCQNDGQSCWCVDSDGREVPGSRQLGRPTVCLSFCQLHKQRILLGSYINSTDALYLPQCQDSGNYAPVQCDLQRVQCWCVDTEGMEVYGTRQQGRPTRCPRSCEIRNRRLLHGVGDRSPPQCTADGEFMPVQCKFVNTTDMMIFDLIHNYNRFPDAFVTFSSFRGRFPEVSGYCYCADSQGRELAETGLELLLDEIYDTIFAGLDQASTFTQSTMYRILQRRFLAIQLVISGRFRCPTKCEVEQFAATRFGHSYIPRCHRDGHYQTVQCQTEGMCWCVDAQGREVPGTRQQGQPPSCAADQSCALERQQALSRFYFETPDYFSPQDLLSSEDRLAPVSGVRSDTSCPPRIKELFVDSGLLRSIAVEHYQRLSESRSLLREAIRAVFPSRELAGLALQFTTNPKRLQQNLFGGTFLANAAQFNLSGALGTRSTFNFSQFFQQFGLPGFLNRDRVTTLAKLLPVRLDSSSTPETLRVSEKTVAMNKRVVGNFGFKVNLQENQDALKFLVSLLELPEFLVFLQRAVSVPEDIARDLGDVMEMVFSAQACKQMPGKFFVPSCTAGGSYEDIQCYAGECWCVDSRGKELDGSRVRGGRPRCPTKCEKQRAQMQSLASAQPAGSSFFVPTCTREGYFLPVQCFNSECYCVDTEGQVIPGTQSTVGEAKQCPSVCQLQAEQAFLGVVGVLLSNSSMVPSISNVYIPQCSASGQWRHVQCDGPHEQVFEWYERWKTQNGDGQELTPAALLMKIVSYREVASRNFSLFLQSLYDAGQQRIFPVLAQYPSLQDVPQVVLEGATTPPGENIFLDPYIFWQILNGQLSQYPGPYSDFNMPLEHFNLRSCWCVDEAGQKLDGTQTKPGEIPACPGPCEEVKLRVLKFIKETEEIVSASNASSFPLGESFLVAKGIQLTSEELDLPPQFPSRDAFSEKFLRGGEYAIRLAAQSTLTFYQSLRASLGKSDGAASLLWSGPYMPQCNMIGGWEPVQCHAGTGQCWCVDGRGEFIPGSLMSRSSQMPQCPTNCELSRASGLISAWKQAGPQRNPGPGDLFIPVCLQTGEYVRKQTSGTGTWCVDPASGEGMPVNTNGSAQCPGLCDVLKSRALSRKVGLGYSPVCEALDGAFSPVQCDLAQGSCWCVLGSGEEVPGTRVVGTQPACESPQCPLPFSGSDVADGVIFCETASSSGVTTVQQCQLLCRQGLRSAFSPGPLICSLESQHWVTLPPPRACQRPQLWQTMQTQAHFQLLLPPGKMCSVDYSGLLQAFQVFILDELIARGFCQIQVKTFGTLVSSTVCDNSSIQVGCLTAERLGVNVTWKLQLEDISVGSLPDLYSIERAVTGQDLLGRFADLIQSGRFQLHLDSKTFSADTTLYFLNGDSFVTSPRTQLGCMEGFYRVPTTRQDALGCVKCPEGSFSQDGRCTPCPAGTYQEQAGSSACIPCPRGRTTITTGAFSKTHCVTDCQKNEAGLQCDQNGQYQASQKNRDSGEVFCVDSEGRKLQWLQTEAGLSESQCLMIRKFDKAPESKVIFDANSPVIVKSSVPSADSPLVQCLTDCANDEACSFLTVSTMESEVSCDFYSWTRDNFACVTSDQEQDAMGSLKATSFGSLRCQVKVRNSGKDSLAVYVKKGYESTAAGQKSFEPTGFQNVLSGLYSPVVFSASGANLTDTHTYCLLACDNDSCCDGFIITQVKGGPTICGLLSSPDILLCHINDWRDTSATQANATCAGVTYDQGSRQMTLSLGGQEFLQGLALLEGTQDSFTSFQQVYLWKDSDMGSRPESMGCERGMVPRSDFPGDMATELFSPVDITQVIVNTSHSLPSQQYWLFTHLFSAEQANLWCLSRCAQEPIFCQLADITKSSSLYFTCFLYPEAQVCDNVMESNAKNCSQILPHQPTALFRRKVVLNDRVKNFYTRLPFQKLTGISIRDKVPMSGKLISNGFFECERLCDRDPCCTGFGFLNVSQLQGGEVTCLTLNSMGIQTCNEESGATWRILDCGSEDTEVHTYPFGWYQKPAVWSDTPSFCPSAALQSLTEEKVTSDSWQTLALSSVIVDPSIKHFDVAHISTAATSNFSMAQDFCLQQCSRHQDCLVTTLQIQPGVVRCVFYPDIQNCIHSLRSHTCWLLLHEEATYIYRKSGIPLVQSDVTSTPSVRIDSFGQLQGGSQVIKVGTAWKQVYRFLGVPYAAPPLADNRFRAPEVLNWTGSWDATKPRASCWQPGTRTPTPPQINEDCLYLNVFVPENLVSNASVLVFFHNTMEMEGSGGQLTIDGSILAAVGNFIVVTANYRLGVFGFLSSGSDEVAGNWGLLDQVAALTWVQSHIGAFGGDPQRVTLAADRSGADVASIHLLISRPTRLQLFRKALLMGGSALSPAAIISPERAQQQAAALAKEVGCPTSSIQEVVSCLRQKPANILNDAQTKLLAVSGPFHYWGPVVDGQYLRELPSRRLKRPLPVKVDLLIGGSQDDGLINRAKAVKQFEESQGRTNSKTAFYQALQNSLGGEDSDARILAAAVWYYSLEHSTDDYASFSRALENATRDYFIICPMVNMASLWARRTRGNVFMYHVPESYGHGSLELLADVQYAFGLPFYSAYQGQFSTEEQSLSLKVMQYFSNFIRSGNPNYPHEFSRKAAEFATPWPDFIPGAGGESYKELSAQLPNRQGLKQADCSFWSKYIQTLKDADGAKDAQLTKSEEEDLEVGPGLEEDLSGSLEPVPKSYSK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_TOR2X_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	504	58	MAVARHGYRPWGSILGLLGLALAAAAAWDVASLRCTFGSFCECDFWPDLPGLECDLAQHLAGQHLAKALVVKSLKAFVQDPAPSKPLVLSLHGWTGTGKSYVSSLLAQHLFRDGLRSPHVHHFSPIIHFPHPSRTEQYKKELKSWVQGNLTACGRSLFLFDEMDKLPPGLMEVLQPFLGPSWVVYGTNYRKAIFIFIRWLLAVWHHGGAPAGRCGALPPAPAASRAPLRTQ	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_TPO_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	643	40	MELTDLLLAAMLLAVARLTLSSPVAPACDPRLLNKLLRDSHLLHSRLSQCPDVDPLSIPVLLPAVDFSLGEWKTQTEQSKAQDILGAVSLLLEGVMAARGQLEPSCLSSLLGQLSGQVRLLLGALQGLLGTQLPLQGRTTAHKDPNALFLSLQQLLRGKVRFLLLVEGPTLCVRRTLPTTAVPSSTSQLLTLNKFPNRTSGLLETNFSVTARTAGPGLLSRLQGFRVKITPGQLNQTSRSPVQISGYLNRTHGPVNGTHGLFAGTSLQTLEASDISPGAFNKGSLAFNLQGGLPPSPSLAPDGHTPFPPSPALPTTHGSPPQLHPLFPDPSTTMPNSTAPHPVTMYPHPRNLSQET	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_TRH_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	184	36	MQGPWLMMALALIFVLTGIPKSCALLEAAQEEGAVTPDLPGLEKVQVRPERRFLRKDLQRVRGDLGAALDSWITKRQHPGKREEKEEDVEAEERGDLGEVGAWRPHKRQHPGRRANQDKDSWSDEGDSDWLPPSWLPDFFLDSWFSDAPQVKRQHPGRRSFPWMESDVTKRQHPGRRFIDPELQRSWEETEGEEGGLMPEKRQHPGKRAVGHPCGPQGICGQTGLLQLLGDLSRGQETLAKQTPQLEAWVREPLEE	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_TSHB_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	99	30	MSAAVLLSVLFALACGQAASFCIPTEYTMYVDRRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPHHVTPYFSFPVAVSCKCGKCNTDNSDCIHEAVRTNYCTKPQSFYLGGFSV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_TTHY_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	194	25	MASLRLFLLCLAGLVFVSEAGPAGAGESKCPLMVKVLDAVRGSPAVDVAVKVFKKTSEGSWEPFASGKTAESGELHGLTTDEKFVEGVYRVELDTKSYWKTLGISPFHEFADVVFTANDSGHRHYTIAALLSPYSYSTTAVVSNPQN	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_UCN1_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	137	22	MIQRGRATLLVALLLLAQLRPESSQWSPAAAAATGVQDPNLRWSPGVRNQGGGVRALLLLLAERFPRRAGSEPAGERQRRDDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSVGK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_UCN2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	340	56	MMTRWALVVFVVLMLDRILFVPGTPIPTFQLLPQNSLETTPSSVTSESSSGTTTGPSASWSNSKASPYLDTRVILSLDVPIGLLRILLEQARYKAARNQAATNAQILAHVGRR	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_UCN3_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	226	41	MLMPTYFLLPLLLLLGGPRTSLSHKFYNTGPVFSCLNTALSEVKKNKLEDVPLLSKKSFGHLPTQDPSGEEDDNQTHLQIKRTFSGAAGGNGAGSTRYRYQSQAQHKGKLYPDKPKSDRGTKFTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQIGKKK	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_UTS2_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	293	57	MDRVPFCCLLFIGLLNPLLSLPVTDTGERTLQLPVLEEDALRALEELERMALLQTLRQTMGTEAGESPGEAGPSTETPTPRGSMRKAFAGQNSNTVLSRLLARTRKQHKQHGAAPECFWKYCI	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_UTS2B_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	162	48	MKVFSTSLWCGLLTLLSVMNLFKSVRGRPHLSSGHELFPAKEHAAQEKLTRNPGLQRPFHAGGDLPSKLEELRQVKKLRDWIMEAKNTGLSNALDNLSSSHTKKRACFWKYCV	ba
uniprotkb_keyword_reviewed_2024_05_30_MurineHormones_VIP_MOUSE.fasta_netMHCIIpan4.0_BA_nocontext_l15_formated.txt	4	15	non-binder (0) >5%, weak binder (1) >2.5%, medium binder (2) >1%, strong binder (3) <=1%	231	53	MEARSKPQFLAFLILFSVLFSQSLAWPLFGPPSVVRLDDRMPFEGAGDPDQVSLKADSDILQNPLAENGTPYYDVSRNARHADGVFTSDYSRLLGQISAKKYLESLIGKRISSSISEDPVPIKRHSDAVFTDNYTRLRKQMAVKKYLNSILNGKRSSEGDSADFLEELEK	ba
